EVALUATING THE ACUTE EFFECTS OF CAFFEINATED WATERPIPE TOBACCO IN WATERPIPE USERS by Cobb, Caroline
Virginia Commonwealth University
VCU Scholars Compass
Theses and Dissertations Graduate School
2012
EVALUATING THE ACUTE EFFECTS OF
CAFFEINATED WATERPIPE TOBACCO IN
WATERPIPE USERS
Caroline Cobb
Virginia Commonwealth University
Follow this and additional works at: http://scholarscompass.vcu.edu/etd
Part of the Psychology Commons
© The Author
This Dissertation is brought to you for free and open access by the Graduate School at VCU Scholars Compass. It has been accepted for inclusion in
Theses and Dissertations by an authorized administrator of VCU Scholars Compass. For more information, please contact libcompass@vcu.edu.
Downloaded from
http://scholarscompass.vcu.edu/etd/2718
 
 
 
 
© Caroline O. Cobb 2012 
All Rights Reserved 
  
  
 
EVALUATING THE ACUTE EFFECTS OF CAFFEINATED WATERPIPE TOBACCO IN 
WATERPIPE USERS 
 
 
A dissertation submitted in partial fulfillment of the requirements for the degree of 
Doctor of Philosophy at Virginia Commonwealth University. 
 
by 
 
CAROLINE O. COBB 
M.S., Virginia Commonwealth University, 2009 
 
 
 
 
Director: Dr. Thomas Eissenberg 
Professor 
Department of Psychology and Institute for Drug and Alcohol Studies 
 
 
Virginia Commonwealth University 
Richmond, Virginia 
April, 2012 
 
ii 
 
Acknowledgements 
  
This work was supported by United States Public Health Service grants 
R01CA120142, R01DA024876, and F31DA028102.  Portions of this work were 
presented at the 73rd Annual Meeting of the College on Problems of Drug Dependence, 
June 18-23, 2011. 
In addition, I would like to thank my gracious committee members Drs. Balster, 
Brunzell, Porter, and Vrana for their consummate advice and constructive critique of this 
work.  I would like to thank my advisor and committee chair, Dr. Eissenberg, for his 
excellent supervision during this project and throughout my graduate career.  I am truly 
grateful to have such an accessible, considerate, and supportive mentor.  I would also like 
to recognize the contributions of my colleagues Dr. Alan Shihadeh, Ezzat Jaroudi, Kamar 
Al Sahmarani, Dr. Andrea Vansickel, Janet Austin, Barbara Kilgalen, and Poonam 
Delvadia, without which the completion of this study would not have been possible.  I 
also owe a huge debt of gratitude to my parents and friends for their encouragement and 
feedback throughout this whole process. Lastly, to Chris, I thank you with all my heart 
for your support and ability to keep me smiling.  
 
  
iii 
 
 
Table of Contents 
Page 
Acknowledgements ............................................................................................................. ii       
List of Tables .................................................................................................................... vii 
List of Figures .................................................................................................................. viii 
List of Abbreviations ...........................................................................................................x 
Abstract .............................................................................................................................. xi 
Introduction ..........................................................................................................................1 
Overview ..................................................................................................................1 
Nicotine’s Pharmacokinetics and Pharmacodynamics ............................................2 
Acute Effects of Nicotine in Humans ......................................................................4 
Chronic Effects of Nicotine in Humans ...................................................................7 
How the Acute and Chronic Effects of Nicotine Influence Tobacco Use Initiation 
and Maintenance ....................................................................................................13 
Positive reinforcement: cigarette smoking .................................................13 
Negative reinforcement/dependence: cigarette smoking ...........................15 
Nicotine’s roles in other forms of tobacco use: waterpipe tobacco smoking17 
Factors Contributing to the Global Spread of Waterpipe Tobacco Smoking ........19 
Misconceptions regarding waterpipe tobacco smoking .............................19 
Easy access to flavored waterpipe tobacco ................................................20 
iv 
 
Waterpipe tobacco and nicotine .................................................................24 
Caffeine’s Pharmacokinetics and Pharmacodynamics ..........................................27 
Acute Effects of Caffeine .......................................................................................29 
Chronic Effects of Caffeine ...................................................................................35 
Interactions Concerning Nicotine and Caffeine .....................................................39 
Preclinical Laboratory Evaluations of Nicotine and Caffeine ...............................42 
Clinical Evaluations of Nicotine and Caffeine ......................................................46 
Novel Caffeine and Nicotine Co-administration: Caffeinated Tobacco ................54 
Volatilized Nicotine and Caffeine .........................................................................56 
Evaluating the Effects of Caffeinated Waterpipe Tobacco ....................................58 
Statement of the Problem .......................................................................................60 
The Present Study ..................................................................................................61 
Statement of Hypothesis ........................................................................................61 
Method ...............................................................................................................................62 
Selection of Participants ........................................................................................62 
Inclusion criteria ..........................................................................................62 
Exclusion criteria .........................................................................................63 
Screening and Informed Consent Procedures ........................................................63 
Materials ................................................................................................................64 
Procedure ...............................................................................................................66 
Physiological Measures .........................................................................................68 
v 
 
Plasma nicotine and caffeine .......................................................................68 
Cardiovascular effects .................................................................................69 
Expired air carbon monoxide ......................................................................69 
Subjective Measures ..............................................................................................69 
Direct Effects Scale .....................................................................................69 
The Profile of Mood States .........................................................................71 
The Positive and Negative Affect Scale ......................................................71 
Puff Topography ....................................................................................................72 
Data Analysis Plan .................................................................................................73 
Results ................................................................................................................................75 
Time Course Analyses ...........................................................................................75 
Physiological measures ..............................................................................75 
Subjective measures ...................................................................................85 
Direct Effects Scale........................................................................85 
The Profile of Mood States and Positive and Negative Affect Scale 
....................................................................................................... 90 
Peak Change Analyses .......................................................................................... 92 
Physiological measures ............................................................................. 92 
Subjective measures .................................................................................. 95 
Direct Effects Scale....................................................................... 95 
vi 
 
The Profile of Mood States and Positive and Negative Affect Scale
......................................................................................................98 
Puff Topography .....................................................................................102 
Discussion ........................................................................................................................106 
Overview ..............................................................................................................106 
Effects of Smoking Nicotine-containing Tobacco in a Waterpipe ......................107 
Potential Non-pharmacological Influences on Waterpipe Smoking Behavior ....114 
Future Study Design for Caffeinated Waterpipe Tobacco ...................................118 
Limitations of the Current Study .........................................................................121 
Conclusions ..........................................................................................................128 
References ........................................................................................................................130 
Appendices .......................................................................................................................151 
A APPENDIX A Telephone Screening Form ...................................................151 
B APPENDIX A Informed Consent ..................................................................157 
Vita ...................................................................................................................................162 
 
 
vii 
 
List of Tables 
Page 
Table 1: Mean puff topography for waterpipe users and cigarette users ...........................21 
Table 2: Caffeine content for a variety of consumer products ...........................................55  
Table 3: Nicotine and caffeine content analysis of study materials ...................................65 
Table 4: Time course statistical analyses for all measures ................................................76 
Table 5: Peak change from baseline statistical analyses for all measures. ........................93 
Table 6: Mean (standard deviation) of all topography measures .....................................103 
Table 7: Statistical analyses for topography measures ....................................................104 
Table 8: Puff topography results for Blank et al., 2011 ...................................................110 
 
 
viii 
 
List of Figures 
Page 
Figure 1: Typical waterpipe apparatus ...............................................................................18 
Figure 2: Ma’assel waterpipe tobacco products ................................................................22 
Figure 3: Caffeine assay calibration/standard curve ..........................................................70 
Figure 4: Mean plasma caffeine concentrations ................................................................78 
Figure 5. Mean plasma nicotine concentrations ................................................................80 
Figure 6. Mean HR ............................................................................................................82 
Figure 7. Mean systolic BP and diastolic BP .....................................................................84 
Figure 8. Mean expired air CO ......................................................................................... 86 
Figure 9. Mean scores for “Do you like the drug effects?” and “Hungry” ....................... 88 
Figure 10. Mean scores for “Do you feel a rush?” and “Do you feel any bad drug 
effects?”  ........................................................................................................................... 89 
Figure 11. Mean scores for the POMS-depression/dejection factor ................................. 91 
Figure 12. Mean peak change data for plasma nicotine .................................................... 94  
Figure 13. Mean peak change data for HR and systolic BP ............................................. 96  
Figure 14. Mean peak change data for expired air CO ..................................................... 97 
Figure 15. Mean peak change data for “Do you feel any drug effects?” .......................... 99 
Figure 16. Mean peak change score for “Do you feel high?” ..........................................100 
Figure 17. Mean peak change for the POMS-tension/anxiety factor ...............................101 
Figure 18. Waterpipe product labels ................................................................................116 
ix 
 
Figure 19.  Two waterpipe tobacco heads .......................................................................124 
Figure 20. Raw plasma caffeine concentrations during CAFF/LN .................................126 
Figure 21. Raw plasma caffeine concentrations during CAFF/NIC ................................127 
  
 
 
x 
 
List of Abbreviations 
 
 
ANOVA    analysis of variance 
CDC    Centers for Disease Control and Prevention 
CO     carbon monoxide 
HSD    Honestly Significant Difference 
LOQ     limit of quantification 
mg     milligram 
min     minute 
ml     milliliter  
ng     nanogram (0.0000000001 grams) 
ppm     concentration in parts per million 
US DHHS   U.S. Department of Health and Human Services 
VAS    visual analog scale 
VTA    ventral tegmental area 
μg    microgram 
  
Abstract 
 
EVALUATING THE ACUTE EFFECTS OF CAFFEINATED WATERPIPE TOBACCO IN 
WATERPIPE USERS 
 
 
 
By Caroline O. Cobb, M.S. 
 
A dissertation submitted in partial fulfillment of the requirements for the degree of 
Doctor of Philosophy at Virginia Commonwealth University. 
 
 
Virginia Commonwealth University, 2012.  
 
Major Director: Dr. Thomas Eissenberg 
Professor 
Department of Psychology and Institute for Drug and Alcohol Studies 
 
Caffeine and nicotine are the two most commonly consumed licit psychoactive drugs in 
the world. In addition, they are frequently co-administered with over 86% of cigarette smokers 
reporting caffeine use versus 77% of non-smokers. Research suggests the combination of 
nicotine and caffeine produces effects that are more rewarding or pleasurable than either drug 
  
alone, and this potential reward enhancement may influence patterns of tobacco use initiation 
and maintenance. Waterpipe tobacco smoking is an alternative tobacco use method that is 
increasing in prevalence in the U.S. and offers a novel opportunity for nicotine and caffeine co-
administration via a caffeinated tobacco product (Tangiers F-Line). Based on previous work, this 
caffeinated tobacco product was hypothesized to enhance reward-related and cardiovascular 
effects in waterpipe users relative to tobacco-only waterpipe preparations. Thirty-two waterpipe 
tobacco smokers who regularly drank caffeinated beverages participated in a four condition, 
Latin-square ordered, within-subjects study. In each condition, there was a 45-minute double-
blind product administration period that differed by the content of waterpipe product smoked: 
caffeine and nicotine (Tangiers F-Line), nicotine and no caffeine (Tangiers), reduced (low) 
nicotine and caffeine (low nicotine Tangiers F-Line), or neither nicotine nor caffeine (Soex). 
Outcome measures included blood plasma caffeine and nicotine, cardiovascular response, 
expired air carbon monoxide (CO), puff topography, and subjective ratings. Plasma analyses 
revealed no detectable levels of caffeine from either caffeinated product, but significant nicotine 
exposure from all nicotine-containing products. Few differences between conditions were 
observed for subjective measures. Larger puff volumes were observed for products that 
contained low or no nicotine, resulting in higher CO concentrations for these conditions. While 
findings do not address whether caffeine can be delivered via volatilization, they suggest that 
measurable caffeine exposure was not observed for the products examined and under the 
conditions explored here. Importantly, study results support continued investigation of the effects 
of waterpipe tobacco smoking using a placebo-controlled design as well as demonstrate that 
  
tobacco dependence and toxicity capabilities are still concerns for these and other waterpipe 
products.  
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Evaluating the acute effects of caffeinated waterpipe tobacco in waterpipe users 
 
Overview 
Caffeine and nicotine are the two most commonly consumed licit psychoactive drugs in 
the world (Frary, Johnson, & Wang, 2005; Tanda & Goldberg, 2000).  Both are considered 
stimulants and share some similar physiological and behavioral effects.  Nicotine is usually 
administered via tobacco products and caffeine is most often consumed orally via beverages.  
While tobacco use is associated with nicotine dependence and serious health effects, caffeine use 
is considered a behavior with low abuse liability and little harm (United States Department of 
Health and Human Services [USDHHS], 2004; Daly & Fredholm, 1998).  The co-administration 
of caffeine and nicotine-containing products is common: over 86% of cigarette smokers report 
using caffeine versus 77% of non-smokers (Swanson, Lee, & Hopp, 1994).  This observation 
may reflect an interaction between these two drugs such that their combination produces more 
rewarding or pleasurable effects than either drug alone.  This reward enhancement may influence 
patterns of tobacco use initiation and maintenance (Tanda & Goldberg, 2000; Jones & Griffiths, 
2003; Gasior, Jaszyna, Munzar, Witkin, & Goldberg, 2002), posing a significant risk to potential 
and current tobacco users.  Although cigarette smoking prevalence has been decreasing over the 
past twenty years in the United States (U.S.), the recent popularity of an alternative tobacco use 
method, waterpipe tobacco smoking, also raises concerns over nicotine and caffeine co-
administration (Centers for Disease Control and Prevention [CDC], 2008; World Health 
Organization, 2005).  This method of tobacco smoking, especially popular among young adults 
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in the U.S., may allow for increased opportunities for nicotine and caffeine co-administration 
among an age group that is especially vulnerable to tobacco use (CDC, 1994).  One such 
opportunity presents itself with the availability of a caffeinated waterpipe tobacco product, that 
enables users to consume this combination of drugs in a single form.  While the individual 
effects of nicotine and caffeine are well-defined, empirical research concerning their interaction, 
reward enhancement, and influence on patterns of tobacco use initiation and maintenance is less 
clear.  Furthermore, no data exist concerning the effects of caffeine delivered via tobacco.  By 
examining the individual and combined effects of nicotine and caffeine, as well as developing a 
technique to assess caffeinated tobacco products, their influence on patterns of tobacco use 
initiation and maintenance may be better illustrated. 
Nicotine’s Pharmacokinetics and Pharmacodynamics 
Nicotine is a mild psychomotor stimulant found in tobacco and produces subjective 
effects similar to other drugs of this classification including cocaine (Jones, Garrett, & Griffiths, 
1999), amphetamine (Grilly, 2000), and caffeine (Garrett & Griffiths, 2001).  While nicotine is 
the primary chemical responsible for tobacco dependence, other tobacco or tobacco smoke 
constituents such as the tobacco specific nitrosamines and polycyclic aromatic hydrocarbons 
(Hecht & Hoffman, 1998; Hecht, 2006) are implicated in the development of damaging health 
effects that include various cancers, pulmonary disease, and adverse pregnancy-related outcomes 
(USDHSS, 2004).  Understanding how the pharmacological properties associated with nicotine 
influence the use of tobacco despite these harmful consequences is vital to decreasing the impact 
this drug has upon public health.  
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Specifically, nicotine’s pharmacokinetics and pharmacodynamics are important factors in 
the effects this drug has upon patterns of tobacco use initiation and maintenance.  Nicotine is 
absorbed easily from multiple sites in the body including the lungs, mucosa, skin, and 
gastrointestinal tract (Julien, 2005, p. 233; Benowitz, 2008).  Tobacco smoke contains nicotine in 
the form of minute particles that are quickly absorbed into the bloodstream from alveoli in the 
lungs (Zevin, Gourlay, & Benowitz, 1998).  During smoking, nicotine reaches the brain within 
about 10 to 20 seconds (Benowitz, 2008), while peak plasma levels of nicotine are observed 
about 5-10 minutes after inhalation (Balfour & Fagerström, 1996).  Brain and plasma levels of 
nicotine decline quickly due to elimination and distribution to peripheral tissues.  Contributing to 
the speed of elimination is nicotine’s short half-life, which is approximately two hours in most 
adults (Benowitz, Kuyt, & Jacob, 1982; Benowitz, 2008).  Cotinine, the primary metabolite of 
nicotine, has a much longer half-life (14-20 hours) and is often used as a biomarker of smoking 
status (Zevin et al., 1998; Benowitz & Jacob, 1993).  This rapid absorption and elimination 
profile has important implications for nicotine’s ability to serve as a drug of abuse for many 
individuals.  In order to maintain the drug's pleasurable effects and prevent symptoms associated 
with tobacco abstinence, continued nicotine self-administration (e.g., smoking) is necessary 
(USDHHS, 2010). 
Nicotine affects a variety of structures in the central nervous system (CNS), peripheral 
nervous system (PNS), and the heart.  Physiological effects include increases in heart rate, blood 
pressure, and cardiac contractility (Benowitz, Porchet, Sheiner, & Jacob, 1988; Zevin et al., 
1998).  Behavioral effects include increases in fine psychomotor activity (Perkins et al. 1990), 
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attention (Bates, Mangan, Stough, & Corballis, 1995), and cognitive task performance (Foulds et 
al., 1996).  Nicotine exerts a majority of its action by activating specific acetylcholine receptors, 
which are distributed throughout the CNS and PNS (nicotinic acetylcholine receptors; Golan et 
al., 2005, p. 257; Benowitz, 2008).  In the CNS, nicotine administration is associated with 
nicotinic acetylcholine receptor activation in the pre-synaptic nerve terminals of dopamine, 
acetylcholine, and glutamate secreting neurons (among many others), which when activated by 
nicotine facilitate the release of these neurotransmitters (Golan et al., 2005, p. 257; Benowitz, 
2008).  Critical to the reinforcing effects of nicotine and other drugs of abuse is the release of 
dopamine (Benowitz, 2008).   
Nicotine increases dopamine levels in the mesocorticolimbic system of the brain 
involving the ventral tegmental area (VTA), nucleus accumbens, and forebrain, as well as the 
corpus striatum and the prefrontal cortex (Corrigal, Coen, & Adamson, 1994; Domino & 
Tsukada, 2009).  These increases may account for some of the acute and chronic effects of 
nicotine which include stimulant, behavioral reinforcement, and dependence-inducing properties 
(Picciotto, 1998; Le Foll & Goldberg, 2009; Zevin et al., 1998).   
Acute Effects of Nicotine in Humans 
Acute nicotine administration in a clinical setting is associated with a reliable set of 
outcomes that include stimulant-related physiological and subjective effects.  Examinations that 
assess these acute outcomes are usually performed in a controlled laboratory setting using classic 
measures of physiological activity (i.e., heart rate, blood pressure) and well-defined measures of 
subjective effects.  Within these examinations, nicotine can be administered in a variety of forms 
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(e.g., intravenous [i.v.], nicotine gum, nicotine-containing cigarette) and among participants with 
and without a nicotine use history.  The breadth of research concerning the acute effects of 
nicotine provides ample and consistent evidence of this drug’s immediate effects, and 
understanding these acute effects may inform the study of patterns of tobacco use initiation and 
maintenance. 
Often the acute effects of nicotine in humans are assessed in a single session dosing 
procedure.  One recent study examined the acute cardiovascular and subjective effects of i.v. 
administered nicotine (Sofuoglu & Mooney, 2009).  Twenty-four male and female smokers who 
were overnight-abstinent from nicotine received a saline infusion followed by 0.5 mg/70 kg and 
1.0 mg /70 kg nicotine i.v.  The infusions were delivered over 60 seconds and were separated by 
a 30-minute interval.  Physiological measures included blood pressure and heart rate.  Subjective 
effects were assessed using multiple measures including visual scale analog (VAS; 0-100) items 
(e.g., “drug strength”, “head rush”, “good drug effects”, “like drug” and “bad effects”; Soria et 
al., 1996) and the 20-item Positive and Negative Affect Schedule (PANAS; Watson, Clark, & 
Tellegen, 1988), which contains two factors defined by factor analysis (positive affect and 
negative affect).  Results for heart rate indicated that both active nicotine doses generated 
significantly greater increases in beats per minute (bpm) as compared with placebo.  For diastolic 
blood pressure, the 0.5 mg/70 kg dose significantly increased blood pressure as compared with 
placebo, while for systolic blood pressure only the 1 mg/70 kg dose of nicotine produced 
significantly greater increases.  For the subjective measures, significant main effects for dose 
were observed on all VAS items including “good drug effects”, “like drug”, and “head rush”.  
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Scores for all of these items were increased by nicotine administration in a dose dependent 
manner (i.e., increases were larger after the higher nicotine dose).  Women and men reported 
similar changes in positive affect on the PANAS from the beginning of the session to the end 
(Sofuoglu & Mooney, 2009).  These findings clarify some common effects associated with acute 
nicotine administration including increased heart rate and blood pressure, and subjective reports 
of “good drug effects” and “head rush”.  Importantly, some of these effects are observed in those 
naïve to nicotine as well.     
Non-smokers report some similar effects in response to acute doses of nicotine.  In a 
within-subject laboratory study, the effects of intranasal nicotine doses of 0, 10, and 20 
micrograms (μg)/kg were compared between a group of 37 non-smokers and 55 smokers 
(Perkins, Gerlach, Broge, Grobe, & Wilson, 2000).  Doses were administered via measured-dose 
nasal spray once every 30 minutes for 90 minutes (total of three times per session).  Outcome 
measures included cardiovascular and subjective assessments (e.g., VAS items of "head rush”, 
"relaxed", "pleasant", and "jittery").  Subjective and cardiovascular responses to nicotine doses 
or placebo were averaged across the three administrations during each session to produce a mean 
response for each dose tested.  Results indicated in both smokers and non-smokers nicotine 
administration produced dose dependent increases in VAS scales of “jittery” and “head rush”, 
heart rate, and blood pressure (Perkins et al., 2000).  These results demonstrate the similarity of 
some of the acute subjective and cardiovascular effects of nicotine between smokers and non-
smokers. 
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In addition, a meta-analysis examining the acute subjective effects of nicotine in humans 
including smokers and non-smokers revealed commonalities of acute effects observed across 
drug use history (Kalman & Smith, 2005).  Six nicotine nasal spray studies among non-smokers 
and eleven nasal spray and four i.v. nicotine studies among nicotine-deprived smokers were 
included in the analyses.  Outcome variables were subjective effects including affective valence 
(pleasant and unpleasant) and arousal (high and low).  Generally, results indicated that in 
smokers and non-smokers, nicotine produced a decrease in feelings of relaxation and increased 
tension/jitteriness.  Similar to previously reported examinations (Perkins et al., 2000; Sofuoglu & 
Mooney, 2009), dose-response relationships were observed for some items.  The largest effect 
sizes were for the subjective items “head rush” and “drug high”, but there was considerable 
variability among the studies due to the nicotine doses used and the route of administration 
(Kalman & Smith, 2005).  Overall, these findings suggested that the subjective effects associated 
with acute nicotine administration are well-defined and can be reliably measured.  
In summary, acute nicotine administration produces quantifiable increases in 
cardiovascular measures including heart rate and blood pressure, as well as some consistent 
subjective effects.  These effects are important as they may be associated with initiation of 
tobacco smoking and the progression to chronic use.  Chronically, nicotine administration may 
be associated with differing symptoms that influence patterns of tobacco use and maintenance.  
Chronic Effects of Nicotine in Humans  
Clinical examinations concerning the chronic effects of nicotine are numerous and, 
similar to acute studies, administration can be achieved via a variety of means (e.g., i.v., nicotine 
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nasal spray, transdermal nicotine patch).  While chronic administration of nicotine is associated 
with comparable cardiovascular and subjective effects to that of nicotine administered acutely, 
there are other phenomena associated with chronic nicotine administration.  These phenomena 
include tolerance to the cardiovascular effects of nicotine and abstinence-related effects.  
Tolerance is an adaptive change of an organism in response to repeated drug administration such 
that there is a reduced effect and increasingly larger doses are required to produce the same 
effect obtained with smaller doses (Kalant, LeBlanc, & Gibbins, 1971).  Abstinence-related 
effects are a set of adverse symptoms that can appear when nicotine administration is terminated 
or reduced, and these effects can be suppressed by re-administration of nicotine (Hughes & 
Hatsukami, 1986; Breland, Evans, Buchhalter, & Eissenberg, 2002).  
Both acute and chronic tolerance to the cardiovascular-related effects of nicotine can be 
observed in smokers.  Acute tolerance is associated with smaller responses to repeated 
administrations of a drug dose during a single session or short period, while chronic tolerance is 
indicated by both a history of drug exposure and the observation of a reduced response to a drug 
dose (Kalant et al., 1971).  One study that demonstrates the distinction between acute and 
chronic tolerance to the cardiovascular effects of nicotine was performed among ten “heavy” (≥ 
20 cigarettes per day) smokers and eight “light” (< 20 cigarettes per day) smokers using a two-
session mixed study design (Perkins, Epstein, Stiller, Marks, & Jacob, 1989).  During sessions, 
participants received four administrations of nicotine via measured nasal spray every twenty 
minutes and sessions differed by nicotine dose administered: high nicotine (15 μg/kg 
approximately equal to a typical cigarette) or low nicotine (7.5 μg/kg).  Heart rate was monitored 
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during the five minutes following each administration.  Analyses of the data collected two 
minutes after nicotine administration suggested acute tolerance to the nicotine-related increase in 
heart rate in both groups, which was indicated by a decline in mean heart rate increase from 
administration 1 to administration 4.  For example, the low dose of 7.5 μg/kg at administration 1 
produced a mean 6.4 bpm increase and at administration 4 produced a mean 3.9 bpm increase.  
In modest support of chronic tolerance, mean baseline heart rate did not differ between the light 
and heavy smokers, but results indicated that relative to the light smokers, heavy smokers had 
significantly smaller heart rate increases in response to the high doses of nicotine (Perkins et al., 
1989).  This study indicates that both light and heavy smokers demonstrate acute cardiovascular 
tolerance, and more frequent self-administration of nicotine is associated with an enhanced 
tolerance effect.   
In addition, tolerance to the subjective effects of chronically administered nicotine has 
been assessed in the clinical laboratory.  A group of eight smokers and seven non-smokers 
participated in a study consisting of three sessions that differed by nicotine dose administered (0, 
7.5, or 15 μg/kg via nasal spray; Perkins et al., 1993).  Nicotine doses were given every thirty 
minutes for two hours, and thirty minutes after the last dose a challenge dose of 30 μg/kg was 
administered among the smokers only.  Prior to each session, participants abstained overnight 
from nicotine, caffeine, and food.  Subjective outcome measures included VAS items assessing 
“jittery”, “light-headed”, “relaxed”, “dizzy”, and “head rush” and specific scales from a mood-
related measure, the Profile of Mood States (POMS; McNair, Lorr, & Droppleman, 1971).  
Results indicated dose-dependent changes in most subjective measures.  These changes included 
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those observed during acute nicotine studies (e.g., increases in “head rush”, “light-headed”, and 
“jittery”).  In addition, responses to some of scales/items tended to be smaller in the smokers 
relative to the non-smokers.  For example, among smokers and non-smokers nicotine 
significantly increased scores on the VAS scales of “lightheaded” and “dizzy”, but smokers’ 
responses were significantly smaller relative to those of nonsmokers for these two items.  For the 
item “light-headed” relative to baseline, 7.5 μg/kg of nicotine increased non-smokers’ scores 
approximately 20 points and increased smokers’ scores approximately 8 points.  In addition, a 
contrast in subjective effects between smokers and non-smokers was observed for the POMS 
scales of vigor, tension, arousal, and fatigue.  Relative to baseline, nicotine tended to increase 
smokers’ low baseline levels of vigor, decrease their ratings of tension, and had little effects on 
arousal and fatigue, while nicotine decreased nonsmokers’ levels of arousal and vigor and 
increased fatigue and tension.  For example, on the vigor scale, 7.5 μg/kg of nicotine decreased 
non-smokers’ scores approximately 6 points and increased smokers’ scores approximately 2 
points.  These differences may reflect the suppression of abstinence-related symptoms in the 
smokers, and the induction of adverse nicotine-related symptomology in the non-smokers.  This 
study provides some evidence for the consistency of subjective response to nicotine as well as 
demonstration of tolerance to the some of the subjective effects of nicotine.  Importantly, this 
study also highlights the effects abstinence-related symptoms and their suppression may incur 
upon smokers’ behavior (i.e., decreased tension and increased vigor; Perkins et al., 1993).   
Evidence from the clinical laboratory indicates that aversive tobacco abstinence-related 
symptoms occur reliably and that administration of a cigarette or pharmacologically pure 
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nicotine can suppress these symptoms.  For example, in an early clinical study of fifty smokers, 
the signs and symptoms of tobacco abstinence during two days of ad-libitum smoking and during 
the first four days of tobacco abstinence were examined (Hughes & Hatsukami, 1986).  Relative 
to days during ad-libitum smoking, during abstinence participants reported increases in ratings of 
anxiety, craving, difficulty concentrating, eating, hunger, impatience, irritability, and 
restlessness.  Decreases in ratings of sleep adequacy and heart rate were also noted during the 
abstinence phase.  To verify these self-reported symptoms, observers were recruited to rate each 
participant on an identical scale for the following symptoms: anxiety, drowsiness, fatigue, 
impatience, irritability, restlessness, and somatic complaints.  All observer ratings were 
significantly related to the corresponding participant ratings.  This study demonstrated that 
tobacco abstinence effects can be measured reliably by both participant-reported symptoms and 
observer-rated signs (Hughes & Hatsukami, 1986).  In another clinical examination of tobacco 
abstinence, participants could press a button on a keyboard to obtain puffs of a cigarette under a 
progressive ratio schedule (Willner, Hardman, & Eaton, 1995).  Participants were either tobacco 
abstinent or smoked normally for the four hours prior to the session.  Significantly increased 
breakpoints were observed in the tobacco abstinent participants (i.e., abstinent participants were 
willing to perform more work to obtain cigarette puffs; Willner et al., 1995).  These results 
demonstrate tobacco abstinence symptomology and how tobacco abstinence can influence 
subsequent nicotine self-administration.  
Smoking-induced abstinence symptom suppression has also been studied in the 
laboratory, and there is little doubt that cigarette smoking and administration of 
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pharmacologically pure nicotine suppresses abstinence effects.  For example, in a short-term 
clinical examination of 20 cigarette smokers (> 15 per day for the past year) who were required 
to be overnight tobacco abstinent prior to each session, own brand cigarette administration was 
associated with a significant decrease on multiple measures of tobacco abstinence including 
“urges to smoke”, “restlessness”, “irritability”, and “craving a cigarette” (Breland et al., 2002).  
Similar abstinence suppression effects have been noted in other studies of tobacco abstinent 
smokers and the changes that occurred during own brand cigarette administration (Buchhalter & 
Eissenberg, 2000; Breland, Kleykamp, & Eissenberg, 2006).  A clinical examination of the 
effects of transdermal nicotine in smokers abstaining from tobacco/nicotine for at least 8 hours 
showed that transdermal nicotine induced partial abstinence symptom suppression (Kleykamp, 
Jennings, Sams, Weaver, & Eissenberg, 2008).  A multi-center, randomized, placebo-controlled 
study conducted among a large group of smokers who quit by using either active or inactive 
nicotine gum for three days showed that smokers using active nicotine gum experienced 
significantly greater craving reductions following exposure to smoking cues relative to inactive 
gum users (Shiffman et al., 2003).  These reports support the notion that own brand cigarettes 
and pharmacologically pure nicotine can suppress tobacco abstinence-related symptomology.  
In summary, chronic nicotine administration is associated with an array of effects that are 
similar to those observed with acute nicotine administration (cardiovascular and subjective) as 
well as those that are not (chronic tolerance and abstinence-related effects).  The relationship 
between the acute and chronic effects of nicotine and patterns of tobacco use initiation and 
maintenance may be better illustrated by examining them collectively. 
 13 
How Do Nicotine’s Acute and Chronic Effects Influence Patterns of Tobacco Use Initiation 
and Maintenance? 
The acute and chronic effects of nicotine have an important bearing on patterns of 
tobacco use initiation and maintenance.  Focusing specifically on cigarette smoking, a primary 
mode of nicotine self-administration, this behavior can provide pleasurable effects in the short-
term while long-term cigarette smoking can lead to adverse effects during abstinence periods.  
These effects, pleasurable and adverse, encourage both tobacco use initiation and maintenance of 
tobacco use via positive and negative reinforcement. 
Positive reinforcement: cigarette smoking. Because nicotine is a stimulant drug that 
cigarette smokers self-administer, and because stimulant drugs often act as positive reinforcers 
(e.g., amphetamine, Rush, Essman, Simpson, & Baker, 2001; caffeine, Griffiths & Woodson, 
1988; cocaine, Higgins, Bickel, & Hughes, 1994) initial tobacco use episodes may be reinforced 
positively (i.e., produce direct effects that make subsequent drug self-administration more likely; 
Koob & Le Moal, 1997; Koob, 1999).  This positive reinforcement may be a result of the acute 
effects described in the previous section at least some of which are likely mediated by the CNS 
dopamine system activation (Benowitz, 2008).  While preclinical research has demonstrated 
repeatedly that nicotine administration is associated with dopamine system activation (e.g., 
Corrigall et al., 1994), recent advances in neuroimaging have enabled researchers to observe 
real-time changes in human neurobiology in response to nicotine administration via cigarettes.  A 
group of sixty-two smokers participated in a within-subject double blind study to examine 
dopamine release before and after smoking either a nicotinized or denicotinized cigarette (Brody 
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et al., 2009).  Positron emission tomography was used to examine neurochemical changes that 
occurred in the immediate thirty minutes after smoking.  Results indicated that the nicotinized 
cigarette produced greater dopamine release relative to the denicotinized cigarette, and increased 
dopamine release was associated with more mood improvement (assessed via subjective 
measures before and after smoking; Brody et al., 2009).  Consistent with other evidence, these 
results strengthen the claim that some of the reinforcing properties of nicotine administration 
may be mediated by dopamine release.   
Other evidence that supports the role of dopamine release in tobacco dependence is the 
pharmacotherapy, varenicline. This drug is a selective nicotinic receptor partial agonist, which 
causes a moderate and sustained release of mesolimbic dopamine (Coe et al., 2005).  This type of 
action is in contrast to nicotine which acts as a nicotine receptor agonist and incurs a strong and 
short-lived dopamine release (Julien, 2005).  Varenicline’s slow release of dopamine is believed 
to counteract nicotine-related withdrawal symptoms during abstinence (Coe et al., 2005).  A 
meta-analysis of varenicline’s cessation success was recently conducted and at standard dose 
levels, varenicline increased the probability of successful abstinence 2 to 3 times compared to 
unassisted quit attempts (Cahill, Stead, & Lancaster, 2011). In addition, more individuals 
abstained successfully with varenicline compared to buproprion and among two open-label trials 
versus nicotine replacement therapy, varenicline was observed to have a small benefit (Cahill et 
al., 2011). These findings using a partial agonist suggest patterns of dopamine activation and 
inactivation are important for maintaining and sustaining patterns of tobacco use.  
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The link between nicotine-induced neurobiological effects including dopamine system 
activation and patterns of tobacco use initiation has been addressed by many models.  One model 
suggests that the first several drug use episodes cause a brief decrease in reward threshold (Koob 
& Le Moal, 1997; Koob, 1999).  This decrease in reward threshold leads to the perception of 
events that are usually perceived as neutral to be perceived as pleasant, and events that are 
usually perceived as pleasant to be perceived as more pleasant.  These drug-induced changes in 
the hedonic value of events increase the likelihood of subsequent or chronic drug self-
administration (i.e., are positively reinforcing; Koob & Le Moal, 1997; Koob, 1999).  Evidence 
supporting this model can be observed during examinations of the acute effects of nicotine 
administration.  These acute effects, which include positive subjective and stimulant-like 
cardiovascular effects, may positively reward initial tobacco use episodes increasing the 
likelihood for chronic use.  Chronic use of nicotine also produces neurobiological effects, some 
of which may be long-lasting neural adaptations, influencing the progression to tobacco 
dependence. 
Negative reinforcement/dependence: cigarette smoking. While initial drug use 
episodes (i.e., cigarette smoking) are reinforced positively, chronic drug administration changes 
the organism’s underlying neurobiology and may make negative reinforcement more relevant in 
explaining chronic drug use (Koob & Le Moal, 1997; Koob, 1999).  For example, one study 
examined the long term changes in brain dopaminergic parameters and nicotinic receptors in 
response to smoking among autopsy samples from normal elderly individuals with an identified 
smoking status and a specific genotype (Court et al., 1998).  Findings indicated dopamine 
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turnover was reduced and levels of dopamine receptors were unchanged in the smokers 
compared to age-matched non-smokers, despite the finding of increased numbers of high-affinity 
nicotine receptors observed in smokers’ brain areas (hippocampus, cerebellum, and striatum).  
This group reported their findings (i.e., reduced turnover and increased nicotine receptors) as 
consistent with the attenuated efficacy of these receptors in smokers (Court et al., 1998).  Results 
indicated the possibility that chronic cigarette smoking was associated with a reduction of 
dopaminergic neuron firing in the nigrostriatal region of the brain (Court et al., 1998).  
According to one model, these and other changes in neurobiology may indicate an overall 
increase in the baseline reward threshold in chronic smokers (Koob & Le Moal, 1997; Koob, 
1999).   
This increased reward threshold is less apparent when the drug is being administered, but 
becomes more noticeable when the drug is not administered.  In a drug dependent organism with 
an increased reward threshold and no access to drug, events that are usually perceived as neutral 
are perceived as unpleasant, and events that are usually perceived as pleasant are perceived as 
neutral (Koob & Le Moal, 1997; Koob, 1999).  In terms of cigarette smoking (i.e., nicotine self-
administration), chronic nicotine exposure may alter the dopamine system and thus may increase 
the smoker’s reward threshold.  This increased threshold becomes more apparent during periods 
of tobacco abstinence, when an aversive syndrome appears (e.g., Hughes & Hatsukami, 1986; 
Breland et al., 2002).  Interestingly, according to the model, drug administration has the potential 
to decrease reward threshold temporarily, even in the dependent organism (Koob & Le Moal, 
1997).  When the reward threshold is reduced, the perception of events is altered (i.e., events 
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perceived as unpleasant are perceived as neutral or pleasant), and this drug-induced alteration of 
events previously perceived as unpleasant increases the likelihood of subsequent drug self-
administration.  In this context, these drug administrations in the dependent organism are 
maintained via negative reinforcement (e.g., Eissenberg, 2004).   
In summary, the positive and negative reinforcing effects of tobacco-delivered nicotine 
may have a direct influence on the initiation and maintenance of cigarette smoking.  These 
effects also may be relevant to an alternative tobacco use method that is gaining popularity in the 
U.S.: waterpipe tobacco smoking.  
Nicotine’s role in other forms of tobacco use: waterpipe tobacco smoking. While 
adult cigarette smoking levels in the U.S. are at their lowest in the past twenty years (19.8%; 
CDC, 2008), recent survey results indicate that the prevalence of an alternative form of tobacco 
use, waterpipe tobacco smoking, may be increasing among U.S. adolescents and young adults 
(Eissenberg, Ward, Smith-Simone, & Maziak, 2008; Smith-Simone, Maziak, Ward, & 
Eissenberg, 2008; Primack et al., 2008; Sutfin et al., 2011).  Interestingly, this method of 
smoking is centuries old and has links to the countries of southwest Asia (e.g., Lebanon, Syria; 
see El-Roueiheb et al., 2008; Ward et al., 2006)  and north Africa (Egypt; El-Setouhy et al., 
2008).  Tobacco waterpipes most often seen in the U.S. have a fired-clay head, metal body, glass 
or acrylic water bowl, and leather or plastic hose (see Figure 1). The bowl is partially filled with 
water and the head is filled with waterpipe tobacco (sweetened and flavored tobacco) upon 
which a lit piece of charcoal is placed (separated from the tobacco by perforated aluminum foil).  
Charcoal is necessary to heat the moistened waterpipe tobacco sufficiently to produce smoke 
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Figure 1. Typical waterpipe apparatus. A waterpipe prepared for tobacco smoking, including 
perforated foil separating the charcoal from the tobacco that has been placed in the head.  
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when the smoker inhales and draws air over the burning charcoal.  The smoke then travels 
through the waterpipe, the water, and finally into the hose to the user (Shihadeh, 2003).  Among 
U.S. college students, prevalence estimates of past 30-day waterpipe tobacco smoking range 
from 10-20% (Eissenberg et al., 2008; Primack et al., 2008; Sutfin et al., 2011).  This U.S. 
prevalence estimate is surprisingly high for a tobacco smoking method associated with the 
southwest Asia and north Africa.  Indeed, waterpipe tobacco smoking appears to be spreading 
globally (e.g., Maziak, Ward, Soweid, & Eissenberg, 2004; WHO, 2005; Cobb, Ward, Maziak, 
Shihadeh, & Eissenberg, 2010), and this spread is likely due to several factors.. 
Factors Contributing to the Global Spread of Waterpipe Tobacco Smoking 
Several factors may be contributing to the global spread of waterpipe tobacco smoking, 
including the perception that waterpipe smoke is less dangerous than cigarette smoke, the easy 
access to flavored waterpipe tobacco, and the fact that waterpipes deliver the reinforcing 
stimulant drug nicotine.  
Misconceptions regarding waterpipe tobacco smoking. One factor that may be 
contributing to the global spread of waterpipe tobacco smoking is the perception that waterpipe 
smoke is less dangerous than cigarette smoke.  This perception has been reported in virtually 
every survey of waterpipe tobacco smokers, from Syria (Maziak, Eissenberg, et al., 2004) to 
England (Jackson & Aveyard, 2008) to Canada (Roskin & Aveyard, 2009) and the U.S. (Smith-
Simone et al., 2008; Smith, Curbow, & Stillman, 2007).  Interestingly, studies that have 
examined waterpipe smoke toxicant content do not support this perception: like cigarette smoke, 
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waterpipe smoke contains nicotine, carbon monoxide (CO), and “tar” containing potent 
carcinogens (Shihadeh, 2003; Shihadeh & Saleh, 2005; Maziak et al., 2009).  Moreover, 
waterpipe smoking behavior (i.e., “topography”) is dramatically different than cigarette 
topography, such that, during a typical 45-minute waterpipe tobacco smoking episode, the 
smoker inhales 50-100 times more smoke than during a 5-minute cigarette smoking episode (see 
Table 1; Cobb et al., 2011).  Cross-study comparisons indicate that, relative to a single cigarette, 
the smoke produced by a 45-minute waterpipe tobacco smoking episode contains 1.7 times the 
nicotine, 6.5 times the CO, and 46 times the “tar” (Shihadeh & Saleh, 2005; Djordjevic, 
Stellman, & Zang, 2000).  Taken in sum, these data concerning waterpipe tobacco smoke 
toxicant content and smoker topography suggest that waterpipe smoke is not less dangerous than 
cigarette smoke, and support growing public health concern and calls for more research 
regarding this tobacco use method (e.g., Maziak, 2008; El-Nachef & Hammond, 2008; Klein, 
2008; WHO, 2005). 
Easy access to flavored waterpipe tobacco.  Another factor that may contribute to the 
global spread of waterpipe use involves easy access of waterpipe products (via the internet with 
little regulation or age verification) that include sweetened and flavored waterpipe tobacco.  
Tobacco used for waterpipe tobacco smoking is distinctly different than the types and 
preparations found in cigarettes or other smokeless tobacco products (see Figure 2).  Although 
other forms exist, the most popular type of waterpipe tobacco preparation is known as ma’assel 
(i.e., “honeyed” tobacco; Knishkowy & Amitai, 2005; Shihadeh, 2003).  Ma’assel preparations   
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Table 1.  
Mean puff topography for waterpipe users and cigarette users 
 
 Waterpipe Cigarette 
Topography variable N = 611 N = 522 N =303 N = 564 
Puff number 169.0 171.0 10.0 12.7 
Puff volume (ml) 511.0 530.0 51.0 48.6 
Puff duration (s) 3.21 2.6 1.4 1.5 
Interpuff interval (s) 12.6 15.5 30.7 21.3 
 
1 Maziak et al., 2009 
2 Shihadeh, Azar, Antonios, & Haddad, 2004 
3 Breland et al., 2006 
4 Djordjevic et al., 2000. 
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Figure 2.  Ma’assel waterpipe tobacco products.  Panel A displays a variety of ma’assel 
waterpipe tobacco products.  Panel B displays a ma’assel non-fruit flavor: X on the Beach.  Panel 
C is a typical label for ma’assel tobacco displaying ingredients.  Panel D shows a waterpipe head 
loaded with ma’assel with perforated foil, ready for tobacco smoking.  Panel E is a close-up of a 
typical ma’assel tobacco preparation.  
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contain approximately 30% tobacco and 70% honey, fruit, or molasses as well as sweeteners and 
flavorings (Knishkowy & Amitai, 2005).This blend of ingredients makes the waterpipe 
preparations very moist.  The moistness of the product is one reason charcoal or another heat 
source must be used to the heat waterpipe tobacco to produce smoke.  The variety of flavors of 
waterpipe tobacco is virtually limitless: there are fruit flavors (e.g., apple, peach, strawberry, 
kiwi, watermelon), candy flavors (e.g., bubble gum, chocolate, licorice), alcohol flavors (e.g., 
pina colada, apple martini, margarita), and others (e.g., kashmir, red tea, jasmine, cloves).  In one 
survey of 201 U.S. waterpipe tobacco smokers, 80% cited flavor as one of the reasons that they 
smoke tobacco in a waterpipe (Smith-Simone et al., 2008).  Among 31 regular waterpipe 
smoking participants recruited for a laboratory study of waterpipe smoking in the U.S., fruit 
flavors were most commonly preferred to smoke during their “favorite” brand session 
(Eissenberg & Shihadeh, 2009).  Flavored waterpipe tobacco availability has been cited as 
important in understanding the increase in waterpipe tobacco smoking in Syria (Rastam, Ward, 
Eissenberg, & Maziak, 2004) and may also be relevant to the U.S.  Alarmingly, adolescents and 
young adults in the U.S. can buy waterpipe tobacco and other supplies easily over the internet 
without age verification.  Many companies based in the Eastern Mediterranean Region 
manufacture and import the specialized tobacco, including Al Fakher, Al Waha, Nakhla, 
Romman, and Fumari (American Lung Association, 2007).  In addition, some companies use 
distributors based in the U.S. in order to sell their products more easily, and several U.S. 
companies manufacture and distribute their own brands of the waterpipe tobacco (e.g., Tangiers 
Tobacco LTD, San Diego, CA; Sahara Smoke Company, Statesboro, GA).  Taken together, easy 
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access to a wide variety of flavored waterpipe tobacco may be another factor contributing to the 
spread of waterpipe tobacco smoking to this country. 
Waterpipe tobacco and nicotine. Cigarettes deliver physiologically active nicotine 
doses (Henningfield, Miyasato, & Jasinski, 1985) and these doses of this stimulant drug are 
thought to reinforce subsequent cigarette smoking (e.g., Glautier, 2004; Eissenberg, 2004).  
Several studies suggest that waterpipes also deliver physiologically active nicotine doses.  One of 
the earliest studies to examine waterpipe smoke composition was performed in Lebanon 
(Shihadeh, 2003).  This study incorporated the use of a smoking machine powered by a vacuum 
pump attached to a waterpipe loaded with 10 grams of a common waterpipe tobacco.  The 
machine replicated a standard smoking pattern of 100 puffs of 300 milliliters (ml) that were 3 
seconds long and separated by 30 seconds.  Results indicated an average nicotine yield of 2.25 
mg nicotine from the smoke produced during the entire session (Shihadeh, 2003).  In 
comparison, an average nicotine yield for a low-yield cigarette was 1.74 mg (Djordjevic et al., 
2000).  Unfortunately, the waterpipe toxicant results (Shihadeh, 2003) are limited in that they 
only report what is present in the smoke and not what is delivered to the smoker.  A clinical 
study that addresses this issue involved 14 men who regularly ( ≥ 3 times per week) smoked 
tobacco using a waterpipe and examined nicotine levels in saliva, urine, and plasma before and 
after a 45-minute waterpipe tobacco smoking episode (Shafagoj, Mohammed, & Hadidi, 2002).  
Prior to the smoking session, participants were required to abstain from tobacco use for at least 
84 hours.  The mean plasma nicotine level prior to smoking was 1.11 ng/ml (SD = 0.62) and 
after smoking was 60.31 ng/ml (SD = 7.58 ng/ml).  The mean saliva nicotine level rose from 
 25 
1.05 ng/ml (SD = 0.72) to 624.74 ng/ml (SD = 149.3) ng/ml after smoking.  The mean amount of 
nicotine excreted during the 24-hour urine collection following smoking was equal to 
approximately 73.59 μg (SD = 18.28; Shafagoj et al., 2002).  In further support of waterpipe 
tobacco smoking’s ability to deliver nicotine, a recent meta-analysis of six waterpipe studies that 
measured nicotine or cotinine levels in human participants suggested that daily use of a 
waterpipe to smoke tobacco produced a 24-hr urinary cotinine level equivalent to that produced 
by smoking 10 cigarettes/day (Neergaard, Singh, Job, & Montgomery, 2007).  However, until 
recently, there have been no published placebo controlled studies demonstrating conclusively 
that waterpipe tobacco smokers are exposed to physiologically active nicotine doses.   
One study performed at VCU has addressed this gap in the literature concerning the 
nicotine-related physiological effects with waterpipe tobacco smoking (Blank et al., 2011).  This 
study was a within-subject, double-blind, randomized design that included thirty-seven 
participants who were occasional waterpipe smokers (2-5 waterpipes per month; Blank et al., 
2011).  In each condition participants smoked a waterpipe loaded with 10 grams of a normally-
marketed waterpipe product.  In one condition the product was the participant’s preferred flavor 
of waterpipe tobacco, and in the other, the product was the same flavor of a non-tobacco 
preparation marketed for use in waterpipes (see www.soex.com/herbalmolasses.html).  Results 
demonstrated clearly that, under these conditions, waterpipe tobacco smokers are exposed to 
nicotine (mean plasma increase=3.6 ng/ml, standard error of mean [SEM]= 0.7).  In addition, the 
results indicated that this exposure increased as the duration of smoking increased, and that the 
nicotine was physiologically active. During the tobacco session, the mean (± SEM) heart rate 
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increase was 8.6 ± 1.4 bpm while during the non-tobacco the mean heart rate increase was 1.3 ± 
0.9 bpm (Blank et al., 2011).  
Another study reveals waterpipe tobacco smoking-associated subjective effects (Maziak 
et al., 2009).  Sixty-one waterpipe tobacco smokers, who were overnight tobacco abstinent, were 
asked to smoke a waterpipe ad libitum in a laboratory using their preferred waterpipe tobacco 
brand and flavor (all participants used a variety of ma’assel).  Participants’ CO levels and 
subjective measures were assessed prior to and after waterpipe tobacco smoking.  Subjective 
questionnaires included VAS items assessing tobacco-related abstinence symptoms (e.g., “urges 
to smoke”, “irritability”) and other nicotine-related items (e.g., “sweaty”, “nauseous”, “dizzy”, 
“light-headed”).  Significant post-smoking decreases were observed for multiple tobacco 
abstinence measures (i.e., “urges to smoke”) and significant post-smoking increases were 
observed for several items associated with the nicotine exposure (i.e., “dizzy”, “light-headed”).   
The results observed in this study support the notion that waterpipe tobacco smoking may relieve 
nicotine abstinence-related effects as well as induce direct effects associated with nicotine 
administration (Maziak et al., 2009).  
The three factors discussed above, misperceptions of waterpipe tobacco smoking, access 
to flavored tobacco, and nicotine exposure, may be contributing the global increase in waterpipe 
tobacco smoking.  Another factor that may contribute to the reinforcing effects of waterpipe 
tobacco smoking is the co-administration of another mild psychomotor stimulant: caffeine. 
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Caffeine’s Pharmacokinetics and Pharmacodynamics  
Caffeine is the most commonly consumed psychoactive substance in the world (Nehlig, 
Daval, & Debry, 1992) and approximately 80% of the U.S. population consumes caffeine daily 
in some form (Hughes, Oliveto, Bickel, Higgins, & Badger, 1993).  In contrast to the tobacco-
related health effects of nicotine, caffeine is associated with few known health risks and low 
abuse liability (Daly & Fredholm, 1998).  
Generally, caffeine is classified a psychomotor stimulant and is consumed usually in 
beverages.  In humans, orally ingested caffeine is rapidly absorbed from the gastrointestinal tract 
and increased blood plasma levels are reached within 30 to 45 minutes; complete absorption 
occurs over the next 90 minutes (Newton et al., 1981; Fredholm, Battig, Holmen, Nehlig, & 
Zvartau, 1999).  The half-life of caffeine is about 3.5 to 5 hours in most people (Newton et al., 
1981; Julien, 2005, p. 227).  Once absorbed, caffeine produces stimulant-like effects in the 
central nervous system as well as cardiac, respiratory, and diuretic effects.  Common behavioral 
effects in humans include descriptions of enhanced alertness, energy, wakefulness, and fatigue 
reduction (see Daly & Fredholm, 1998; Griffiths & Mumford, 1996), but these effects are often 
dose-dependent.  Large doses of caffeine can cause adverse symptoms such as agitation, anxiety, 
tremors, rapid breathing, and insomnia (Ashton, 1987; Chait, 1992; Schuh & Griffiths, 1997; 
Griffiths & Mumford, 1996).  This diverse array of effects may be associated with caffeine’s 
different mechanisms of action at high versus low doses (Daly & Fredholm, 1998; Garrett & 
Griffiths, 1997). 
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In doses regularly achieved by humans, caffeine’s primary mechanism of action is as a 
competitive adenosine receptor antagonist (Nehlig et al., 1992; Daly & Fredholm, 1998).  
Adenosine is a neuromodulator that stimulates the release some neurotransmitters in the CNS; it 
also acts as a vasodilator and can exert sedative, depressant, and anticonvulsant actions 
(Eltzschig, 2009; Hasko, Linden, Cronstein, & Pacher, 2008; Julien, 2005, p. 229).  Currently, 
there are four common adenosine receptors denoted A1, A2A, A2B, and A3 (Jacobson, 2009).  By 
blocking adenosine receptors, primarily A1 and A2A (G-protein coupled), caffeine’s effects are 
often described as opposite to those of adenosine.  Adenosine A1 receptors are present in almost 
all brain areas (Goodman & Snyder, 1982; Fastbom, Pazos, Probst, & Palacios, 1987) and appear 
to be present on cell bodies as well as nerve terminals.  Adenosine A2A receptors are more 
strongly expressed in the striatum, nucleus accumbens, and tuberculum olfactorium (Fredholm et 
al., 1999; Parkinson & Fredholm, 1990; Schiffmann et al., 2003; Schiffmann, Fisone, Moresco, 
Cunha, & Ferré, 2007).  Specifically in the striatum, there is evidence of a colocalization of A2A 
and D2 receptors (Svenningsson et al., 1997) and A1 receptors and D1 and D2 receptors (Ferre et 
al., 1996; Agnati, Ferre, Lluis, Franco, & Fuxe, 2003; Franco et al., 2007).  This co-expression 
may account for caffeine’s mediation of neurotransmitter release including dopamine within this 
system (Ferre, 2008; Latini, Pazzagli, Pepeu, & Pedata, 1996). Also in support of this hypothesis 
is the finding that some effects of caffeine can be blocked by selective D1 and D2 antagonists, 
and caffeine can also potentiate effects produced by indirectly acting dopamine receptor agonists 
like amphetamine (Schechter, 1977) and cocaine (Misra, Vadlamani, & Pontani, 1986). These 
results suggest that caffeine administration may activate dopaminergic systems indirectly.   
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There is still debate as to whether other unknown receptor systems also may be 
responsible for caffeine’s array of effects (Daly & Fredholm, 1998).  Chronic caffeine exposure 
results in the development of tolerance to many acute effects including physiological, subjective, 
and behavioral effects (see Griffiths & Mumford, 1996).  This tolerance may be associated with 
the alteration of receptor densities (e.g., up regulation of the A1 adenosine receptors), which 
occurs in response to chronic caffeine administration (Ferré, 2008; Johansson, Georgiev, 
Lindström, & Fredholm, 1997).  Taken together, caffeine’s mechanism of action both acutely 
and chronically may account for the various effects associated with its use. 
Acute Effects of Caffeine  
Similar to nicotine, caffeine is a stimulant drug that users self-administer, and the acute 
physiological and subjective effects associated with caffeine administration may act as a positive 
reinforcer for subsequent use (Smith, 2002; Garrett & Griffiths, 1997).  Like other drugs that act 
as positive reinforcers, caffeine administration is associated modestly with dopamine system 
activation.  There is debate to whether caffeine induces dopamine concentration increases in 
areas usually associated with drugs of abuse (i.e., nucleus accumbens, VTA, striatum), but there 
is evidence of dopamine increase in some areas of the brain following caffeine administration 
(Solinas et al., 2002; Acquas, Tanda, & Di Chiara, 2002).  Some believe the mechanism for 
dopamine release associated with caffeine administration is due to both presynaptic and 
postsynaptic activity in the striatum, due to the presence of A1 and A2A receptors in both areas as 
well as their colocalization with dopamine receptors (D1 and D2; Ferré, 2008).  
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Preclinical research has demonstrated some areas of the brain are associated with 
dopamine concentration increases following acute caffeine administration.  One study examined 
the effects of caffeine on extracellular dopamine in freely moving rats implanted with probes in 
the nucleus accumbens shell and core and in the medial prefrontal cortex (Acquas et al., 2002).  
This study included five caffeine doses (0.25, 0.5, 1.0, 2.5, and 5.0 mg/kg) administered i.v. and 
four caffeine doses (1.5, 3, 10, and 30 mg/kg) administered intraperitoneally (i.p.).  For the 
caffeine doses administered i.v., researchers observed dose dependent dopamine concentration 
increases in the medial prefrontal cortex while levels in the nucleus accumbens were unaffected.  
These concentration peak effects appeared 10, 20, or 30 minutes after administration depending 
on dose.  The dopamine concentrations after the i.p. caffeine doses were tested only in the 
nucleus accumbens shell and core and produced no significant changes in dopamine 
concentrations.  The effects of i.v. administered caffeine (i.e., dopamine increases in prefrontal 
cortex and none in the nucleus accumbens) were duplicated after intravenously administering 
doses of either an adenosine A1 receptor antagonist or A2A receptor antagonist (Acquas et al., 
2002).  A similarly designed study which examined the effects of four doses of caffeine (3, 10, 
30 and 100 mg/kg) delivered i.p. on dopamine concentrations in the nucleus accumbens shell and 
core reported contrasting results (Solinas et al., 2002).  In the shell of the nucleus accumbens, 10 
and 30 mg/kg caffeine doses were observed to produce significant increases in extracellular 
concentrations of dopamine, but at other caffeine doses, effects were not significantly different 
than saline.  In the core of the nucleus accumbens, only the 30 mg/kg dose of caffeine produced a 
significant increase in dopamine levels, but this effect was lower and significantly different than 
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the increase observed in the nucleus accumbens shell.  The effects in the nucleus accumbens 
shell were duplicated after intravenously administering doses of an adenosine A1 receptor 
antagonist, but not after administering an A2A receptor antagonist (Solinas et al., 2002).  Both of 
these findings differ from those of nicotine, which unequivocally increases dopamine 
concentrations in nucleus accumbens core and shell (see Ponteri, Tanda, Orzi, & Di Chiara, 
1996; Watkins, Koob, & Markou, 2000) via stimulation of dopamine releasing neurons.  
Importantly, an absence of dopamine release in the either the nucleus accumbens shell or core, 
which is linked to the reinforcement and reward properties of many drugs of abuse, does not 
imply that caffeine lacks these actions.   
Some clinical research suggests that caffeine has acute positive effects that reinforce use.  
One early survey revealed that coffee drinkers report having coffee in the morning because of its 
pleasant taste and stimulating effects, and heavy (≥5 cups per day) coffee drinkers were more 
likely to report these reasons (Goldstein & Kaizer, 1969).  In addition, more heavy coffee 
drinkers emphasized the increased sense of well-being associated with coffee drinking, and cited 
that coffee increased alertness and activity (Goldstein & Kaizer, 1969).  Given that caffeine users 
can identify several positive effects associated with coffee drinking, positive reinforcement may 
be a factor influencing caffeine use.   
Other more controlled clinical laboratory designs have examined the acute subjective 
effects associated with caffeine administration (Bruce, Scott, Lader, & Marks, 1986; Garrett & 
Griffiths, 2001; Childs & de Wit, 2006).  In a recent study, 102 light caffeine users (< 300 mg 
per week from diet) were recruited to participate in four double-blind laboratory sessions that 
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differed by caffeine dose administered via capsule (0, 50, 150, or 450 mg; Childs & de Wit, 
2006).  Participants were overnight caffeine abstinent prior to any session, and subjective 
measures included the POMS and VAS scaled items (e.g., “Do you feel any drug effect?”, “Are 
you high?”, and “stimulated”).  Results indicated that relative to placebo the 450 mg dose 
significantly increased ratings of “feel drug” and “drug high” and both the 150 mg and 450 mg 
dose significantly increased ratings of “stimulated”.  The authors concluded that at the doses 
tested in this study, caffeine could produce some beneficial mood enhancing effects (Childs & de 
Wit, 2006).  These results and other laboratory examinations of caffeine (see also Garrett & 
Griffiths, 2001; Bruce et al., 1986) indicate that caffeine may produce acute positive subjective 
effects in humans. 
The clinical laboratory has also been used to demonstrate cardiovascular effects 
associated with acute caffeine administration.  A placebo controlled within-subject examination 
of caffeine doses of 100, 300, and 400 mg delivered via capsules was performed among six 
participants who were at least daily coffee drinkers (Astrup et al., 1990).  Participants abstained 
overnight from tobacco, food, and all caffeinated products.  Outcome measures included heart 
rate and blood pressure.  Relative to placebo, measures of heart rate after all doses of caffeine did 
not show any significant increases, but there was a trend for decreased heart rate following 
caffeine administration.  For systolic and diastolic blood pressure, small increases were observed 
after the 100 and 200 mg caffeine doses, but these increases were not significantly different from 
placebo.  In contrast, the 400 mg caffeine dose significantly increased systolic blood pressure 
and diastolic blood pressure (average increase for both was 6.5 mm Hg).  Limiting these results 
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was the sample size and use of only one cardiovascular measurement per post-administration 
time point (Astrup et al., 1990).  This study is a good example of common cardiovascular effects 
associated with acute caffeine administration (i.e., increased blood pressure and little change in 
heart rate), as well as common methodological issues (i.e., small sample size).  
Two separate reviews of caffeine and cardiovascular-related effects literature support the 
notion that acute caffeine administration is associated with an increase in blood pressure and 
often little change in heart rate (Mort & Kruse, 2008; Nurminen, Niittynen, Korpela, & 
Vapaatalo, 1999).  Among twenty studies that used a controlled design, random selection, and a 
population of normotensive participants, a single dose of caffeine of 200-250 mg (approximately 
2-3 cups of coffee) on average produced an increase of 3-14 mm Hg systolic and 4-13 mm Hg 
diastolic pressure (Nurminen et al., 1999).  Blood pressure elevations in response to caffeine 
were reported to occur within 30 minutes post-administration with maximal increases occurring 
60-120 minutes after caffeine intake (Nurminen et al., 1999).  In addition, this review indicated 
that acute caffeine administration may be associated with little change or a slight decrease in 
heart rate (Nurminen et al., 1999).  Both literature reviews indicated that many factors may 
impact an individual’s cardiac response to caffeine including dose, administration route, caffeine 
use history, and risk/history of hypertension (Mort & Kruse, 2008; Nurminen et al., 1999).  
 Overall, individual laboratory data and literature reviews examining the acute 
cardiovascular and subjective effects of caffeine indicate that caffeine administration may 
produce positive subjective effects, quantifiable increases in blood pressure, and little to no 
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change in heart rate.  These acute subjective and cardiovascular effects may impact the positive 
reinforcement-related effects of caffeine use.  
Unlike some drugs of abuse (e.g., nicotine), evidence concerning caffeine’s ability to 
produce reinforcing effects leaves many unconvinced despite numerous laboratory-based studies 
that have examined the acute reinforcing effects of caffeine (Griffiths & Woodson, 1988; Evans, 
Critchfield, & Griffiths, 1994).  One double-blind design assessed the reinforcing effects of 
caffeine among twelve regular caffeine users (Griffiths & Woodson, 1988).  Each caffeine 
condition consisted of a three day sequence where each experimental session day, participants 
orally ingested two color-coded capsules.  One capsule always contained placebo and the other 
contained 0, 100, 200, 400, or 600 mg of caffeine.  Two days were forced exposure days where 
participants received two different types of color-coded capsules (e.g., red then green), followed 
by a choice day.  On the choice day, participants could choose the color of capsule they received.  
The exposure and choice procedure periods were repeated for each dose of caffeine.  Subjective 
effect measures included scales from the POMS, mood-related items rated using a four-point 
scale (e.g., “alert/attentive/observant/able to concentrate”, “active/stimulated/energetic”, 
“jittery/nervous/shaky” headache”), and a general “liking” scale of capsule effects.  Although the 
variability across participants was high, a significantly greater percentage of participants chose to 
receive caffeinated capsules after a pairing with 100 mg or 200 mg caffeine dose, and these 
choices diminished at the higher caffeine doses.  Subjective effect data indicated that caffeine 
administration produced significant increases in ratings of “liking” and 
“active/stimulated/energetic” as well as significant decreases in ratings of 
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“sleepy/tired/drowsy/half-awake” and “headache”.  Higher doses of caffeine increased some of 
these subjective effects.  Using the choice data for their basis, the authors of this study reported 
significant caffeine positive reinforcement was demonstrated in five of the twelve subjects at one 
or more caffeine doses (Griffiths & Woodson, 1988).  Similarly, another study found that 
caffeine deprived and non-deprived individuals picked caffeine over a placebo in 80% of choice 
trials (Evans et al., 1994).  Results from these studies suggest that on some level, caffeine does 
positively reinforce use. 
In summary, the acute effects of caffeine include modest increases in dopamine release  
in some areas of the brain, positive subjective effects, predictable cardiovascular responses (i.e., 
increased blood pressure, decreased heart rate), and reinforcing effects.  While acute caffeine 
effects may increase the likelihood of subsequent or chronic use of caffeine via positive 
reinforcement, like nicotine, chronic caffeine ingestion may impact users differently via 
tolerance and the suppression of abstinence-related symptomology (i.e., negative reinforcement).  
Chronic Effects of Caffeine 
Like many drugs of abuse (e.g., nicotine) caffeine is capable of producing patterns of 
habitual use.  Chronic or heavy users of caffeine undergo neurobiological and behavioral 
changes in response to caffeine.  As with the dependence model described earlier concerning 
nicotine, these changes in neurobiology may indicate an overall increase in the baseline reward 
threshold in chronic caffeine users (Koob & Le Moal, 1997; Koob, 1999).  There is clear 
evidence that chronic use of caffeine even in daily doses is associated with tolerance (Griffiths, 
& Mumford, 1996), and discontinuation of caffeine use may produce an abstinence syndrome 
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(Juliano & Griffiths, 2004).  Caffeine abstinence symptoms include headache, fatigue, and 
negative mood states (Griffiths & Mumford, 1996).  These symptoms often climax over the first 
1 to 2 days following caffeine abstinence and tend to decrease within a few days (Daly & 
Fredholm, 1998).  Re-administering caffeine often relieves caffeine withdrawal symptoms 
(Juliano & Griffiths, 2004)   
The fact that caffeine consumption reverses the effects of abstinence suggests at least 
some of caffeine’s reinforcing value is prevention of these negative symptoms (Juliano & 
Griffiths, 2004; Strain, Mumford, Silverman, & Griffiths, 1994).  One study performed among 
eleven “caffeine dependent” individuals found strong evidence in support of this theory (Strain et 
al., 1994).  These eleven participants were selected from a larger population using a structured 
clinical interview with classic drug dependence criteria taken from Diagnostic and Statistical 
Manual of Mental Disorders, fourth edition (DSM-IV; American Psychological Association, 
1994).  Post-screening, two double-blind caffeine-abstinence periods of two days in length were 
administered.  Caffeine abstinence periods were achieved by asking participants to adhere to a 
strict diet for two days that restricted caffeine intake although these restrictions were given 
without reference to caffeine (Strain et al., 1994).  Each day during the two-day periods, 
participants received capsules containing in random order, either caffeine (an amount equal to 
their individual average daily caffeine consumption) or placebo.  Capsule administration times 
were spaced throughout the day to match the pattern of the individuals reported caffeine 
consumption (typically three times per day) and assessments occurred on the second day of each 
of the 2-day study periods.  Assessments included the POMS and a checklist that assessed 
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symptoms related to caffeine abstinence (e.g., headache, drowsy/sleepy).  Nine of the subjects 
showed evidence of caffeine abstinence symptomology during the placebo period and seven 
reported maximal ratings of headache during the day they received placebo.  In addition, eight of 
the subjects reported functional impairment in normal daily activities during the placebo periods 
and almost half of the participants also reported use of an analgesic during the placebo period.  
There was only one report of functional impairment during the caffeine period (Strain et al., 
1994).  These results and others (Griffiths, Bigelow, & Liebson, 1986) suggest that caffeine  
alleviates the unpleasant symptoms associated with acute abstinence among chronic users.  
 Further support for caffeine’s ability to act as a negative reinforcer in chronic users 
comes from a double-blind study where 48 moderate caffeine consumers were randomly 
assigned into two groups (caffeine maintenance or abstinence) for two weeks and entered an 
additional two week caffeine conditioning procedure (Tinley, Yeomans, & Durlach, 2003).  
Throughout the 4 week period participants were supplied with drinks (caffeinated or 
decaffeinated) that replaced their normal caffeinated tea and coffee consumption.  During the 
final two week conditioning procedure, all participants attended four non-consecutive laboratory 
sessions where they evaluated a novel drink containing either 100 mg caffeine or placebo.  Prior 
to each conditioning session, participants were asked to only drink water the night before to 
induce acute caffeine abstinence.  During the conditioning sessions, participants were asked to 
rate the novel drink using VAS scales (e.g., “bitter”, “sweet,” and “pleasant”).  Only acutely 
abstaining participants (i.e., the caffeine maintained group) showed an increase in rated drink 
pleasantness for the caffeinated drink during the conditioning phase.  Chronically abstinent 
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participants (i.e., caffeine abstinence group) showed a decrease in ratings of drink pleasantness 
for the caffeinated drink and no change for the decaffeinated drink during conditioning.  These 
data suggest that the ability of caffeine to reinforce changes in ratings of “pleasantness” or 
“flavor liking” are driven by the alleviation of abstinence symptoms among chronic caffeine 
consumers and not by the induction of positive effects (Tinley et al., 2003).  These findings 
highlight caffeine’s role as a negative reinforcer in regular caffeine users. 
Another way of experimentally differentiating the positively reinforcing components 
from the negatively reinforcing components is to use a multiple-choice procedure in which 
participants choose between receiving a drug and receiving different amounts of money.  Using 
this technique to determine how much money moderate caffeine users (mean = 379 mg/day 
caffeine) would sacrifice for caffeine, researchers reported that caffeine was worth an amount not 
significantly different from $0.00, and participants would forfeit on average $2.51 in order not to 
receive the placebo (and instead receive caffeine; Schuh & Griffiths, 1997).  Those who received 
the placebo reported symptoms such as headaches and feeling worn out, and those who had more 
headaches and felt less alert were willing to sacrifice more money in order to avoid the placebo 
(Schuh & Griffiths, 1997).  Based on these results, the authors concluded that caffeine 
consumption is motivated more by desire to avoid negative abstinence effects than by the 
positive effects of caffeine in moderate caffeine users. 
The previous two sections demonstrate that, like nicotine, caffeine offers positive and 
negative reinforcement which according to some models of drug abuse may increase the 
likelihood for subsequent use (Koob & Le Moal, 1997; Koob, 1999).  Interestingly, the 
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rewarding/reinforcing aspects of nicotine and caffeine may also act in combination as they are 
commonly co-administered.  In a review of six epidemiological studies, over 86% of cigarette 
smokers reported daily caffeine use versus 77% of non-smokers (Swanson et al., 1994).  A 
laboratory study of 40 smokers and 40 non-smokers matched on multiple characteristics 
including age, gender, race, and body mass index found an even larger difference: 95% of 
smokers used caffeine versus 75% of non-smokers (p < 0.05; Zhang, Samet, Caffo, Bankman, & 
Punjabi, 2008).  Empirical evidence also indicates that the interaction of these two drugs may 
produce an enhancement of rewarding or pleasurable effects that could impact patterns of 
tobacco use initiation and maintenance. 
Interactions Concerning Nicotine and Caffeine 
Drugs may interact on many levels within an organism.  Already well-defined is the 
finding that the metabolism of caffeine is greatly enhanced in tobacco users (Kroon, 2007; Zevin 
& Benowitz, 1999; Kalow & Tang, 1991).  This increased clearance of caffeine may contribute 
to the higher volumes of caffeine ingested by tobacco users compared to non-smokers (Swanson 
et al., 1994), but it may not account completely for the higher levels of overall use between 
smokers and non-smokers (Swanson et al., 1994; Zhang et al., 2008).  Potentially, tobacco (i.e., 
nicotine administration) and caffeine may be interacting at another site that produces enhanced 
reward/reinforcement-related effects.   
Sophisticated models exist to examine drug interactions in the realm of behavioral 
pharmacology, and there is often some confusion over the terms and definitions used to describe 
results obtained (Mitchell, 1976; Wessinger, 1986; Hertzberg & MacDonell, 2002).  One means 
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of understanding types of drug interactions is by first classifying the relationship between the 
two drugs and the variable of interest into either a hetergic or homergic category (Wessinger, 
1986).  Hetergic drugs are two drugs that do not have similar effects; one drug produces the 
effect measured, and the other does not (e.g., consider two drugs that have opposite effects on 
heart rate).  Homergic drugs are considered drugs that both produce the effects measured (e.g., 
consider caffeine and nicotine’s positive reinforcement-related subjective effects).  Two 
proposed models to examine homergic drugs are the effect-addition model and dose-addition 
model (Wessinger, 1986).  The simplistic effect-addition model proposes that the combination of 
each drug of interest will produce an effect equal to the sum of each effect alone (i.e., effective-
additive effect).  Terms to describe results that are not equal to sum of each individual effect 
include “greater than effect-additive” or “less than effect-additive”.  These terms indicate results 
that are greater than the individual effects combined or less than the individual effects combined.  
The second model, the dose-addition model, incorporates the influences of dose and effect and 
examines the magnitude of effect a specific dose as a measure of drug potency (Wessinger, 
1986).  Both drugs of interest are considered different forms of the same substance with different 
potencies affecting the variable of interest (Wessinger, 1986).  Dose response testing of each 
drug is necessary in order to utilize the dose-addition model.  Although the dose-addition model 
may provide more information concerning the nature and magnitude of potential drug 
interactions than the effect-addition model, dose-addition is not used frequently among 
researchers examining the effects of nicotine and caffeine.  Much of the research concerning 
these two drugs uses a small range or discrete drug doses and either compares the individual 
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effects of each drug versus the combination or a variation of this method (see Perkins et al., 
1994; Rose & Behm, 1991).  These methods appear to lend themselves to the effect-addition 
model.  Importantly, among clinical studies that evaluate marketed products (e.g., cigarettes and 
coffee) testing a complete dose response curve to utilize the more precise dose-addition model 
may be less feasible. 
Of the empirical research examining the potential interaction of nicotine and caffeine, 
some evidence indicates caffeine can enhance some of nicotine’s effects in preclinical models 
(Cohen, Welzl, & Battig, 1991; Gasior, Jaszyna, Peters, & Goldberg, 2000) and in humans.  In 
clinical models, enhancement has been observed for some reward/reinforcement-related 
subjective effects (Perkins et al., 1994; Jones & Griffiths, 2003) and cardiovascular effects (Ray, 
Nellis, Brady, & Foltin, 1986; Smits, Temme, & Thien, 1993; Perkins et al., 1994).  In addition, 
contradictory results have also been observed in smokers (e.g., attenuation of nicotine’s 
subjective effects by caffeine, Rose & Behm, 1991; no effect of caffeine pretreatment upon 
nicotine-associated discriminative stimulus, subjective, or reinforcing effects; Perkins, Fonte, 
Stolinski, Blackesley-Ball, & Wilson, 2005), and among a group of non-smokers, nicotine’s 
effects were not influenced by co-administration of a variety of caffeine doses (Blank, 
Kleykamp, Jennings, & Eissenberg, 2007).  This growing body of literature demonstrates that 
caffeine and nicotine may interact on some measures including the enhancement of 
reward/reinforcement-related effects.  Examinations of both preclinical and clinical laboratory 
work highlight important study design considerations when investigating the interaction of these 
two drugs. 
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Preclinical Evaluations of Nicotine and Caffeine 
Over the past few decades, many preclinical studies have examined the individual and 
combined effects of nicotine and caffeine.  There is some evidence to support that acute caffeine 
administration can enhance the effects of nicotine that are related to its abuse potential.  Acute 
pre-session co-administration of nicotine and caffeine has produced increases of locomotor 
activity (Cohen et al., 1991) and schedule-controlled behavior (White, 1988) under some 
conditions in rats.  Chronic exposure to caffeine (which may more closely approximate human 
self-administration patterns) paired with nicotine has also been observed to facilitate the 
acquisition of nicotine self-administration (Shoaib, Swanner, Yasar, & Goldberg, 1999) and 
nicotine discrimination (Gasior et al., 2000; 2002) under certain conditions in rats.  One 
mechanism used to explain these findings involves caffeine- induced dopamine release in tandem 
with nicotine-induced dopamine release (Garrett & Holtzman, 1994; Tanda & Goldberg, 2000), 
which may increase the likelihood of subsequent drug self-administration via the mechanism of 
positive reinforcement (Garrett & Griffiths, 1997).   
Acute pre-treatment with caffeine is one means to examine how caffeine and nicotine 
interact.  One preclinical study measured locomotor activity levels after acute nicotine and 
caffeine pretreatment in nicotine tolerant and nicotine naïve rats within a tunnel maze (Cohen et 
al., 1991).  After two 6-minute trials in a tunnel maze, animals from each pre-treatment group 
(nicotine tolerant and nicotine naïve) were given a subcutaneous (s.c.) injection of saline, 
nicotine (0. 2 mg/kg), caffeine (8 mg/kg) or nicotine (0.2 mg/kg) and caffeine (8 mg/kg).  In the 
nicotine naïve rats, nicotine exposure significantly decreased locomotor activity, which is a 
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common effect of nicotine administration.  Interestingly, this decrease was not observed when 
nicotine and caffeine were administered simultaneously in the nicotine naïve rats, and in these 
animals this level of locomotor activity was not significantly different from saline.  Among the 
nicotine tolerant rats, caffeine and nicotine in combination significantly increased locomotor 
activity above the saline level, but individually nicotine and caffeine had a small, not significant 
locomotor increase (Cohen et al., 1991).  These results highlight caffeine’s ability to influence 
some of the behavioral effects of nicotine, despite nicotine tolerance. 
Chronic dosing with caffeine is another means to examine the interaction of caffeine and 
nicotine.  A commons means to achieve chronic dosing among rodents is to add caffeine to their 
drinking water.  One study that used this paradigm examined changes in ambulatory activity and 
discriminative stimulus effects to a variety of psychostimulants including nicotine (Gasior et al., 
2000).  Three groups of drug naive rats were randomly assigned to receive either tap water, a 
solution with 0.25/ml caffeine, or a solution with 1.0 mg/ml caffeine throughout the experiment.  
Rats were exposed to their solutions for at least one week before testing.  Nicotine discrimination 
was trained with 0.4 mg/kg of nicotine delivered s.c.  Exposure to the lower concentration of 
caffeine enhanced the stimulatory effects of nicotine and did not produce tolerance to the acute 
stimulatory effects of caffeine, while the higher caffeine concentration did not alter the effects of 
nicotine on ambulatory behaviors, and resulted in the development of complete tolerance to the 
acute stimulatory effects of caffeine.  In the nicotine discrimination paradigm, rats exposed to the 
lower caffeine concentration acquired the nicotine discrimination significantly faster than the 
placebo (tap water) animals, while the animals exposed to the higher concentration did not.  In 
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summary, pretreatment with the lower dose of caffeine enhanced the stimulatory and 
discriminative stimulus effects of nicotine while the higher dose had little effect of nicotine’s 
behavioral effects and produced tolerance to caffeine’s acute stimulatory effects (Gasior et al., 
2000).  This study indicates that caffeine dose may be an important determinant of the behavioral 
effects observed in response to nicotine co-administration.  
A later study by the same group of researchers used a similar continuous dosing 
procedure to examine the effects of chronic dosing in combination with acute caffeine dosing 
prior to nicotine discrimination (Gasior et al., 2002).  Two groups of rats (drinking solution: tap 
water or 1.0 mg/ml caffeine) were trained to discriminate 0.4 mg/kg nicotine s.c. from saline.  A 
range of caffeine doses (1.0-30.0 mg/kg) were administered i.p. 15 minutes prior to 
discrimination testing.  These doses produced an enhancement of the discriminative-stimulus 
effects of the threshold dose of nicotine (0.05 mg/kg) in the placebo (tap water) and caffeine 
pretreatment animals (Gasior et al., 2002).  Chronic caffeine pretreatment did not significantly 
alter the responses observed with acute caffeine in combination with nicotine.  The results, while 
complex, support the idea that caffeine interacts with the discriminative effects of nicotine.  In 
contrast, another group performed a similarly designed study (Justinova et al. 2009), and did not 
observe caffeine’s enhancement of nicotine’s discriminative properties.  If caffeine use enhances 
nicotine’s discriminative stimulus properties, this action may intensify other reward or 
reinforcement-related properties of nicotine such that co-administration contributes to tobacco 
use initiation and maintenance. 
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In further support of this notion, one study has examined the effects of chronic caffeine 
exposure on i.v. nicotine self-administration (Shoaib et al., 1999).  After catheter implantation 
surgery, rats were assigned to one of three groups: 1) access to tap water at all times, 2) access to 
caffeinated drinking water 7 days prior and for the first 14 days of nicotine self-administration, 
or 3) access to tap waterpipe before and during the first 14 days of nicotine self-administration.  
After the first 14 days, caffeine was either added to or removed from the drinking water for the 
last two groups to achieve the double cross-over design.  Rats consumed on average 150-180 
mg/kg of caffeine per day and following the first 7 days of exposure to tap water or caffeine 
water, rats were allowed to administer nicotine (0.03 mg/kg per infusion) in daily sessions.  
Results indicated that animals maintained on caffeinated drinking water acquired nicotine self-
administration more rapidly than tap water maintained animals and a greater percentage of 
animals met the acquisition criteria.  Furthermore, this caffeine-related enhancement of 
nicotine’s reinforcing effects was specific; during extinction, the speed and final levels of 
extinction responding for caffeine and the tap water maintained animals were similar (Shoaib et 
al., 1999).  
Some researchers have described the mechanism of action concerning a caffeine-induced 
enhancement of nicotine’s effects as dopaminergically based (Garrett & Griffiths, 1997).  If 
accurate, this premise would further support caffeine’s possible augmentation of reinforcement-
related properties of nicotine.  Few researchers have examined dopamine concentrations after 
nicotine administration in rats chronically exposed to caffeine.  One examination reported within 
a literature review of caffeine and nicotine’s effects (Tanda & Goldberg, 1994) describes the 
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results when group of rats received caffeine (3 mg/ml) in their drinking water for three weeks 
and control rats drank plain tap water (Tanda & Goldberg, 2000).  In all animals s.c. nicotine 
administrations (0.2 and 0.4 mg/kg) produced a significant dose-related increase in dopamine 
levels in the shell of the NA.  This effect was significantly enhanced in caffeine drinking rats 
relative to the control (tap water) rats.  Although the mechanism of action is unclear, the effects 
observed during this study provide support for the role of enhanced dopamine transmission in the 
nucleus accumbens shell during concurrent caffeine and nicotine exposure (Tanda & Goldberg, 
2000).  If the co-administration of nicotine and caffeine produce this enhancement in humans as 
it does in rats, their use may affect patterns of tobacco use behavior. 
While some preclinical studies provide support for the premise of caffeine-related 
enhancement of nicotine’s effects, clinical studies may better approximate realistic human 
behavior patterns.  Not surprisingly, the issue of nicotine/caffeine interactions in humans has 
received some empirical attention.  
Clinical Laboratory Evaluations of Nicotine and Caffeine 
Several clinical laboratory investigations among smokers and non-smokers have 
examined the effects of concurrent nicotine and caffeine administration.  Many of these 
evaluations offer more uncertainty concerning the combined effects of these two drugs, as 
caffeine/nicotine dose, caffeine use history, and study design vary greatly across studies, but 
some results suggest that nicotine and caffeine may produce enhanced cardiovascular and 
subjective effects related to reward and reinforcement.  These effects, if present, may impact 
patterns of tobacco use initiation and maintenance. 
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An early naturalistic study examined the relationship between cigarette smoking and 
caffeine administration (Emurian, Nellis, Brady, & Ray, 1982).  In this study, eight participants 
who smoked cigarettes and drank coffee resided in a controlled laboratory environment for 7-12 
days with their own brand cigarettes and caffeinated coffee available constantly (Emurian et al., 
1982).  Results revealed a relationship between cigarette smoking and coffee drinking.  A coffee 
drinking event tended to occur late in the inter-cigarette interval, and cigarette smoking was most 
likely during the 20 minutes immediately following coffee drinking.  Also, an examination of the 
frequency of smoking and coffee drinking revealed a significant positive correlation between 
coffee drinking and smoking, thus those who smoked more cigarettes throughout the day also 
tended to drink more coffee (Emurian et al., 1982).  This study was limited by the absence of a 
control group who drank de-caffeinated coffee.  Determining whether caffeine, the act of coffee 
drinking, or some combination of the two was time-related to cigarette (i.e., nicotine 
administration) smoking is difficult.  Nonetheless, this study provided impetus for determining 
whether smoking and coffee drinking was merely a coincidental pairing.  
Clinical examinations that are more systematic provide better support for the relationship 
between nicotine and caffeine use.  For example, investigators in another early study measured 
the effects of nicotine and caffeine on multiple measures including cardiovascular effects (Ray et 
al., 1986).  Nine cigarette smokers who also drank coffee participated in four sessions 
corresponding to decaffeinated coffee only, decaffeinated coffee with own brand cigarette 
smoking, caffeinated coffee (4 mg/kg) only, and caffeinated coffee (4 mg/kg) with cigarette 
smoking.  Participants were required to be overnight abstinent from nicotine and caffeine prior to 
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each session.  Results indicated that the administration of caffeinated coffee with cigarette 
smoking increased blood pressure levels higher than cigarette smoking with decaffeinated coffee 
and caffeinated coffee alone.  Although these results supported an enhancement of nicotine’s 
effects by caffeine, the lack of a denicotinized cigarette or sham smoking (i.e., puffing on an 
unlit cigarette) condition was one limitation of this study (Ray et al., 1986).  The somatosensory 
effects of smoking along may have had effects on blood pressure and other outcome measures.   
Another clinical evaluation that examined the individual and combined effects of nicotine 
and caffeine recruited 10 participants who were non-smokers and regular caffeine users (Smits et 
al, 1993).  All participants completed four sessions that differed by drug administered: 
combination of nicotine (4 mg gum) and caffeine (250 mg i.v.), placebo gum and caffeine (250 
mg i.v.), nicotine (4 mg gum) and placebo infusion, and placebo gum and placebo infusion.  
Outcomes measures included blood pressure, which was increased during the nicotine, caffeine, 
and the combination conditions.  To determine whether the combination of nicotine and caffeine 
differed from the effects of each drug administered individually, the individual effects were 
summed and compared to the combination (i.e., effect-addition model; Wessinger, 1986).  
Although there was slight trend of the combination to produce higher blood pressure than the 
sum of the nicotine’s and caffeine’s effects, there was no significant difference between the two.  
The researchers here deemed that the combination of nicotine and caffeine produced an 
“additive” (i.e., effect-additive) effect upon blood pressure, larger than either drug administered 
individually but not significantly different when compared to these individual effects added 
together (Smits et al., 1993).  Importantly, these researchers recognized that the route of 
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administration may have affected their results.  Nicotine gum delivers nicotine at a much slower 
rate than cigarette smoking and the lower plasma nicotine levels achieved during this study may 
have affected the interaction between nicotine and caffeine (Smits et al., 1993). 
Similar to preclinical work, enhancement of the discriminative and subjective effects of 
nicotine by acute caffeine doses has been examined in the clinical laboratory.  Twenty smokers 
who used caffeine regularly were trained to discriminate between placebo and 1 mg nicotine 
chewing gum (Duka, Tasker, Russell, & Stephens, 1998).  Generalization was then tested (0, 
0.25, 0.5, 1 mg nicotine) with either a placebo or 50 mg caffeine preload (via capsule).  The 
caffeine preload increased subjective ratings of “stimulated” and “alert” at the 0 mg nicotine 
dose, and “jittery” at the 0.5 and 1 mg nicotine dose.  In addition, the caffeine preload partially 
substituted for nicotine at the 0 mg nicotine dose.  While this study provided little support for a 
caffeine-induced enhancement for the subjective qualities of nicotine, caffeine’s partial 
substitution demonstrated the possibility of common interoceptive stimulus properties of nicotine 
and caffeine (Duka et al., 1998).   
The effects of chronic caffeine administration upon nicotine-related subjective effects 
have also been assessed in smokers within the clinical laboratory.  One long-term study 
compared the effects of nicotine (0, 1.0, and 2.0 mg/70 kg i.v.) observed in cigarette smokers 
maintained on caffeine as compared to when they were caffeine abstinent in a within-subjects, 
double-blind, clinical laboratory study (Jones & Griffiths, 2003).  Outcome measures included 
subjective ratings of VAS items “Do you feel a rush?”, “Do you feel a drug effect?”, and “Do 
you feel stimulated?”.  Relative to ratings observed during caffeine abstinent condition, 
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participant ratings of “drug effect” and “stimulated” were significantly higher after the 2.0 mg/70 
kg nicotine dose during caffeine maintenance (e.g., peak change “stimulated” scores for caffeine 
maintenance group = approximately 30 points and for the caffeine abstinence group = 
approximately 17 points).  These results are consistent with the caffeine maintenance adding to 
the effect of the 2.0 mg/70 kg i.v. nicotine dose, but without a caffeine maintenance group 
exposed to placebo infusions or a placebo control group, the study design lacks the ability to 
allow the authors to make this inference (Jones & Griffiths, 2003). 
Additional evidence supports the potential for an effect-additive effect of nicotine and 
caffeine on measures of cardiovascular and subjective effect.  Nineteen smokers who regularly 
drank coffee were assessed using a within-participants, placebo control design in which they 
received nicotine (15 μg/kg, intranasally) and caffeine (5 mg/kg, p.o.) in combination, and the 
effects were compared to these doses of nicotine alone, caffeine alone, and placebo during both 
rest and activity periods (Perkins et al., 1994).  Outcome measures included tension and arousal 
scales of POMS, VAS items (e.g., “jittery”, “dizzy”), and cardiovascular effects (heart rate and 
blood pressure).  The POMS scale of arousal revealed a main effect of caffeine and nicotine, and 
during the rest period, mean change from baseline scores indicated the summed individual drug 
effects versus the combination of nicotine and caffeine were not significantly different (i.e., 
effect-additive; Wessinger, 1986).  Interestingly, the individual and combination effects of 
nicotine and caffeine on arousal were attenuated during the activity period.  The POMS scale of 
tension  revealed a significant interaction between caffeine and nicotine and the mean change 
from baseline score during the combination was observed to be greater than the sum of the 
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individual drug effect scores (i.e., greater than effect-additive) during both the activity and rest 
periods.  Similarly to the POMS scale of tension, for the VAS item “jittery” mean change from 
baseline scores were observed to be greater during the combination than the sum of the 
individual drug effect scores, but only during the rest period.  During the activity period, changes 
were only effect-additive (i.e., approximately equal between the combination and the sum of 
individual drug effects).  In contrast for the VAS item “dizzy”, nicotine increased scores during 
both activity and rest, while caffeine only increased reports during rest.  For cardiovascular 
reports, nicotine increased heart rate and blood pressure and caffeine decreased heart rate and 
increased blood pressure during both activity and rest.  Similar to previous observations, during 
the combination of nicotine and caffeine effect-additive effects were observed for blood 
pressure.  In summary, this study showed evidence of an enhancement of subjective effects (e.g., 
arousal, tension, ‘jittery”, and “dizzy”) under some conditions and enhanced blood pressure 
effects during nicotine and caffeine co-administration and is one of the few examinations that 
provides evidence for greater than effect-additive effects concerning the co-administration of 
these two drugs (Perkins et al., 1994). 
Another within-subject clinical laboratory study has shown both the attenuation and 
enhancement of nicotine-related effects by caffeine (Rose & Behm, 1991).  Twelve smokers who 
regularly drank coffee received nicotine (approximately 0.75 mg, via cigarette) and caffeine (150 
mg, p.o.) in combination, and the effects were compared to these doses of nicotine alone, 
caffeine alone, and placebo.  Measures included the arousal and tension scales from the POMS 
and blood pressure.  Results indicated that caffeine attenuated the nicotine induced increase in 
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participant-rated arousal when compared to the increases observed during the nicotine only 
condition.  During the caffeine only and caffeine in combination with nicotine condition, relative 
to the no caffeine conditions there were significant increases in mean diastolic blood pressure.  
The combination of drugs produced the highest increase in mean diastolic blood pressure, which 
appeared higher than the sum of nicotine alone and caffeine alone.  Unfortunately, the 
researchers did not examine these results in terms of the effect-addition model of interaction 
(Rose & Behm, 1991).  Common to other studies of caffeine and nicotine co-administration, 
sample size could be a limiting factor of these results.  Interestingly, the attenuation effect of 
caffeine upon nicotine’s subjective effects under resting conditions observed in this study (Rose 
& Behm, 1991) is inconsistent with some findings (Perkins et al., 1994, observed attenuation 
only under activity conditions), but the enhanced increase of blood pressure during the 
nicotine/caffeine condition is consistent with other results (Smits et al., 1993; Ray et al., 1986; 
Perkins et al., 1994).   
Other clinical laboratory research provides less support for the notion that caffeine 
enhances nicotine’s effects, at least on some outcome measures (Perkins et al., 2005; Blank et al., 
2007; Kerr, Sherwood, & Hindmarch, 1991; Pritchard, Robinson, deBethizy, Davis, & Stiles, 
1995).  A double blind within-subject study of five non-smokers and five smokers measured 
performance on a variety of cognitive measures (Kerr et al., 1991).  Participants were 
administered caffeine (300 mg p.o.) and nicotine (2 mg gum), caffeine placebo and nicotine (2 
mg gum), caffeine (300 mg p.o.) and nicotine placebo, and caffeine placebo and nicotine 
placebo.  The results indicated that the combination of nicotine and caffeine produced no greater 
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effects on the cognitive tasks relative to each drug administered individually.  The relatively 
small sample size and lack of control for the varied nicotine history of the participants may limit 
the applicability of these findings (Kerr et al., 1991).  Another study that did not find evidence 
for enhancement between nicotine and caffeine recruited only non-smoking moderate caffeine 
users (Blank et al., 2007).  This double blind, within-subject examination consisted of four 
sessions where twenty participants were preloaded with 0, 75, or 150 mg caffeine via capsule 
prior to each nicotine administration (2 and 4 mg).  Measures including physiological and 
subjective ratings were taken periodically.  Nicotine increased heart rate and blood pressure 
significantly, but these increases were independent of caffeine dose administered.  In addition, no 
significant main effects of caffeine were observed for any of the subjective items.  This study 
provided little evidence that the effects of nicotine are influenced by concurrent caffeine 
administration.  Limitations for this study included a small sample size and lack of a nicotine 
placebo (Blank et al., 2007).  
In sum, clinical laboratory studies provide some evidence of common interoceptive 
stimulus properties of nicotine and caffeine and effect-additive effects on some subjective 
measures (e.g., arousal, “stimulated”,” jittery”, and “dizzy”) and blood pressure.  Taken with the 
preclinical work demonstrating a potential interaction during nicotine and caffeine co-
administration, these two drugs when administered in combination may induce heightened 
reward/reinforcement-related effects that could impact patterns of tobacco use initiation and 
maintenance.  In addition, examination of these caffeine co-administration studies highlights the 
need for controlled study design, careful attention to sample size, and use of outcome measures 
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sensitive to the combined effects of nicotine and caffeine.  Importantly, a study examining the 
combined effects of nicotine and caffeine should include conditions where each drug is presented 
alone and in combination (as in Perkins et al., 1994; Kerr et al., 1991; Smits et al., 1993; Rose & 
Behm, 1991) as this design allows for systematic comparison and determination of the effects of 
combination, as well as the use of the effect-addition model of interaction.   
Novel Caffeine and Nicotine Co-Administration: Caffeinated Tobacco 
In the past, nicotine and caffeine co-administration outside the clinical laboratory has 
been limited by the products available (see Table 2).  Generally, users achieve co-administration 
in the form of caffeinated beverages or pills used in the combination with tobacco or nicotine 
replacement products.  With the advent of caffeinated tobacco products, the potential for 
simultaneous, single product administration of nicotine and caffeine exists.  Most recently, 
caffeinated smokeless products (Revved Up Energy Dip, Elixyr Power Energy Snus, and 
Northern Energy Snus) have been marketed to users as a “substitute/complement for energy 
drinks and coffee” (Elixyr Power Energy Snus; buysnus.com) and “a convenient and discreet 
way to enjoy smokeless tobacco and achieve increased energy levels” (Revved up Energy Dip; 
southernsmokeless.com).  In addition, a brand of caffeinated waterpipe tobacco (Tangiers F- 
Line) has been available for the past five years.  While these products have not received 
systematic study, anecdotal reports suggest the possibility of enhanced effects.  For example 
regarding Tangiers F-line caffeinated waterpipe tobacco, users write “Tangiers caffeinated line 
of hookah tobacco will knock you out of your boots” (TimL, 9/19/08, Yelp.com), and “If regular 
Tangiers can give you a massive buzz, the F-Line brings it to a whole new level!” (Zeodynamic,   
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Table 2.   
Caffeine content for a variety of consumer products 
Product  Mean caffeine (mg) 
Coffee    
 Generic filtered (8 oz) 1 133 
 Generic instant (8 oz)1 66 
Tea (depending on brew) 1  53 
Food   
    Haagen-Dazs Coffee Ice Cream (8 oz)1  10 
    Hershey’s Chocolate Bar (1.45 oz)1 36 
Soft drink    
 Coca-Cola Classic (12 oz) 1 35 
 Mountain Dew (12 oz) 1 71 
Energy drink   
 AMP (8.4 oz)1 74 
 Red Bull (8.3 oz)1 80 
Over-the-counter drugs  
 No Doz (1 tablet)1  200 
 Vivarin (1 tablet)1  200 
 Anacin (2 tablets)1  64 
 Excedrin (2 tablets)1  130 
Tobacco Products   
 Elixyr Power Energy Snus (per portion)2 28 mg 
 Northern Energy Snus (per portion)2 20 mg 
 Revved Up Energy Dip N/A3 
 Tangiers F-Line N/A3 
1 Center for Science in the Public Interest, 2007 
2 Data available at http://thenortherner.com. 
3 No data available from manufacturer. 
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6/28/07, Hookahpro.com).  These anecdotal reports suggest that when caffeinated tobacco 
products are heated and the smoke inhaled the resulting effect may be greater than those 
experienced when inhaling the smoke of non-caffeinated products.  Of course the validity of this 
notion rests on the idea that volatilized caffeine is physiologically active. 
Volatilized Nicotine and Caffeine  
Nicotine delivered by inhalation of volatilized tobacco smoke particles (e.g., smoking) 
has been examined in a large number of empirical studies (e.g., Hoffman & Hoffman, 1997).  
Because inhaled drugs escape first-pass intestinal and hepatic metabolism, they are rapidly 
absorbed and enter of the brain more quickly than those administered via other methods 
(Benowitz, 2008).  Many believe the speed of entry of nicotine into the brain by smoking is a 
strong determinant of the reinforcing effects and abuse liability of a drug (Farré & Cami, 1991; 
Benowitz, 2008).  A number of other drugs of abuse are consumed by the inhalation route 
including marijuana, cocaine, and opiates, perhaps because access to the brain is so rapid with 
this method.  Little research has been performed concerning the delivery characteristics of 
volatilized caffeine, but if, like other drugs of abuse, this method of administration produces 
more rapid access to the brain, it is not unlikely that inhaled caffeine may offer a more 
heightened abuse liability than other modes of ingestion.   
Three studies have analyzed samples of caffeine post-volatilization  (Klous, Lee, 
Hillebrand, et al., 2006; Klous, Lee, Van den Brink, et al., 2006; Brenneisen & Hasler, 2002) to 
determine delivery characteristics, and one clinical laboratory study has examined the 
pharmacokinetics of volatilized caffeine in humans (Zandvliet et al., 2005).  Importantly all of 
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these studies have utilized the anhydrous base form of caffeine (i.e., 1,3,7-Trimethylxanthine, 
C8H10N4O2) not the salt form (i.e., caffeine citrate; C14H18N4O9).  One examination demonstrated 
that caffeine was a heat stable compound after preparations underwent temperatures of 250-400 
C° with 0% of the caffeine compound experiencing degradation (Brenneisen & Hasler, 2002).  
Other studies produced similar results with near complete recovery of caffeine from mixtures 
that were heated by standardized methods to 200-350 C° (Klous, Lee, Van den Brink, et al., 
2006) or by samples heated by human participants to similar temperatures (Klous, Lee, 
Hillebrand, et al., 2006).  In the only clinical study of volatilized caffeine, 10 volunteers inhaled 
the smoke produced by heating a preparation with a lighter or a heating plate containing 100 mg 
caffeine (anhydrous base) on five separate sessions (Zandvliet et al., 2005).  During each session 
blood was sampled at baseline and at standardized intervals after inhalation (inhalation period 
averaged 10 minutes; 1, 2, 5, 7.5, 10, 15, 22.5, 30, 45, 60, 120, 240, and 480 minutes).  Plasma 
was analyzed from each sample for caffeine levels and four caffeine metabolites.  Participants’ 
plasma samples that indicated recent caffeine ingestion prior to session were excluded from the 
analyses.  According to the researchers’ pharmacokinetic modeling, caffeine appeared in 
circulation rapidly following inhalation; this finding indicated absorption of caffeine from the 
lungs (Zandvliet et al., 2005).  Estimates also indicated that inhalation of 100 mg caffeine 
produced comparable plasma caffeine concentrations as drinking a beverage with 80 mg of 
caffeine.  One limitation of these results was the lack of plasma concentration data available 
during inhalation, thus the speed of absorption was not accessed.  As speed of absorption is an 
important factor in the abuse ability of a drug and inhalation has been shown to be a rapid 
 58 
method of absorption and distribution, the absence of this outcome is disappointing.  Fortunately, 
the elimination rate of caffeine corresponded well with previous reports of p.o. and i.v. caffeine 
administration (Bonati et al., 1982; Renner, Wietholtz, Huguenin, Arnaud, & Preisig, 1984) 
demonstrating that the inhaled caffeine metabolizes at a similar rate compared to other 
administration routes (Zandvliet et al., 2005).  In sum, these studies demonstrate that caffeine can 
be volatilized without degradation to its chemical properties and volatilized caffeine can be 
inhaled and metabolized similarly to other routes of administration (Brenneisen & Hasler, 2002; 
Zandvliet et al., 2005).   
These results along with the anecdotal reports described earlier support the idea that 
smoking caffeinated tobacco may expose users to active caffeine doses.  The extent to which 
those caffeine doses interact with tobacco-delivered nicotine is another question. 
Evaluating the Effects of Caffeinated Waterpipe Tobacco 
Evaluations examining the interaction of nicotine and caffeine described in the preceding 
sections demonstrate many techniques and methods than can be applied to examine the effects of 
caffeinated waterpipe tobacco in the clinical laboratory.  While other study designs are used, 
within-subject methods are most common (e.g., Blank et al., 2007; Rose & Behm, 1991; Smits et 
al., 1993; Perkins et al., 1994).  Outcome measures also differ across studies, though plasma 
nicotine, cardiovascular response, and detailed subjective effect measures are particularly 
common in assessing effects and interactions of these two drugs.  Study duration is also an 
important variable.  Short term examinations can be more feasible and practical (see Perkins et 
al., 1994), while longer term studies may better replicate actual dosing patterns in humans (e.g., 
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Emurian et al., 1982; Jones & Griffiths, 2003).  Longer term studies may be also be more 
difficult and expensive to perform.  Blood samples collected before and after drug administration 
address the exposure associated with acute administration of nicotine and caffeine (e.g., Shafagoj 
et al., 2002; Zandliviet et al., 2005).  Similarly, subjective questionnaires administered before 
and after provide valuable information concerning pleasurable and adverse subjective effects and 
direct effects (e.g., dizzy, nausea, and lightheadedness) associated with nicotine and caffeine 
administration.  Designing a study that examines these two drugs must take into consideration 
peak effects and duration of action.  As caffeine’s half-life is longer and duration of peak effects 
occurs over much longer time than nicotine, the time course of subjective and physiological 
assessment should reflect these pharmacokinetic differences.  Appropriate controls are another 
important study design consideration.  Specifically, designs that examine an interaction should 
include conditions where each factor of interest is examined individually and in combination, as 
well as a placebo control.  These measures ensure effects can be examined discretely (see 
Perkins et al., 1994; Rose & Behm, 1991) as well as provide the ability to utilize 
pharmacological models of interaction such as the effect-addition model (Wessinger, 1986).  
Lastly, previous studies examining the interaction of caffeine and nicotine co-administration may 
have used inadequate sample sizes (see Blank et al., 2007), so that an increased sample size to 
examine this pharmacological interaction may be warranted.  Thus, clinical laboratory studies 
that use acute exposure methodology can address many questions related to effects of nicotine 
and caffeine use individually and in combination. 
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Statement of the Problem 
Caffeine and nicotine are the two of most commonly consumed licit psychoactive drugs 
in the world.  Nicotine is usually administered via tobacco products and caffeine is most often 
consumed orally via beverages.  Tobacco use is associated with nicotine dependence and is 
considered the leading cause of preventable death in the U.S., while caffeine is considered a drug 
with low abuse liability and little harm.  The co-administration of caffeine and nicotine-
containing products is common: over 86% of cigarette smokers report using caffeine versus 77% 
of non-smokers, and this observation may reflect an interaction between these two drugs.  Some 
research suggests the combination of nicotine and caffeine may produce effects that are more 
rewarding or pleasurable than either drug alone.  This reward enhancement may also influence 
patterns of tobacco use initiation and maintenance.  Alarmingly, despite decreases in cigarette 
smoking prevalence over the past twenty years, an alternative tobacco use method, waterpipe 
tobacco smoking, is experiencing recent popularity in the U.S.  This method of tobacco smoking, 
especially popular among young adults, may allow for increased opportunities for nicotine and 
caffeine co-administration via a caffeinated tobacco product (Tangiers F-Line).  This product 
enables users, who may be among an age group that is especially vulnerable to tobacco use 
initiation, to consume this combination of drugs in a single form.  Data concerning “smoked” 
(i.e., volatilized) caffeine are sparse, but reports indicate it is absorbed and metabolized similarly 
to other methods of caffeine administration.  Taken with the evidence from previous nicotine and 
caffeine co-administration studies, this caffeinated tobacco product may produce enhanced 
reward-related effects in users compared to typical waterpipe tobacco preparations.  An 
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empirical laboratory study that assesses both the effects of caffeinated waterpipe tobacco as well 
as describes the effects of volatilized caffeine is both a feasible and practical option. 
The Present Study 
The aims of this study were to compare, using a within-subject, factorial design, the 
subjective and cardiovascular effects of smoking caffeinated waterpipe tobacco with the effects 
of smoking waterpipe preparations containing nicotine and no caffeine, low nicotine and caffeine 
(a preparation with no nicotine and caffeine was desired but was unavailable), or neither nicotine 
nor caffeine.  This study design allowed us to examine the effects of the combination of nicotine 
and caffeine in comparison to low nicotine and caffeine, nicotine alone, and a placebo.  This 
experiment also was the first systematic evaluation of the physiological and subjective effects 
associated with the volatilized caffeine.  
Statement of Hypothesis 
The primary goal of the study was to examine caffeinated waterpipe tobacco in 
comparison to non-caffeinated tobacco, and the primary hypothesis reflects this goal: caffeinated 
waterpipe tobacco would produce some cardiovascular and subjective effects that are greater 
than non-caffeinated waterpipe tobacco.   
Secondary hypotheses include: caffeinated and non-caffeinated waterpipe tobacco 
preparations would increase plasma nicotine levels while the placebo preparation would not, the 
caffeinated waterpipe tobacco and low nicotine caffeinated preparations would increase plasma 
caffeine levels, and the nicotine-containing preparations would induce subjective effects 
characteristic of acute nicotine administration. 
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Method 
Selection of Participants 
Thirty-two waterpipe tobacco smoking community volunteers (16 men) completed this 
within-subject, Latin-square ordered study.  Power analysis suggested that thirty participants 
were necessary to detect a moderate effect size (i.e., f ≥ 0.35) with a small or moderate 
correlation between repeated measures (i.e., r ≥ 0.50) with a power of 0.80 and alpha level < 0.05 
(Barcikowski & Robey, 1985).  While forty participants were proposed initially to maximize 
study sensitivity to detect an interaction, based upon the preliminary analysis of the first twenty 
participants, the lack of caffeine exposure detected supported the use of fewer participants and 
early closure of the study. To continue to enroll participants in a study that cannot address its 
hypotheses presents an unacceptable risk/benefit ratio (see Chapter 3 of the Institutional Review 
Board Guidebook, 1993).  The thirty-two participants ensured that 8, 4-condition Latin squares 
could be completed to minimize order effects.  
Inclusion criteria.  Participants were included if they reported that they were healthy, 
between 18 and 50 years of age, reported smoking tobacco using a waterpipe at least four times a 
month for the past 6 months (ensured participants were not exposed to waterpipe smoke 
toxicants above what they usually consume), and reported daily caffeine use of at least 100 mg 
(e.g., 1 cup of caffeinated coffee) for the past year (see Jones & Griffiths, 2003; Perkins et al., 
 1994).  All participants provided informed consent and agreed to abstain from all 
tobacco/nicotine-containing products and caffeine/caffeinated beverages for at least 12 hours 
prior to each of four required sessions.   
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Exclusion criteria.  Individuals were excluded if they reported a history of chronic 
health problems or psychiatric conditions.  Women were also excluded if they tested positive for 
pregnancy (assessed by urinalysis during screening) or reported current breastfeeding.  Regular 
use of cigarettes (> 5 cigarettes/day) for the past year was exclusionary (participants with a 
higher cigarette use history may have been nicotine dependent and had more difficulty abstaining 
from tobacco use).  In addition, regular use of prescription medication (except for vitamins or 
birth control) was also exclusionary to reduce any potential drug interaction with nicotine and 
caffeine administration (Zevin & Benowitz, 1999).  Any potential participant reporting a current 
attempt to cease tobacco use was excluded and referred to a smoking cessation treatment 
provider.  Participants were excluded if they reported past month use of opioids or cocaine or 
had a positive urine drug screen for these drugs; individuals who reported > 5 days of marijuana 
use in the past month or > 20 days of alcohol use in the past month were also excluded.  To 
reduce flavor bias for the products used in the current study, participants who reported “Melon” 
as their favorite waterpipe tobacco flavor were excluded (see Materials).  
Screening and Informed Consent Procedures 
All individuals interested in participating in the study completed a two-part screening 
process.  The first part consisted of a phone interview where potential participants responded to 
questions about their health and tobacco use (see Appendix A).  Individuals whose responses 
suggested that they were eligible were invited to appear in the laboratory for an in-person 
screening.  Prior to completing the in-person screening, individuals provided their informed 
consent to participate in the study (see Appendix B).  They then provided information 
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concerning their health, tobacco use, and basic demographics.  In addition, a urine sample was 
required for immediate semi-quantitative analysis of illicit drug use and, for women, a pregnancy 
test.  
A total of 48 participants (22 women) consented to participate in the study.  However, 15 
failed the in-person screening process (i.e., 8 did not report consuming at least 100 mg caffeine 
daily for the past year; 7 did not meet other inclusion criteria).  In addition, one participant was 
discontinued after the first two sessions due to high blood pressure.  Of the 32 participants who 
provided complete blood plasma, cardiovascular, subjective and topography results, 16 were men 
(10 non-white) and 16 were women (12 non-white). These participants were on average, 21.6 
years old (SD = 2.7) and reported smoking tobacco using a waterpipe 11.4 occasions/month for 
the past 2.2 years (SD = 1.6).  Eleven of the participants smoked cigarettes (on average 2 
cigarettes/day for 23.5 months).  These participants also reported consuming on average 308.1 
mg (SD = 181.6) of caffeine per day for the past 4.5 years (SD = 3.1). 
Materials 
Conditions differed by waterpipe preparation: combination of caffeine and nicotine 
(CAFF/NIC; Tangiers F-Line), caffeine and reduced (low) nicotine (CAFF/LN; low nicotine 
Tangiers F-Line), nicotine and no caffeine (NIC; Tangiers original), or neither caffeine nor 
nicotine (PLACEBO; Soex; a sugarcane based waterpipe product, see 
www.soex.com/herbalmolasses.html). Table 3 displays the nicotine and caffeine content for each 
product.  The melon flavor was the only flavor available in all four varieties and was the flavor    
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Table 3.   
Mean (standard deviation) nicotine and caffeine content analysis of study materials.a 
 
 Condition 
 PLACEBO NIC CAFF/LN CAFF/NIC 
Nicotine (mg/g) <LOQb 3.25 (0.07) 0.846 (0.005) 3.82 (0.08) 
Caffeine (mg/g) Not tested Not tested 0.481 (0.012) 0.507 (0.026) 
 
a Arista Laboratories ISO 17025 accredited.  
b Lower than limit of quantification (LOQ).  
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used for all sessions.  In order to control for flavor preference, we excluded all individuals who 
reported that “Melon” was their preferred flavor.  Thus, for all study participants, the flavor used 
in this study was a non-preferred one (a similar technique has been used to reduce cigarette brand 
bias, see Buchhalter, Schrinel, & Eissenberg, 2001).  
 Procedure 
After all screening procedures were completed (including informed consent), the first of 
four experimental sessions was scheduled, with each session corresponding to one of the four 
product conditions (i.e., CAFF/NIC, CAFF/LN, NIC, or PLACEBO).  The four double-blind, 
Latin-square ordered sessions occurred at least 48 hours apart, and lasted for approximately 3 
hours.  On each session day, participants reported to VCU’s Clinical Behavioral Pharmacology 
Laboratory at a pre-determined time (time of day varied between subjects, but was constant 
within-subject) and their expired air CO was assessed as a measure of compliance with 
theovernight tobacco abstinence criterion (CO < 10 parts per million [ppm] is an indicator of 
overnight abstinence; see Breland et al., 2002; Buchhalter et al., 2001; Schuh, Schuh, 
Henningfield, & Stitzer, 1997).  If the initial CO assessment did not indicate abstinence, 
participants could wait until their CO level reached criterion, or they could reschedule the 
session for another day.  In addition, participants were asked to provide a saliva sample for 
“verification” of greater than 12 hours of caffeine abstinence, though the sample was not tested 
(bogus pipeline method used to improve participant compliance; see Rose & Behm, 1991; 
Nastase, Ioan, Braga, Zagrean, & Moldovan, 2007).  Overnight tobacco and caffeine abstinence 
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avoids the effects of acute tolerance to nicotine’s and/or caffeine’s cardiovascular effects 
(Perkins et al., 1995; Whitsett, Manion, & Christensen, 1984).   
Once the participant met the pre-session CO criterion and provided a saliva sample, a 
catheter was placed in a forearm vein and the session began with continuous measurement of 
physiological response during a 20-minute adaptation period followed by a 10-minute baseline 
period.  Once the baseline period was complete, a baseline expired air CO was measured, 
participants responded to subjective measures, and 15 ml of blood was sampled.  Participants 
then began a 45-minute, double-blind waterpipe use period.   
In this study, laboratory staff with no participant contact packed the waterpipe head with 
10 g (as in Shihadeh, 2003) of the day’s preparation (i.e., CAFF/NIC, CAFF/LN, NIC, or 
PLACEBO).  For smoking, we adopted a variant of the protocol used elsewhere (Shihadeh, 
2003): the loaded head was covered with a 9 cm x 9 cm piece of aluminum foil that was 
perforated using a “screen pincher” that standardizes the number and size of the holes in the foil 
(see www.smoking-hookah.com).  Initially, a single quick-light charcoal disk (Three Kings, 
Holland; this brand is used in Richmond waterpipe cafés) was lit and placed on the foil.  
Laboratory experimentation reveals that a single disk is insufficient for an average use episode (it 
yields smoke-free puffs at the end), and naturalistic observation makes clear that waterpipe users 
exhibit idiosyncratic behavior regarding charcoal application.  We made available several (pre-
weighed) ½ charcoal disks that participants could add to the top of the head, ad libitum.  Also for 
standardization, the waterpipes used in all studies were of the same brand/size used in the 
waterpipe cafés found in the area surrounding Richmond VA (MYA, 23 inch), with 870 ml of 
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water placed into the base.  In every session, the waterpipe hose was tipped with a new, sterile, 
disposable mouthpiece.   
Participants smoked ad libitum, and puff topography was measured throughout the 45-
minute smoking session. At baseline and 5, 15, 30, 45, 60, 90, and 120 minutes after use began, 
15 ml blood was sampled and subjective measures were administered.  During each of the four 
sessions, participants could watch a movie of their choice on a laboratory-provided DVD player, 
read, or listen to music; importantly, these activities were restricted during completion of any of 
the subjective questionnaires.  The session terminated 5 minutes after the last subjective 
assessment was completed, the catheter removed, and if necessary, another session was 
scheduled.  The total amount of blood taken in a single session was 120 ml and for the entire 4-
session study was 480 ml (slightly more than the ~450 ml taken in a single blood donation).  
Participants who completed the study were paid $350. 
Physiological Measures 
Plasma nicotine and caffeine. Plasma nicotine is relevant to waterpipe tobacco 
smoking’s acute effects and is often measured in studies examining the short-term effects of 
tobacco products in tobacco smokers (e.g., Breland et al., 2002).  Plasma caffeine levels were 
used to indicate how much volatilized caffeine is being delivered to the smoker.  After 15 ml 
blood collected was collected at each sampling time point, the sample was centrifuged and two 
separate aliquots of plasma were frozen immediately at 70⁰C for analysis of nicotine and caffeine 
concentrations.  For plasma nicotine, standard methods (described in Breland et al., 2006) 
include a limit of quantification (LOQ) of 2 ng/mL (as in Gray, Breland, Weaver, & Eissenberg, 
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2008; Cobb, Weaver, & Eissenberg, 2010).  Caffeine in plasma were analyzed by reverse phase 
chromatographic separation (Shimadzu pump systems, Phenomenex Gemini column [C18, 
110Å, 100mm X 2mm, 5µm column]) in hyphenation with the tandem mass spectrometric 
determination (Waters Quattro API Micro, Triple Quadrupole Instrument with Masslynx 4.1 
software). The assay method was linear from 20 to 20000 ng/mL and results were quantified by 
linear regression method with 1/X^2 weighting (see Figure 3 for the calibration/standard curve).  
Cardiovascular effects. Heart rate was monitored every 20 seconds while systolic and 
diastolic blood pressure were measured every 5 minutes (Noninvasive Patient Monitor model 
507E, Criticare Systems, Waukesha, WI).   
Expired air carbon monoxide (CO): Expired air CO was recorded by the research 
assistant at 50, 60, 90, and 120 minutes post product administration (BreathCO monitor, 
Vitalograph, Lenaxa, KS). 
Subjective Measures  
During each session, participants responded to computerized questionnaires (each 
questionnaire administered a total of 8 times per session).  These questionnaires consisted of the 
Direct Effects Scale, the Profile of Mood States, and the Positive and Negative Affect Scale.  
The Direct Effects Scale (DES): This measure was developed using reports describing 
the effects of nicotine and caffeine administered individually and in combination (Perkins et al., 
1994; Jones & Griffiths, 2003; Blank et al., 2007; Garrett & Griffiths, 2001; Pullan et al., 1994; 
Gourlay, Forbes, Marriner, Pethica, & McNeil et al., 1995; Liguori, Hughes, & Grass, 1997).    
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Figure 3. Caffeine assay calibration/standard curve. X symbols denote standards and diamonds 
represent quality controls tested. Concentration on the X-axis is caffeine concentration in ng/ml, 
and response on the Y-axis is the peak area of caffeine / peak area of caffeine d-3. Peak area is 
obtained from the individual chromatogram of each sample or standard when caffeine is the 
analyte and caffeine-d3 is the internal standard. 
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These computerized items were presented as a visual analog scale (VAS) consisting of a word or 
phrase above a horizontal line anchored on the left with “Not at all” and on the right with 
“Extremely”.  Participants used the mouse to make a mark along the horizontal line and item 
scores were calculated as a percentage responding the mark’s distance from the left anchor.  The 
18 VAS (0-100) items are: “Nauseous”, “Dizzy”, “Lightheaded”, “Nervous”, “Sweaty”, 
“Headache”, “Excessive salivation”, “Heart pounding”, “Confused”, “Weak”, “Hungry”, “Do 
you feel a rush?”, “How high are you?”, “Do you feel any drug effects?”, “Do you like the drug 
effects?”, “Do you dislike the drug effects?”, “Do you feel any good drug effects?”, and “Do you 
feel any bad drug effects?”.  
The Profile of Mood States (POMS): The POMS (McNair et al., 1971) consists of 65 
items relating to mood that are rated on a 5-point scale ranging from 0 (Not at all) to 4 
(Extremely).  Items were reported as six previously defined factors: anger/hostility, 
confusion/bewilderment, depression/dejection, fatigue/inertia, tension/anxiety, and vigor/activity.  
Common to a few examinations of the concurrent effects of nicotine and caffeine (Perkins et al., 
1994), the POMS composite scale of arousal was assessed by adding the tension/anxiety and 
vigor/activity scales and subtracting the fatigue/inertia and confusion/bewilderment scales (de 
Wit, Pierri, & Johanson, 1989).  The POMS measure has been used extensively in studies 
examining the effects of concurrent nicotine and caffeine administration (Chait & Griffiths, 
1983; Rose & Behm, 1991; Oliveto et al., 1991; Perkins et al., 1994). 
The Positive and Negative Affect Scale (PANAS): The PANAS (Watson et al., 1988) 
consists of 20 items: “Enthusiastic”, “Inspired”, “Attentive”, “Active”, “Alert”, “Excited”, 
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“Determined”, “Strong”, “Proud”, “Interested”, “Upset”, “Hostile”, “Ashamed”, “Distressed”, 
“Guilty”, “Irritable”, “Afraid”, “Scared”, “Nervous”, and “Jittery”.  Participants rated each item 
on a 5-point scale ranging from 0 (Not at All) to 4 (Extremely).  Items were then collapsed into 
two factors previously defined by factor analysis: positive affect and negative affect.  Positive 
affect reflects the extent to which a person feels enthusiastic, active, and alert; high positive 
affect is characterized by high energy, full concentration, and pleasurable activity (Watson et al., 
1988).  Negative affect generally indicates distress and displeasure; low negative affect implies a 
state of calm and peacefulness (Watson et al., 1988).  This measure has been used in previous 
studies of nicotine’s interactions with other concurrently administered drugs (Sofuoglu, Waters, 
& Mooney, 2008; Epstein & King, 2004) and examinations of concurrent nicotine and caffeine 
administration (Blank et al., 2007).  
Puff Topography 
Puff topography is a sensitive measure of drug self-administration in cigarette smokers 
that has been used for decades (e.g., Robinson & Forbes, 1975; Herning et al, 1981; Brauer et al., 
1996).  Waterpipe puff topography was measured with a non-invasive device developed for this 
purpose (Shihadeh, Antonios, & Azar, 2005).  In order to assess waterpipe topography, a 
pressure transducer was integrated into the waterpipe hose, and inhalation-induced pressure 
changes are amplified, digitized, and sampled.  Software converts signals to air flow (ml/sec) and 
integrates the flow data, producing measures of average puff volume, average puff duration, total 
smoke volume, number of puffs, and average interpuff interval.  Digital records of puff 
topography were made for all sessions. 
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Data Analysis Plan 
All data analyses were performed using IBM SPSS (version 19).  Plasma nicotine results 
below the LOQ were replaced with the LOQ (i.e., 2 ng/ml; Gray et al., 2008; Cobb et al., 2010), 
and plasma caffeine results below the LOQ were replaced with the LOQ (i.e., 20 ng/ml).  Heart 
rate data was analyzed by averaging values in five-minute bins for the duration of the study as in 
previous work (Blank et al., 2007; Cobb et al., 2010).  Across all subjective, topography, and 
physiological measures (except for systolic and diastolic BP) less than 0.4% of data were 
missing.  For these outcomes, the average of the value before and after was used to impute 
missing data.  For systolic and diastolic blood pressure 6% of data were missing, and multiple 
imputation methods (MI) were employed via IBM SPSS (Rubin, 1987; Schafer, 1997; Little and 
Rubin, 1987). The MI procedure generates imputed datasets by estimating missing values using a 
Markov chain Monte Carlo technique.  Imputed datasets (at least 5) are then analyzed separately 
using user-specified statistical analyses, and results are combined using set rules (Rubin, 1987) 
or by averaging the analysis results of each imputed dataset.  Ten imputed datasets were 
generated for systolic and diastolic BP and results (see time course and peak change) are based 
on averaging the analysis results for each of these imputations. 
The primary outcome measures (physiological, puff topography, and subjective effects) 
were analyzed in two ways.  First, to characterize the time course of effects, data were analyzed 
using a three-factor repeated measures analysis of variance (ANOVA) where the factors are 
nicotine (yes/no), caffeine (yes/no) and time (baseline, 5, 15, 30, 45, 60, 90, and 120 for plasma 
and subjective effect data).  Second, in order to address specifically the effects of nicotine and 
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caffeine in combination, time course data in each of the four conditions was converted to peak 
change scores (i.e., baseline value subtracted from all subsequent values and then the highest 
value observed is the peak; Childs et al., 2008).  Peak change scores were used initially to 
examine any effects associated with condition order (i.e., the order of sessions for each 
participant).  For these peak change repeated measures ANOVA analyses, condition order (1, 2, 
3, 4) was used as a between subjects factor and the two within-subjects factors were nicotine 
(yes/no) and caffeine (yes/no). Of the 198 main effects and interactions analyzed, 10 were 
expected by chance and only 8 interactions involving the between subjects factor were 
significant (p < 0.05).  Because these significant results may reflect chance rather than a real 
difference between the effects of different condition orders, the between-subjects factors was 
dropped and all analyses were repeated using the within-subjects factors only.  In addition, puff 
topography data were analyzed by a two-factor repeated measures ANOVA where the factors 
were nicotine (yes/no) and caffeine (yes/no).  For all analyses, Huynh-Feldt corrections was used 
to adjust for violations of sphericity (Huynh & Feldt, 1976) and Tukey's Honestly Significant 
Difference (Keppel, 1991) was used to explore differences between means (as in Breland et al., 
2006; Gray et al., 2008; Cobb et al., 2010).  
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Results 
Time Course Analyses 
Table 4 displays time course statistical analyses (main effects and interactions) for all 
measures.  Interactions that involve the time factor and either the nicotine and/or caffeine factors  
are the most relevant as they indicate that the results observed differed across time and between 
nicotine and caffeine-containing products. 
Physiological measures. As Table 4 shows, a significant nicotine by time interaction 
(p<0.05) was observed for plasma caffeine.  As displayed in Figure 4 Panel A, no reliable 
increases in plasma caffeine concentration in any condition were observed across time, but there 
were significant differences between other conditions and CAFF/NIC for almost all time points 
(p < 0.05, Tukey’s HSD). Some indications of decreases in plasma caffeine concentrations over 
time were observed when conditions were collapsed across nicotine-containing products (NIC 
and CAFF/NIC) and those that contained less or none (PLACEBO and CAFF/LN).  Mean 
caffeine concentration (M) for NIC-CAFF/NIC was decreased relative to baseline (M = 422.9 
ng/ml; standard error of the mean [SEM] = 124.7) at 120 minutes post product administration (M 
= 334.7 ng/ml; SEM = 107.5; n.s., Tukeys HSD), and for PLACEBO-CAFF/LN mean caffeine 
concentration was decreased relative to baseline (M = 303.9 ng/ml; SEM = 75.5) at 120 minutes 
post product administration (M = 251.4 ng/ml; SEM = 64.9, n.s., Tukeys HSD).  Mean caffeine 
concentrations were significantly different between conditions by nicotine content status at 30 
and 45 minutes post product administration (Tukey’s HSD, p < 0.05).  When time points were 
collapsed across all conditions, mean plasma caffeine concentration was 363.4 ng/ml (SEM =  
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Table 4.   
 
Time course statistical analyses for all measures.  
 
  Nicotine (N) Caffeine (C) Time (T) N X C N X T C X T N X C X T 
  F P ηp2 F p ηp2 F p ηp2 F p ηp2 F p ηp2 F p ηp2 F p ηp2 
Physiological                       
Plasma caffeinea 2.5 n.s.   .074 0.5 n.s. .017 12.0 .000 .280 2.3 n.s. .069 2.7 .037 .080 1.6 n.s. .049 .9 n.s. .028 
Plasma nicotinea 24.4 .000 .441 11.2 .002 .265 19.2 .000 .382 3.9 n.s. .113 13.0 .000 .295 4.8 .003 .133 2.8 .042 .083 
Heart rateb 5.7 .023 .155 3.1 n.s. .090 55.2 .000 .640 3.8 n.s. .109 3.3 .000 .097 2.0 .020 .060 1.4 n.s. .043 
Systolic BPb 13.5 .001 .304 2.2 n.s. .066 2.2 .001 .067 1.8 n.s. .053 .9 n.s. .028 1.6 .030 .050 1.1 n.s. .033 
Diastolic BPb 8.4 .007 .214 5.6 .024 .153 2.8 .000 .082 4.5 .042 .127 2.0 .003 .060 1.5 n.s. .045 .9 n.s. .028 
Expired air COc 43.7 .000 .610 4.5 .043 .138 99.7 .000 .781 1.4 n.s. .046 45.2 .000 .617 4.3 .040 .132 2.2 n.s. .072 
                                            
DESa                                           
Nauseous  .2 n.s. .006 0.5 n.s. .015 3.5 .005 .101 6.0 .020 .163 1.3 n.s. .040 .7 n.s. .022 1.1 n.s. .035 
Dizzy .7 n.s. .023 0.8 n.s. .027 6.0 .000 .161 3.1 n.s. .091 1.0 n.s. .032 .7 n.s. .021 2.5 n.s. .073 
Lightheaded 3.4 n.s. .098 0.7 n.s. .024 14.4 .000 .317 3.3 n.s. .097 2.0 n.s. .062 .5 n.s. .015 2.1 n.s. .063 
Nervous .1 n.s. .002 1.3 n.s. .041 3.6 .028 .105 4.4 .045 .124 .8 n.s. .025 .6 n.s. .019 2.2 n.s. .066 
Sweaty 3.4 n.s. .099 2.5 n.s. .073 0.8 n.s. .026 .8 n.s. .024 .1 n.s. .004 .4 n.s. .013 1.4 n.s. .043 
Headache 1.0 n.s. .031 0.8 n.s. .024 3.7 .006 .107 3.6 n.s. .105 .8 n.s. .025 1.3 n.s. .041 1.1 n.s. .035 
Salivation .2 n.s. .005 0.0 n.s. .001 3.3 .017 .097 1.4 n.s. .043 .9 n.s. .029 .4 n.s. .012 1.3 n.s. .040 
Heart pounding .2 n.s. .006 3.3 n.s. .095 3.1 .033 .092 2.5 n.s. .075 .4 n.s. .014 2.2 n.s. .067 .8 n.s. .025 
Confused .0 n.s. .001 0.6 n.s. .018 4.2 .020 .119 3.6 n.s. .103 .9 n.s. .028 1.0 n.s. .032 1.1 n.s. .036 
Weak .3 n.s. .009 0.1 n.s. .002 3.6 .010 .104 3.0 n.s. .089 .9 n.s. .029 0.3 n.s. .009 2.2 n.s. .067 
Hungry  .0 n.s. .001 0.0 n.s. .001 12.3 .000 .284 3.9 n.s. .111 1.8 n.s. .053 .4 n.s. .011 2.6 .031 .076 
Rush  2.3 n.s. .070 1.3 n.s. .039 10.9 .000 .260 4.8 .035 .135 2.4 .040 .072 .9 n.s. .028 1.6 n.s. .050 
High 6.4 .017 .170 0.8 n.s. .024 15.5 .000 .333 4.3 .046 .122 2.3 n.s. .068 1.1 n.s. .034 2.3 n.s. .069 
Feel drug effects 2.7 n.s. .079 0.8 n.s. .026 19.2 .000 .382 3.9 n.s. .111 1.6 n.s. .050 1.2 n.s. .038 2.0 n.s. .062 
Like drug effects .6 n.s. .020 0.2 n.s. .005 21.2 .000 .406 2.0 n.s. .060 1.8 n.s. .056 1.0 n.s. .033 3.1 .010 .090 
Dislike drug effects .3 n.s. .008 0.3 n.s. .010 7.1 .000 .185 .2 n.s. .008 .9 n.s. .027 .7 n.s. .021 1.1 n.s. .034 
Good drug effects 2.4 n.s. .072 0.0 n.s. .000 23.1 .000 .427 1.3 n.s. .041 2.4 n.s. .071 .6 n.s. .020 1.6 n.s. .048 
Bad drug effects 1.2 n.s. .038 0.6 n.s. .020 8.2 .000 .210 3.4 n.s. .098 1.0 n.s. .030 2.5 .035 .074 1.0 n.s. .031 
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a N = 32: dfNicotine (N) = (1,31); dfCaffeine (C) = (1,31); dfTime (T) = (7,217); dfN X C = (1,31); dfN X T = (7,217); dfC X T = (7,217); dfN X C X T = (7,217) . 
b N = 32: dfNicotine (N) = (1,31); dfCaffeine (C) = (1,31); dfTime (T) = (24,744); dfN X C = (1,31); dfN X T = (24,744); dfC X T = (24,744); dfN X C X T = (24,744).  
c N = 29: dfNicotine (N) = (1,28); dfCaffeine (C) = (1,28); dfTime (T) = (4,112); dfN X C = (1,28); dfN X T = (4,112); dfC X T = (4,112); dfN X C X T = (4,112).  
 
 
 Nicotine (N) Caffeine (C) Time (T) N X C N X T C X T N X C X T 
 F P ηp2 F p ηp2 F p ηp2 F p ηp2 F p ηp2 F p ηp2 F p ηp2 
POMSa                                           
Tension .3 n.s. .008 1.0 n.s. .030 3.5 .014 .100 3.2 n.s. .093 1.1 n.s. .034 3.6 .002 .104 1.0 n.s. .032 
Depression 1.1 n.s. .035 .2 n.s. .006 2.4 n.s. .071 1.5 n.s. .045 .7 n.s. .023 4.2 .010 .118 .8 n.s. .026 
Anger 1.4 n.s. .044 .1 n.s. .002 2.4 n.s. .072 4.1 n.s. .118 .6 n.s. .020 2.3 n.s. .070 .7 n.s. .021 
Vigor .2 n.s. .006 .0 n.s. .001 6.1 .001 .164 .6 n.s. .018 1.4 n.s. .043 1.3 n.s. .040 .5 n.s. .017 
Fatigue .8 n.s. .024 .0 n.s. .000 2.2 n.s. .067 1.7 n.s. .051 .7 n.s. .021 .3 n.s. .010 .3 n.s. .010 
Confusion .2 n.s. .008 1.6 n.s. .050 2.9 n.s. .085 1.6 n.s. .048 1.5 n.s. .047 1.6 n.s. .049 1.2 n.s. .039 
Arousal .4 n.s. .012 .0 n.s. .000 3.7 .016 .107 .8 n.s. .025 .4 n.s. .014 .5 n.s. .016 .4 n.s. .013 
                                            
PANASa                                           
Positive .0 n.s. .000 .1 n.s. .004 3.7 .011 .108 .1 n.s. .002 .4 n.s. .013 .5 n.s .016 1.0 n.s. .030 
Negative .9 n.s. .027 .4 n.s. .013 3.6 .020 .103 .8 n.s. .025 .1 n.s. .003 3.1 0.018 .091 1.3 n.s. .041 
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Figure 4. Mean data (±1 SEM) for plasma caffeine across conditions (PLACEBO = no caffeine/ 
no nicotine; NIC = nicotine/no caffeine; CAFF/LN = low nicotine/caffeine; CAFF/NIC = 
caffeine/nicotine). Panel A includes all completers (N = 32) and Panel B only includes 
individuals with a plasma caffeine concentration below 1000 ng/ml at baseline N = 27). Filled 
symbols indicate a significant difference relative to baseline, and asterisks (*) indicate a 
significant difference relative to CAFF/NIC at that time point (p < 0.05, Tukey’s HSD). 
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100.1) at baseline, 344.0 ng/ml (SEM = 103.1) at 45 minutes (termination of product 
administration), and 293.0 (SEM = 86.2) at 120 minutes (end of session).   
Inspection of the raw data revealed that five individuals had a baseline plasma caffeine 
concentration above 1000 ng/ml during at least one session.  Other clinical examinations indicate 
after 24 hours of caffeine abstinence all or most individuals’ plasma caffeine concentrations 
would be < 1 mg/L (1000 ng/ml; Jacobson et al., 1994; Zheng & Williams, 2002), and after 12 
hours approximately 75% of individuals would be under 1000 ng/ml (Majd-Ardekani et al., 
2000).  Using this conservative plasma caffeine concentration cut-off (1000 ng/ml), those five 
individuals were removed from the dataset and plasma caffeine data were re-analyzed (N = 27).  
Results mirrored the analysis of 32 participants with a significant main effect of time (F[7,182] = 
10.1, p < 0.001), but without a significant interaction of nicotine by time (F[7, 182] = 1.1. p = 
0.355).  Figure 4 Panel B displays the time course of plasma caffeine concentrations by condition 
for individuals with a baseline plasma caffeine concentration less than 1000 ng/ml.   
For plasma nicotine, a significant nicotine by caffeine by time interaction was observed 
(p = 0.04).  As seen in Figure 5, relative to baseline (collapsed across all conditions, 2.1 ng/ml, 
SEM = 0.1) CAFF/NIC and NIC were associated with significant increases in plasma nicotine 
level at most time points (p < 0.05, Tukey’s HSD).  The greatest mean increase for CAFF/NIC 
and NIC was observed at forty-five minutes post product administration: CAFF/NIC M = 10.4 
ng/ml, SEM = 1.5; NIC M = 8.5 ng/ml, SEM = 1.2; p < 0.05, Tukey’s HSD).  During the 
CAFF/LN condition, mean plasma nicotine concentration was elevated significantly relative to   
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Figure 5. Mean data (±1 SEM) for plasma nicotine across conditions (PLACEBO = no caffeine/ 
no nicotine; NIC = nicotine/no caffeine; CAFF/LN = low nicotine/caffeine; CAFF/NIC = 
caffeine/nicotine; N = 32).  Filled symbols indicate a significant difference relative to baseline, 
and asterisks (*) indicate a significant difference relative to CAFF/NIC at that time point (p < 
0.05, Tukey’s HSD). 
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baseline at 30 minutes (M = 5.7, SEM = 0.8) and 45 minutes (M = 5.8, SEM = 0.7) post product 
administration (p < 0.05, Tukey’s HSD).  In contrast, plasma nicotine concentration did not 
increase significantly during PLACEBO.  Relative to CAFF/NIC plasma nicotine concentrations 
post product administration, all PLACEBO concentrations and CAFF/LN concentrations at 45 
and 60 minutes were lower significantly (p < 0.05, Tukey’s HSD). 
For heart rate, Table 4 shows that a significant nicotine by time and caffeine by time 
interaction were observed (Fs > 1.9, ps < 0.05).  Figure 6 displays the results across conditions 
and significant increases relative to baseline were observed during all conditions except for 
PLACEBO, and PLACEBO was the only condition where significant differences relative to 
CAFF/NIC were observed (ps <0.05, Tukey’s HSD).  When conditions were collapsed across 
nicotine-containing products (NIC and CAFF/NIC) and those that contained less or none 
(PLACEBO and CAFF/LN), the greatest mean increase relative to baseline (collapsed across all 
conditions, 70.4 bpm) occurred during conditions that contained nicotine at 10 minutes post 
product administration (M = 79.6 bpm, SEM = 1.8; p < 0.05; Tukey’s HSD), and there were no 
significant differences between product types at any time point.  When conditions were collapsed 
across caffeine-containing products (CAFF/NIC and CAFF/LN) and those that contained none 
(PLACEBO and NIC), the greatest mean increase relative to baseline occurred during conditions 
that contained caffeine at 10 minutes post product administration (M = 78.9, SEM = 1.8; p < 
0.05, Tukey’s HSD), and there were no significant differences between product types at any time 
point.   
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Figure 6. Mean data (±1 SEM) for HR across conditions (PLACEBO = no caffeine/ no nicotine; 
NIC = nicotine/no caffeine; CAFF/LN = low nicotine/caffeine; CAFF/NIC = caffeine/nicotine; N 
= 32).  Filled symbols indicate a significant difference relative to baseline, and asterisks (*) 
indicate a significant difference relative to CAFF/NIC at that time point (p < 0.05, Tukey’s 
HSD). 
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As Table 4 shows, a significant caffeine by time interaction was observed for systolic 
blood pressure and a significant nicotine by time interaction was observed for diastolic blood 
pressure (Fs > 1.5 ps < 0.05).  Figure 7 Panel A displays systolic BP data across conditions, and 
there were no significant differences relative to baseline or to CAFF/NIC (n.s., Tukey’s HSD) . 
When conditions were collapsed across caffeine-containing products (CAFF/NIC and CAFF/LN) 
and those that contained none (PLACEBO and NIC), the greatest mean systolic blood pressure 
increase relative to baseline (collapsed across all conditions, 116.1 mm Hg) occurred during 
conditions that contained caffeine at 45 minutes post product administration (M = 122.6 mm Hg, 
SEM = 2.5; n.s., Tukey’s HSD), and there were no significant differences relative to baseline or 
between product types at any time point (n.s., Tukey’s HSD).  Figure7 Panel B displays diastolic 
BP across conditions, and while there were no significant differences relative to baseline for any 
condition, there were two time points during PLACEBO that were significantly different relative 
to CAFF/NIC (ps < 0.05,Tukey’s HSD).  For diastolic BP, when conditions were collapsed 
across nicotine-containing products (NIC and CAFF/NIC) and those that contained less or none 
(PLACEBO and CAFF/LN), the greatest mean diastolic blood pressure increase relative to 
baseline (collapsed across all conditions, 64.0 mm Hg) occurred during conditions that contained 
nicotine at 55 minutes post product administration (M =70.1 mm Hg, SEM = 1.8; see Figure 7 
Panel B; n.s., Tukey’s HSD) and there were no significant differences relative to baseline or 
between product types at any time point (n.s., Tukey’s HSD). 
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Figure 7. Mean data (±1 SEM) for systolic BP (Panel A; N = 32) and diastolic BP (Panel B; N = 
32) across conditions (PLACEBO = no caffeine/ no nicotine; NIC = nicotine/no caffeine; 
CAFF/LN = low nicotine/caffeine; CAFF/NIC = caffeine/nicotine). No significant differences 
relative to baseline were observed, and asterisks (*) indicate a significant difference relative to 
CAFF/NIC at that time point (p < 0.05, Tukey’s HSD).  
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For expired air CO, significant nicotine by time and caffeine by time interactions were 
observed (Fs > 4.2, ps < 0.05).  Figure 8 displays mean expired air CO data across conditions 
and significant increases relative to baseline were observed in all conditions as well as significant 
differences for PLACEBO and CAFF/LN relative to CAFF/NIC (ps  < 0.05, Tukey’s HSD).  
When conditions were collapsed across nicotine-containing products (NIC and CAFF/NIC) and 
those that contained less or none (PLACEBO and CAFF/LN), both product groups displayed 
significant increases relative to baseline (all ps <0.05, Tukey’s HSD).  The greatest mean expired 
air CO increase relative to baseline (collapsed across all conditions, 2.9 ppm) occurred during 
conditions that contained less or no nicotine at 50 minutes post product administration (M = 29.3 
ppm , SEM = 3.3; p <0.05, Tukey’s HSD), and all time points post product administration were 
significantly higher for conditions that contained less or no nicotine (PLACEBO and CAFF/LN) 
compared to those containing higher amounts of nicotine (NIC and CAFF/NIC; all ps < 0.05, 
Tukey’s HSD). When expired air CO results were examined by caffeine content status, both 
product types produced significant increases in expired air CO relative to baseline (all ps <0.05, 
Tukey’s HSD), but there were no differences in mean expired air CO between caffeine 
containing products (CAFF/NIC and CAFF/LN) and those that did not (PLACEBO and NIC) at 
any time point (n.s., Tukey’s HSD).  
Subjective measures. 
Direct effects scale. As shown in Table 4, significant nicotine by caffeine by time 
interactions were observed for the DES items assessing “Hungry” and “Do you like the drug 
effects?” (Fs > 2.5, ps < 0.05), a significant nicotine by time interaction was observed for   
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Figure 8. Mean data (±1 SEM) for expired air CO across conditions (PLACEBO = no caffeine/ 
no nicotine; NIC = nicotine/no caffeine; CAFF/LN = low nicotine/caffeine; CAFF/NIC = 
caffeine/nicotine; N = 29).  Filled symbols indicate a significant difference relative to baseline, 
and asterisks (*) indicate a significant difference relative to CAFF/NIC at that time point (p < 
0.05, Tukey’s HSD).  
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 “Do you feel a rush?”, and a significant caffeine by time interaction was observed for “Do you 
feel any bad drug effects?” (Fs > 2.3, ps < 0.05).  Figure 9 Panel A displays the results for “Do 
you like the drug effects?” across conditions an  item which significant differences relative to 
baseline (collapsed across conditions, 2.4) were observed in all conditions following product 
administration until the 90 minute time point (p < 0.05, Tukey’s HSD).  The greatest mean 
increase relative to baseline occurred during NIC at 15 minutes post product administration (M = 
31.4, SEM = 4.5), and there were no differences between CAFF/NIC and other conditions at any 
time point (n.s., Tukey’s HSD).  For the item “Hungry”, significant increases relative to baseline 
were observed at the 90 minute time point for PLACEBO and at the 120 minute time point for all 
conditions except for CAFF/LN (see Figure 9 Panel B; p < 0.05, Tukey’s HSD).  There were no 
significant differences relative to the CAFF/NIC condition at any time point.   
Results for the “Do you feel a rush?” item are displayed in Figure 10 Panel A. Across 
conditions, significant increases relative to baseline were observed the smoking administration 
period during all conditions (p < 0.05, Tukey’s HSD), but there were no significant differences 
relative to CAFF/NIC (n.s., Tukey’s HSD).  When results were collapsed across nicotine- 
containing products (NIC and CAFF/NIC) and those that had little or none (PLACEBO and 
CAFF/LN), significant increases relative to baseline (collapsed across all conditions; M = 1.7, 
SEM = 1.0) were observed at 15 (M = 15.3, SEM = 3.6), 30 (M = 17.7, SEM = 3.8), and 45 (M = 
17.2, SEM = 4.3) minutes for NIC-CAFF/NIC and at 30 (M = 12.7, SEM = 3.0) and 45 (M = 
15.8, SEM = 3.9) minutes for PLACEBO-CAFF/LN (ps < 0.05, Tukey’s HSD). There were no 
differences between product types at any time point. Results for the item “Do you feel any bad   
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Figure 9. Mean scores (±1 SEM) for “Do you like the drug effects?” (Panel A; N = 32) and 
“Hungry” (Panel B) across conditions (PLACEBO = no caffeine/ no nicotine; NIC = nicotine/no 
caffeine; CAFF/LN = low nicotine/caffeine; CAFF/NIC = caffeine/nicotine; N = 32). Filled 
symbols indicate a significant difference relative to baseline, and asterisks (*) indicate a 
significant difference relative to CAFF/NIC at that time point (p < 0.05, Tukey’s HSD).  
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Figure 10. Mean scores (±1 SEM) for “Do you feel a rush?” (Panel A) and “Do you feel any bad 
drug effects?” (Panel B) across conditions (PLACEBO = no caffeine/ no nicotine; NIC = 
nicotine/no caffeine; CAFF/LN = low nicotine/caffeine; CAFF/NIC = caffeine/nicotine; N = 32).  
Filled symbols indicate a significant difference relative to baseline (p < 0.05, Tukey’s HSD), and 
asterisks (*) indicate a significant difference relative to CAFF/NIC at that time point (p < 0.05, 
Tukey’s HSD).  
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drug effects?”are displayed in Figure 10 Panel B, and significant increases relative to baseline 
were observed during NIC, CAFF/LN and CAFF/NIC.  When this item was examined by 
caffeine content status, significant increases relative to baseline (collapsed across conditions, 0.9) 
were observed at 30 (M = 10.7, SEM = 3.1), 45 (M = 11.6, SEM = 3.3), and 60 (M = 11.0, SEM = 
3.5) minutes post product administration during conditions that contained caffeine (CAFF/NIC 
and CAFF/LN; ps < 0.05; Tukey’s HSD).  There were no differences between product types for 
any time point. 
The profile of mood states and positive and negative affect scale. The POMS factors 
tension/anxiety and depression/dejection and the PANAS negative affect factor had significant 
caffeine by time interactions (Fs > 3.0, ps < 0.05).  When depression/dejection (factor with the 
largest F-value; see Figure 11) was examined across conditions, no significant differences 
relative to baseline or to CAFF/NIC at any time point were observed (n.s., Tukey’s HSD).  When 
results for this item were collapsed across caffeine content status, there were no significant 
differences relative to baseline for either product group. The greatest increase relative to baseline 
occurred during caffeine-containing conditions (CAFF/NIC and CAFF/LN) at 45 minutes (M = 
2.3, SEM = 0.8) post product administration  (n.s., Tukey’s HSD).  There were no differences 
between product types for any time point (n.s., Tukey’s HSD).  Results for POMS-
tension/anxiety and PANAS-NA displayed a near identical pattern when collapsed across 
caffeine content status with the highest increases relative to baseline occurring during caffeine-
containing conditions. 
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Figure 11.  Mean scores (±1 SEM) for the POMS-Depression/Dejection factor across conditions 
(PLACEBO = no caffeine/ no nicotine; NIC = nicotine/no caffeine; CAFF/LN = low 
nicotine/caffeine; CAFF/NIC = caffeine/nicotine; N=32).  No significant differences relative to 
baseline or to CAFF/NIC at any time point were observed (n.s., Tukey’s HSD). 
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Peak Change Analyses 
Table 5 displays peak change statistical analyses (main effects and interactions) for all 
measures. Interactions that involve both nicotine and caffeine factors are the most relevant as 
they indicate that the results observed differed between nicotine and caffeine-containing 
products. 
Physiological measures. As Table 5 shows there were no significant peak change effects 
for plasma caffeine and there was a significant main effect of nicotine and a significant main 
effect of caffeine for plasma nicotine (Fs > 13.5, ps <0.01). Plasma nicotine mean peak change 
across conditions is displayed in Figure 12 and PLACEBO and CAFF/LN were significantly 
lower than CAFF/NIC (ps < 0.05, Tukey’s HSD).  When peak plasma nicotine levels were 
collapsed into conditions that contained nicotine (NIC and CAFF/NIC) and those that contained 
less or none (PLACEBO and CAFF/LN), mean peak change of plasma nicotine was 
approximately 4 times higher during NIC-CAFF/NIC (M = 8.7, SEM = 1.7) compared to 
PLACEBO-CAFF/LN (M = 2.4, SEM = 0.4; p < 0.05, Tukey’s HSD).  When plasma nicotine 
levels were collapsed into conditions that contained caffeine (CAFF/NIC and CAFF/LN) and 
those that did not (PLACEBO and NIC), mean peak change of plasma nicotine was 
approximately 2 times higher during CAFF/NIC-CAFF/LN (M = 7.3, SEM = 1.4) compared to 
PLACEBO-NIC (M = 3.9, SEM = 0.7; p < 0.05, Tukey’s HSD). 
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Table 5.   
 
Peak change from baseline statistical analyses for all measures.  
  Nicotine (N)  Caffeine (C)  N X C 
  F p ηp2 
 
F P ηp2 
 
F p ηp2 
Physiological measures            
Plasma caffeinea 2.4 n.s. .072  .7 n.s. .021  3.9 n.s. .111 
Plasma nicotinea 27.5 .000 .470  13.6 .001 .305  3.9 n.s. .111 
Heart ratea 25.7 .000 .454  8.3 .007 .210  5.8 .022 .159 
Systolic BPa .9 n.s. .027  .0 n.s. .001  7.3 .011 .191 
Diastolic BPa 2.1 n.s. .063  .1 n.s. .003  .4 n.s. .012 
Expired air COb 45.3 .000 .618  3.9 n.s. .123  1.9 n.s. .062 
                     
DESa                    
Nauseous .0 n.s. .000  .0 n.s. .001  3.3 n.s. .095 
Dizzy 1.4 n.s. .042  .0 n.s. .002  2.8 n.s. .083 
Lightheaded 7.7 .009 .198  .1 n.s. .004  2.4 n.s. .072 
Nervous 2.2 n.s. .067  .0 n.s. .001  5.4 .027 .147 
Sweaty 5.4 .027 .148  .3 n.s. .010  2.8 n.s. .083 
Headache .2 n.s. .008  .6 n.s. .020  .8 n.s. .026 
Salivation .7 n.s. .023  .0 n.s. .000  1.7 n.s. .051 
Heart pounding .1 n.s. .004  2.6 n.s. .078  .6 n.s. .020 
Confused .5 n.s. .016  1.2 n.s. .039  3.3 n.s. .095 
Weak .1 n.s. .002  .4 n.s. .012  .1 n.s. .003 
Hungry .9 n.s. .030  .8 n.s. .024  .0 n.s. .002 
Rush 4.0 n.s. .115  .6 n.s. .018  3.8 n.s. .110 
High 8.3 .007 .210  .5 n.s. .014  3.2 n.s. .094 
Feel drug effects 5.2 .030 .143  .9 n.s. .029  8.4 .007 .213 
Like drug effects 3.5 n.s. .102  .3 n.s. .009  1.7 n.s. .051 
Dislike drug effects .6 n.s. .020  .1 n.s. .004  .9 n.s. .027 
Good drug effects 2.8 n.s. .083  .4 n.s. .014  1.7 n.s. .053 
Bad drug effects 3.0 n.s. .089  .7 n.s. .023  .6 n.s. .018 
                     
POMSa                    
Tension 2.2 n.s. .066  8.7 .006 .219  1.4 n.s. .042 
Depression .5 n.s. .017  6.6 .015 .175  .8 n.s. .026 
Anger .1 n.s. .003  1.1 n.s. .036  3.5 n.s. .102 
Vigor 1.3 n.s. .040  .0 n.s. .000  .0 n.s. .000 
Fatigue .1 n.s. .005  .1 n.s. .004  .9 n.s. .028 
Confusion .1 n.s. .004  3.4 n.s. .098  .3 n.s. .009 
Arousal .1 n.s. .002  .2 n.s. .006  .7 n.s. .023 
                     
PANASa                    
Positive .1 n.s. .004  0.0 n.s. .001  .4 n.s. .014 
Negative 1.4 n.s. .043  5.3 .028 .147  1.4 n.s. .043 
a N = 32: dfNicotine (N) = (1,31); dfCaffeine (C) = (1,31); dfN X C = (1,31) 
b N = 29: dfNicotine (N) = (1,28); dfCaffeine (C) = (1,28); dfN X C = (1,28)  
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Figure 12. Mean peak change data (±1 SEM) for plasma nicotine across conditions (PLACEBO 
= no caffeine/ no nicotine; NIC = nicotine/no caffeine; CAFF/LN = low nicotine/caffeine; 
CAFF/NIC = caffeine/nicotine; N = 32). Asterisks (*) indicate a significant difference relative to 
CAFF/NIC at that time point (p < 0.05, Tukey’s HSD).  
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For both HR and systolic BP, a significant nicotine by caffeine interaction was observed 
(Fs > 5.7, ps < 0.05).  Mean peak change for HR was the highest and identical for NIC and 
CAFF/NIC (M = 14.1, SEM = 1.3) and was followed by CAFF/LN (M = 11.6, SEM = 1.4) and 
PLACEBO (M = 7.1, SEM = 0.9; see Figure 13 Panel A).  Mean peak change HR for PLACEBO 
differed significantly from CAFF/NIC (p < 0.05, Tukey’s HSD).  Mean peak change for systolic 
BP was the highest for NIC (M = 29.4, SEM = 2.6) followed by CAFF/LN (M = 26.2, SEM = 
2.2), CAFF/NIC (M = 23.2, SEM = 2.6), and PLACEBO (M = 20.9, SEM = 2.7; see Figure 13 
Panel B).  There were no significant differences for systolic BP between other conditions and 
CAFF/NIC (n.s., Tukey’s HSD).   
For expired air CO, there was a significant main effect of nicotine.  Figure 14 displays 
results across conditions, and PLACEBO and CAFF/LN peak change concentrations for expired 
air CO were significantly higher than CAFF/NIC (ps < 0.05, Tukey’s HSD). When results were 
examined by nicotine content status, significantly higher mean peak change was observed for 
conditions that contained little or no nicotine (PLACEBO and CAFF/LN; M = 27.6, SEM = 3.5) 
compared to those contained nicotine (NIC and CAFF/NIC; M = 11.0, SEM = 1.4; p < 0.05, 
Tukey’s HSD).  
Subjective measures. 
Direct effects scale. For the items “Nervous” and “Do you feel any drug effects?” a 
significant nicotine by caffeine interaction was observed (Fs > 5.3, ps < 0.05) and for the items 
“Lightheaded”, “Sweaty”, and “How high are you?” a main effect of nicotine was observed (Fs 
>5.1, ps < 0.05).  For the “Do you feel any drug effects?” item (largest interaction F-value   
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Figure 13. Mean peak change data (±1 SEM) for HR (Panel A; N= 32) and systolic BP (Panel B) 
across conditions (PLACEBO = no caffeine/ no nicotine; NIC = nicotine/no caffeine; CAFF/LN 
= low nicotine/caffeine; CAFF/NIC = caffeine/nicotine; N = 32). Asterisks (*) indicate a 
significant difference relative to CAFF/NIC (p < 0.05, Tukey’s HSD).   
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Figure 14. Mean peak change data (±1 SEM) for expired air CO across conditions (PLACEBO = 
no caffeine/ no nicotine; NIC = nicotine/no caffeine; CAFF/LN = low nicotine/caffeine; 
CAFF/NIC = caffeine/nicotine; N= 32). Asterisks (*) indicate a significant difference relative to 
CAFF/NIC (p < 0.05, Tukey’s HSD). 
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observed; see Figure 15), mean peak change was the highest for NIC (M = 39.9, SEM = 5.2) 
followed by CAFF/NIC (M = 31.8, SEM = 5.0), CAFF/LN (M = 28.6, SEM = 4.9), and 
PLACEBO (M = 26.2, SEM = 5.6).  There were no significant differences relative to CAFF/NIC 
(n.s., Tukey’s HSD).  Results for “Nervous” were near identical with the highest mean peak 
change scores observed during NIC (M = 8.3, SEM = 3.0) and the lowest during PLACEBO (M 
= 1.7, SEM = 0.5) with no significant differences relative to CAFF/NIC.  The DES item with the 
largest main effect F-value for nicotine was “How high are you?”, and results across conditions 
indicated there were no significant differences relative to CAFF/NIC (see Figure 16; n.s., 
Tukey’s HSD).  When mean peak change values were collapsed by nicotine-containing status, 
mean score for nicotine-containing conditions (NIC and CAFF/NIC; M = 28.3, SEM = 4.7) was 
higher than those that contained little or none (PLACEBO and CAFF/LN; M = 20.5, SEM = 4.4; 
n.s.; Tukey’s HSD).  This identical pattern of results was observed for the items “Lightheaded”, 
and “Sweaty”.  
The profile of mood states and positive and negative affect scale.  Among these two 
subjective measures, a significant main effect of caffeine was observed for the POMS factors 
tension/anxiety and depression/dejection and for the PANAS negative affect factor. The POMS 
factor tension/anxiety had the largest main effect F-value for caffeine, and results across 
conditions are displayed in Figure 17.  Across conditions, peak change score for PLACEBO was 
significantly lower than CAFF/NIC (p < 0.05; Tukey’s HSD). When scores for this item were 
collapsed by caffeine content status, mean peak change score was higher among conditions that 
contained caffeine (CAFF/NIC and CAFF/LN; M = 3.2, SEM = 0.7) compared those did not   
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Figure 15. Mean peak change data (±1 SEM) for the DES item “Do you feel any drug effects?” 
across conditions (PLACEBO = no caffeine/ no nicotine; NIC = nicotine/no caffeine; CAFF/LN 
= low nicotine/caffeine; CAFF/NIC = caffeine/nicotine; N= 32). There were no significant 
differences relative to CAFF/NIC for any condition (n.s., Tukey’s HSD).  
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Figure 16. Mean peak change data (±1 SEM) for the DES item “Do you feel high?” across 
conditions (PLACEBO = no caffeine/ no nicotine; NIC = nicotine/no caffeine; CAFF/LN = low 
nicotine/caffeine; CAFF/NIC = caffeine/nicotine; N= 32). There were no significant differences 
between conditions relative to CAFF/NIC (n.s., Tukey’s HSD). 
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Figure 17. Mean peak change data (±1 SEM) for the POMS factor tension/anxiety across 
conditions (PLACEBO = no caffeine/ no nicotine; NIC = nicotine/no caffeine; CAFF/LN = low 
nicotine/caffeine; CAFF/NIC = caffeine/nicotine; N= 32). Asterisks (*) indicate a significant 
difference relative to CAFF/NIC (p < 0.05, Tukey’s HSD). 
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(PLACEBO and NIC; M = 1.8, SEM = 0.5; see Figure 17; n.s.; Tukey’s HSD).  Results for 
POMS-depression/dejection and PANAS-NA factors displayed an identical pattern of results 
when collapsed by caffeine content status with higher scores observed during conditions that 
contained caffeine but not significantly different between product types (n.s., Tukey’s HSD).  
Puff Topography 
Mean values for all puff topography measures by condition are displayed in Table 6 and 
the results of statistical analyses are shown in Table 7.  A significant main effect of nicotine was 
observed for mean IPI, total volume, and mean puff volume, total puffing time, and puff duration 
(Fs > 19.2, ps < 0.001), and a significant main effect of caffeine was observed for mean puff 
volume and puff duration (Fs > 5.7 p < 0.001).  When IPI was examined by nicotine status, a 
shorter IPI between puffs was observed during conditions containing little or no nicotine 
(PLACEBO and CAFF/LN; M = 34.1 s, standard deviation [SD] = 23.4) compared to those with 
nicotine (NIC and CAFF/NIC; M = 41.3 s, SD = 29.8), but this difference was not significant; 
n.s.; Tukey’s HSD).  When total volume was examined by nicotine status, a significantly higher 
total volume was observed during conditions containing little or no nicotine (PLACEBO and 
CAFF/LN; M = 53.4 L, SD = 32.0) compared to those with nicotine (NIC and CAFF/NIC; M = 
31.2 L, SD = 19.7; p < 0.05; Tukey’s HSD).   
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Table 6.   
Mean (standard deviation) of all topography measures.  
  PLACEBO NIC CAFF/LN CAFF/NIC 
Mean IPI (s) 34.7 (21.8) 44.9 (33.6) 33.5 (25.0) 37.7 (26.0) 
Puffs 94.8 (57.7) 94.8 (115.3) 121.4 (144.9) 104.4 (113.5) 
Total volume (l) 56.8 (33.8) 31.2 (22.4) 49.9 (30.2) 31.2 (17.0) 
Mean puff volume (ml) 683.1 (327.6) 422.5 (250.4) 508.0 (227.2) 369.4 (192.1) 
Total puffing time (min) 4.9 (2.5) 2.9 (1.8) 4.8 (2.5) 3.1 (1.8) 
Puff duration (s) 3.5 (2.0) 2.3 (.9) 3.0 (1.4) 2.2 (1.5) 
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Table 7.   
 
Statistical analyses for topography measures.  
 
 Nicotine (N) p ηp2 Caffeine (C) p ηp2 N X C p ηp2 
Mean IPI (s) 19.3 .000 .383 2.1 n.s. .062 2.2 n.s. .067 
Puffs 2.1 n.s. .064 2.9 n.s. .087 .7 n.s. .023 
Total volume (l) 55.7 .000 .643 .9 n.s. .027 1.6 n.s. .050 
Mean puff volume (ml) 43.8 .000 .585 15.3 .000 .331 2.4 n.s. .072 
Total puffing time (min) 72.7  .000 .701 .0 n.s. .000 .4 n.s. .011 
Average puff duration (s) 36.9 .000 .543 5.8 .022 .158 1.0 n.s. .032 
          
Note: N = 32: dfNicotine (N) = (1,31); dfCaffeine (C) = (1,31); dfN X C = (1,31)
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When mean puff volume was examined by nicotine content, higher mean puff volumes 
were observed during conditions that contained little or no nicotine (PLACEBO and CAFF/LN; 
M = 595.5 ml, SD = 302.4) compared to those with nicotine (NIC and CAFF/NIC; M = 395.9 ml, 
SD = 221.3; p < 0.05; Tukey’s HSD).  When mean puff volume was examined by caffeine 
content status, conditions containing none (PLACEBO and NIC; M = 552.8 ml, SD = 289.0) 
were not significantly different compared to those that contained caffeine (CAFF/NIC and 
CAFF/LN; M = 438.6 ml, SD = 234.7; n.s., Tukey’s HSD). 
Total puffing time was significantly shorter during conditions that contained nicotine 
(CAFF/NIC and CAFF/LN; M = 3.0 min, SD = 1.9) compared to those that contained little or 
none (PLACEBO and NIC; M = 4.8 min, SD = 2.5; p < 0.05; Tukey’s HSD).  Average puff 
duration was also significantly shorter during conditions that contained nicotine (CAFF/NIC and 
CAFF/LN; M = 2.3 s, SD = 1.2) compared to those that contained little or none (PLACEBO and 
NIC; M = 3.3 s, SD = 1.7; p < 0.05; Tukey’s HSD).  When average puff duration was examined 
by caffeine content status, there was not a significant difference between condition groups (n.s., 
Tukey’s HSD). 
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Discussion 
Overview  
Caffeine and nicotine are the two most commonly consumed licit psychoactive drugs in 
the world.  In addition, their co-administration is relatively common with over 86% of cigarette 
smokers report using caffeine versus 77% of non-smokers (Swanson et al., 1994).  Some 
previous research suggests the combination of nicotine and caffeine may produce effects that are 
more rewarding or pleasurable than either drug alone (Jones & Griffiths, 2003; Perkins et al., 
1994) and this potential reward enhancement may influence patterns of tobacco use initiation and 
maintenance.  Waterpipe tobacco smoking is an alternative tobacco use method that is increasing 
in prevalence in the U.S. especially among adolescent and young adult populations (Barnett 
Curbow, Soule, Tomar, & Thombs, 2009; Akl et al., 2011; Smith et al., 2011) and offers a novel 
opportunity for nicotine and caffeine co-administration via a caffeinated tobacco product: 
Tangiers F-Line.  This product enables users, who may be among an age group that is especially 
vulnerable to tobacco use initiation, to consume this combination of drugs in a single form.  Data 
concerning “smoked” (i.e., volatilized) caffeine are sparse (Zandvilet et al., 2005; Brenneisen, & 
Hasler, 2002), but reports indicate it is absorbed and metabolized similarly to other methods of 
caffeine administration.  Taken with the evidence from previous nicotine and caffeine co-
administration studies, this caffeinated tobacco product was hypothesized to enhance reward-
related and cardiovascular effects in users relative to typical waterpipe tobacco preparations.   
The purpose of this study was to compare, using a within-subject, factorial design, the 
subjective and cardiovascular effects of smoking caffeinated waterpipe tobacco with the effects 
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of smoking waterpipe preparations containing nicotine and no caffeine, low nicotine and 
caffeine, or neither nicotine nor caffeine.  To that end, data were analyzed from thirty-two 
waterpipe smokers who participated in four Latin-squared ordered sessions that differed by 
product administered.  During each session, there was a 45-minute double-blind product 
administration period.  In addition, blood plasma was collected, cardiovascular, expired air CO, 
and puff topography measurements were made, and subjective measures were administered.  The 
outcome measures of primary interest were cardiovascular (BP) and subjective effects as well as 
plasma caffeine exposure.  As noted in the results (see Figure 4), the caffeine-containing 
waterpipe products failed to deliver measurable caffeine doses in this study.  Therefore, the 
discussion below focuses primarily on (1) the effects of smoking nicotine-containing tobacco in 
a waterpipe, (2) potential non-pharmacological influences on waterpipe smoking behavior, (3) a 
future study design, and (4) limitations of the study.  
Effects of Smoking Nicotine-containing Tobacco in a Waterpipe 
 Several results of the current study were similar to those observed in another placebo-
controlled examination of smoking nicotine-containing tobacco in a waterpipe in a clinical 
laboratory (Blank et al., 2011). That previous study involved two double-blind counterbalanced 
sessions in which participants smoked their preferred flavor and brand of waterpipe tobacco or a 
flavor matched non-tobacco preparation for 45 minutes or longer (Blank et al., 2011). Similar to 
the current study, physiological (plasma nicotine, HR, BP, and expired air CO) and subjective 
responses were measured periodically.  At the conclusion of the smoking period, the mean 
nicotine concentration during the placebo condition was 2.1 ng/ml (SEM = 0.0), and during the 
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active tobacco condition was 5.6 ng/ml (SEM = 0.7).  In the current study, the highest plasma 
nicotine exposure during nicotine-containing conditions was observed at the conclusion of the 
smoking period during CAFF/NIC (M  = 10.4, SEM = 1.5) and NIC (M  = 8.5, SEM  = 1.2), and 
CAFF/LN (M  = 5.8, SEM  = 0.7).  CAFF/NIC plasma nicotine concentrations were significantly 
higher than all of those observed during PLACEBO and at 45 and 60 minutes during CAFF/LN. 
During both placebo-controlled studies reliable increases in HR were observed during the active 
or tobacco-containing conditions but not during the placebo (nicotine-free) condition.  No 
reliable BP effects were observed during the previous examination (Blank et al., 2011) or the 
current study. 
For the subjective effect measures of the earlier study, there were few interactions of 
condition and time and many significant main effects of time (Blank et al., 2011).  For example, 
significant main effects of time were observed for the items “Urges to smoke” and “Anxious” 
with decreases post-smoking observed during both conditions. This pattern of results indicates 
that these subjective effects decreased independent of the nicotine content of the product 
smoked.  Other subjective effect items including “Dizzy”, “Lightheaded”, and “Was the 
waterpipe pleasant?” were observed to increase post-smoking with no significant differences 
between conditions.  This pattern of results also was observed for most subjective items during 
the current study (see Table 4).  Thus, in both the previous study (Blank et al., 2011) and the 
current study, experienced waterpipe tobacco smoking participants reported similar subjective 
effects across nicotine-containing and nicotine-free conditions.  
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Important differences between the above mentioned placebo-controlled waterpipe study 
and the current study are related to puff topography and expired air CO exposure. Table 8 
displays the puff topography results for Blank et al. (2011), and when these mean values were 
analyzed by condition there were no significant differences.  However, results for puff 
topography did differ between conditions in the current study (see Table 7), with a significantly 
smaller mean total volume and mean puff volume during NIC-CAFF/NIC compared to 
PLACEBO-CAFF/LN.  As total smoke volume was positively correlated with expired air CO 
during all conditions (r = 0.54-0.80; N = 29, p < 0.01), the larger smoke volumes observed for 
PLACEBO-CAFF/LN may explain the higher CO concentrations observed during these 
conditions compared to NIC-CAFF/NIC (see Figure 8).  This finding was not observed during 
Blank et al., (2011) where nicotine content did not influence puff  topography or expired air CO 
concentrations.  Compensation or a change in smoking behavior to adjust to the mainstream 
smoke nicotine yield has been observed among cigarette smokers (Baldinger, Hasenfratz, & 
Bättig, 1995; Guyatt, Kirkham, Mariner, Baldry, & Cumming, 1989), and may also be driving 
the differences in puff topography observed in this study.  Interestingly, mean total puff volumes 
for the previous placebo controlled study (Placebo=55.7 l, Active=57.0 l; Blank et al., 2011) 
were more similar to conditions during the current study that contained little to no nicotine 
(PLACEBO=56.8; CAFF/LN=49.9) compared to conditions that contained nicotine (CAFF/NIC 
and NIC=31.2 l).  These differences may also be associated with the higher plasma nicotine 
concentrations observed during the current study for CAFF/NIC and NIC.  Compared to mean 
plasma nicotine concentrations in the active condition at the conclusion of smoking (Blank et al.,  
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Table 8.  
 
Puff topography statistics for a double-blind placebo-controlled waterpipe study among current 
waterpipe users (Blank et al., 2011).  
 
Note: Active=participant preferred waterpipe tobacco flavor/brand smoked; 
Placebo=flavor matched non-nicotine waterpipe product smoked (i.e., Soex).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 Active Placebo 
 Mean SD Mean  SD 
Inter-puff-interval (s) 47.5 21.4 45.8 26.4 
Puff number   66.3 42.2 71.2 48.6 
Total puff volume (l) 57.0 45.6 55.7 32.0 
Mean puff volume (ml) 906.1 517.4 873.0 366.7 
Puff duration (s)      3.9 1.5 3.7 1.4 
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2011), mean nicotine concentration was 2.9 ng/ml greater during NIC and 4.8 ng/ml greater 
during CAFF/NIC.  With reduced smoke inhalation and increased nicotine exposure compared to 
this previous study (Blank et al., 2011), these results suggest that participants in this study may 
have reduced their puff volumes in an attempt to compensate for the greater nicotine delivery 
associated with the NIC and CAFF/NIC conditions.  However, this interpretation is speculation: 
with two studies reporting contradictory results, more work is needed to clarify the extent to 
which behavioral compensation occurs in waterpipe tobacco smokers. 
A finding specific to the current study was the observation that neither caffeinated 
waterpipe tobacco product (CAFF/NIC, CAFF/LN) produced reliable increases in plasma 
caffeine concentrations under the conditions utilized here.  This failure to observe increases in 
plasma caffeine could be due various reasons. One is that the assay used to detect caffeine 
concentrations in plasma was not sensitive. Caffeine assay calibration/standard curve indicates 
that this insensitivity was unlikely using the current method (see Figure 3). There is also a 
chance that the caffeine used in the tobacco was a salt form (i.e., caffeine citrate) which could 
have impacted volatilization capacity/delivery characteristics. All previous work examining 
caffeine volatilization has been performed using an anhydrous base form of caffeine (see Klous, 
Lee, Hillebrand, et al., 2006; Klous, Lee, Van den Brink, et al., 2006; Brenneisen & Hasler, 
2002). Unfortunately more specific information concerning the methodology of adding caffeine 
to these tobacco products was unavailable. Lastly according to chemical analysis conducted 
specifically for this study, on average CAFF/NIC and CAFF/LN contained 0.5 mg/g of caffeine, 
and 10 grams of product were loaded in the waterpipe head for each session. Thus, the maximal 
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amount of caffeine in each head was 5 mg.  Inhalation of a 100 mg caffeine tablet heated via a 
lighter or heating plate has been estimated to produce plasma concentrations of caffeine in a 
typical individual of 1312 ng/ml (similar to consumption of a beverage with 80 mg of caffeine, 
1335 ng/ml; Zandvliet et al., 2005).  If this relationship was equivalent for caffeine consumed via 
inhalation of tobacco smoke (1312/100=13.12 ng/ml per mg of caffeine inhaled), the potential 
plasma caffeine increase possible from the products used for the current study would have been 
66 ng/ml (5*13.12 ng/ml).  Thus, the small amounts of caffeine present in the caffeinated 
products studied is another likely explanation for the observation that participants in this study 
were not exposed to caffeine, as indexed by plasma caffeine concentrations.  Importantly,  this 
study was sensitive enough to detect smoking-induced changes in plasma nicotine: the time 
course analysis of plasma nicotine concentration indicated the ηp2 term for the nicotine by time 
interaction and main effect of nicotine were of moderate size (accounted for 30-44 % of 
variance; see Table 4).  In sum, there are several factors which may have influenced the ability of 
this study to detect changes in plasma caffeine, and results here are limited to the caffeinated 
tobacco products analyzed as well as the conditions used.  Under these conditions, there was no 
evidence for a nicotine and caffeine interaction. Current study findings do not address the 
capacity to which other caffeinated waterpipe tobacco products or any combustible caffeinated 
product may deliver caffeine or interact with nicotine-related effects.  
For the current study, results from subjective measures did not indicate reward-related or 
pleasurable effects were enhanced in either caffeinated condition (CAFF/NIC or CAFF/LN) 
relative to the nicotine-only condition (NIC).  For example, the mean score for the item “Do you 
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like the drug effects?” was increased significantly relative to baseline at 30 minutes post product 
administration during NIC, and scores did not differ significantly  for CAFF/NIC and CAFF/LN.  
Other items, such as  “Do you feel a rush?”, “Do you feel any drug effects?”, “Lightheaded”, 
“Sweaty, and “How high are you?”, also were influenced by nicotine exposure as indexed by 
peak effects analysis, but these effects did not differ significantly between NIC and caffeinated 
tobacco product conditions.  In addition, there were four subjective items that showed effects 
specific to the caffeinated product conditions (CAFF/LN and CAFF/NIC): DES item “Do you 
feel any bad drug effects?”, POMS factors tension/anxiety and depression/dejection, and the 
PANAS scale of negative affect. Scores for the item “Do you feel any bad drug effects?” were 
significantly increased relative to baseline at three time points post product administration when 
scores were averaged across caffeine containing products (CAFF/LN, CAFF/NIC; 30, 45, and 60 
minutes).  While the time course analysis indicated a significant caffeine by time effect for the 
POMS factors tension/anxiety and depression/dejection and the PANAS scale of negative affect, 
for none of these items was a significant difference relative to baseline observed.  While minor, 
these effects may have been mediated by nicotine exposure (observed during CAFF/NIC and 
CAFF/LN) and other product differences (e.g., additives, taste differences) that were not present 
in NIC or PLACEBO.  Importantly, these measures indicated potentially adverse rather than 
positive effects associated with caffeinated tobacco products and are not likely to contribute to 
the reinforcing effects of these products. Overall, there were few subjective measures that 
significantly differed between product conditions including PLACEBO.  
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In summary, many of the findings with respect to the effects of tobacco containing and 
placebo waterpipe preparations in the current study were similar to those reported elsewhere 
(Blank et al., 2011).  In addition, this study revealed  no evidence of caffeine exposure when 
waterpipe smokers smoke a waterpipe loaded with 10 grams of a caffeinated waterpipe tobacco 
preparation, and also no indication of enhanced positive effects produced when smoking this 
preparation, at least under double-blind conditions.  Interestingly, anecdotal reports regarding 
Tangiers F-line (CAFF/NIC) contrast with the current study findings: “Tangiers caffeinated line 
of hookah tobacco will knock you out of your boots” (TimL, 9/19/08, Yelp.com), and “If regular 
Tangiers can give you a massive buzz, the F-Line brings it to a whole new level!” (Zeodynamic, 
6/28/07, Hookahpro.com). Together, these results and user reports suggest that, if present, the 
enhanced effects of caffeinated waterpipe tobacco may be due to other non-pharmacological 
influences. 
Potential Non-pharmacological Influences on Waterpipe Smoking Behavior  
Results reported here and elsewhere (Blank et al., 2011) suggest that there is little 
difference in subjective response between waterpipe tobacco products that contain nicotine and 
those that do not.  Potentially, this observation may indicate that other non-pharmacological 
factors and/or the “placebo effect” may be influencing user behavior and subjective response 
when individuals smoke non-nicotine-containing waterpipe products. Evidence from the 
cigarette smoking literature demonstrates that the administration of denicotinized cigarettes 
suppresses tobacco abstinence symptoms (Buchhalter et al., 2001; Butschky, Bailey, 
Henningfield, & Pickworth, 1995; Rose, Behm, Westman, & Johnson, 2000) and reduces ad 
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libitum smoking rates (Rose, Behm, Westman, Bates, & Salley, 2003) similarly to own brand 
smoking.  Some have suggested that non-pharmacological factors such as sensory stimulation 
(e.g., smell, smoke in the throat) and motor components (e.g., lighting the cigarette, moving the 
cigarette to mouth) can produce significant effects on smoking behavior even in the absence of 
nicotine (Rose, 2006; Rose, Tashkin, Ertle, Zinser, & Lafer, 1985; Westman, Behm, & Rose, 
1996). These various stimuli may acquire reinforcing properties via an associative mechanism 
such as classical conditioning (Rose & Levin, 1991).  
Besides the effects of prior conditioning, placebo effects also may be shaped by an 
individual’s expectations about a product’s drug content (e.g., nicotine, caffeine) via information 
from others or product packaging (see Figure 18) and expectations of the potential effects of that 
drug has on mood, behavior, and physiological sensations (Kirsch, 1999; Perkins et al., 2003). 
Expectancies that depend on contextual stimuli of instructions or salient cues are termed stimulus 
dependencies (Perkins, Sayette, Conklin, & Caggiula, 2003) and expectancies that refer to beliefs 
about the likely effects of a drug are termed response expectancies (Maddux, 1999; Martin & 
Sayette, 1993).  Response expectancies are associated usually with consequences of drug 
administration, such as fear, arousal, pain, and physiological reactions.  For example, cigarette 
response expectancies may be weight control, positive mood enhancement, and/or relief from 
urge or craving and waterpipe tobacco smoking response expectancies may be relaxation and/or 
stress reduction (Smith-Simone et al., 2008).  Specifically manipulating stimulus expectancies 
(e.g., telling participants they are receiving drug or no drug) can activate response expectancies 
associated with administration of that drug or with no drug.  
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Figure 18. Labels from three waterpipe product brands: Tangiers (top), Nakha (middle), and 
Soex (bottom).  
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In the current study, many of the cues present during each session were chosen to be 
consistent with participant’s smoking history including dim lighting, videos, comfortable chairs,  
waterpipe, quick-lighting charcoal, and flavored tobacco (albeit not the participants’ favorite 
flavor).  Likely, many of smoke-related sensations were similar during the current study as when 
participants were engaged in typical smoking behavior.  Without any instructions or direct 
manipulation of stimulus expectancies (Perkins et al., 2003), these cues may have acted as 
conditioned stimuli which could have activated conditioned responses and/or stimulus and 
response expectancies associated with typical (nicotine-containing) waterpipe tobacco smoking.  
Sensory characteristics play an important role in smoking and ratings of satisfaction and some  
deem them “critical in mediating the immediate subjective response to smoking” (Rose et al., 
2000).  If these conditioned effects were activated during all study sessions, it is possible that 
differences between product types (i.e., particularly PLACEBO and nicotine-containing 
products) may have been more difficult to discern. 
This study and another placebo-controlled waterpipe examination (Blank et al., 2011) 
demonstrated that in experienced users nicotine may be unrelated to subjective effects on many 
measures for waterpipe tobacco smoking at least in a single 45-minute laboratory session.  
Potentially, previous repeated pairings of the nicotine with waterpipe-associated cues such as 
taste, smell, and other stimuli may have produced a strong conditioned response in this 
population. Perhaps a better way to understand the effects of these different waterpipe products 
would be instead to manipulate systematically stimulus expectancies of certain products or in the 
case of current study, the drugs nicotine and caffeine. 
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Future Study Design for Caffeinated Waterpipe Tobacco 
Some agree that the best method to examine the specific influences of active drug and 
stimulus expectancies separately and together may be the balanced-placebo design (Marlatt & 
Rohsenow, 1981). For this two by two between-subjects manipulation, participants are randomly 
assigned to one of four conditions, corresponding to each combination of instruction (told drug 
vs. told no drug) and actual drug administration (given drug vs. given no drug). Thus, four 
effects are analyzed and the interaction of expectancies and pharmacological stimuli can be 
discriminated (Brandon, Juliano, & Copeland, 1999; Perkins et al., 2004; Juliano & Brandon, 
2002).  
A representative study that utilized this design examined the role of instructional set 
(concerning nicotine content) and actual nicotine content on measures of anxiety among 132 
cigarette smokers (Juliano & Brandon, 2002).  Participants were assigned to one of four 
conditions in a clinical laboratory setting: told nicotine/given nicotine, told nicotine/given de-
nicotinized cigarette (de-nic), told de-nic/given nicotine, and told de-nic/given de-nic.  Prior to 
cigarette administration, anxiety was induced by telling participants that they would give a short 
speech that would be videotaped.  Manipulation checks indicated that 12% of participants 
reported they were deceived about the content of the cigarette, and this suspicion was distributed 
evenly across the four groups.  Overall, the authors deemed the instruction set manipulation was 
effective for 74% of the total sample and analyses were restricted to these individuals except for 
certain cases.  Results indicated that individuals who smoked nicotine cigarettes experienced 
greater anxiety reduction and there was no effect of instructional set.  Analysis of self-reported 
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urge and craving indicated that instructional set had no effects in reductions of urge for those 
given nicotine, but among those given de-nic, individuals who were told nicotine had greater 
reductions in urge compared to those who were told de-nic.  Additional analyses indicated that 
for measures of anxiety reduction post-smoking for the full set of participants (N = 132), the 
impact of the instructional set manipulation was related to participants baseline expectancies 
(high or low) that smoking reduced negative affect.  Specifically, individuals with high 
expectancies for negative affect reduction who were told nicotine reported higher levels of 
anxiety reduction, while those told no nicotine had less reduction.  This interaction was less 
robust for those with low baseline expectancies of negative affect reduction from smoking.  This 
finding suggested to the authors that instructional set may have greater effects for those with 
these stronger expectancies (Juliano & Brandon, 2002).   
To address these influences, a study that manipulates stimulus expectancies as well as 
actual product content may be the best means to determine whether pharmacological and/or non-
pharmacological factors mediate anecdotal reports concerning caffeinated waterpipe tobacco.  
This proposed study again would aim to examine whether the effects of caffeinated waterpipe 
tobacco differ to those associated with smoking typical waterpipe tobacco products (nicotine-
containing).  Individuals who regularly smoked waterpipe and ingested caffeine would be 
recruited and randomized to one of four conditions: (1) told nicotine/caffeine and smoked 
nicotine/caffeine, (2) told nicotine/caffeine and smoked nicotine, (3) told nicotine and smoked 
nicotine/caffeine, (4) told nicotine and smoked nicotine.  Physiological and subjective responses 
would be recorded during each session.  In addition to the subjective measures used in the 
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current study, subjective items would also assess tobacco abstinence symptom suppression and 
smoking satisfaction. Also, an objective measure of behavior/performance would be included.  
This task would need to be sensitive to drug effects of nicotine and caffeine and could assess 
vigilance and/or memory.  Importantly, baseline expectancies would need to be assessed by 
either a novel or adapted measure such as the Smoking Consequences Questionnaire (SCQ; 
Brandon & Baker, 1991).  This scale would help identify individuals with varying levels of 
positive expectancies associated with smoking.  These expectancies may interact with how these 
products induce mood changes and behavioral or subjective responses. To induce appropriate 
stimulus expectancies, participants would be read a prepared script concerning the product 
smoked during session.  This script would give examples of typical side effects associated with 
the product assignment (i.e., potential nicotine-related effects and/or caffeine-related effects).  
Another important feature would be manipulation checks after product administration (i.e., “Did 
you believe you received nicotine and/or caffeine today?”).   
If the subjective measure results from the proposed study indicated that the groups who 
were deceived about the drug content of the products they smoked (i.e., told nicotine/caffeine 
and smoked nicotine or told nicotine and smoked nicotine/caffeine) did not differ from groups 
were given congruent instructions and drug content (i.e., told nicotine/caffeine and smoked 
nicotine/caffeine or told nicotine and smoked nicotine), one may be able to conclude that non-
pharmacological factors have more influence than the actual product content.    If both “told 
nicotine/caffeine” groups reported greater stimulant-like effects than both “told nicotine” groups, 
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one may conclude that stimulus/response expectancies may be responsible for the anecdotal 
reports observed.  
Limitations of the Current Study 
Data from the current study must be interpreted within the context of several study 
limitations. These limitations include the participant population, the study setting, study design, 
and Type I and Type II error. 
Participants were frequent users of waterpipe who smoked on average 11.4 occasions per 
month for on average 2.2 years, but it is possible that those with a higher use frequency (i.e., 
daily use; potentially more nicotine/tobacco dependent) could report different effects when using 
these products.  If in fact higher frequency waterpipe users are more nicotine dependent, they 
may be more sensitive to product differences in nicotine content and could have rated the low 
nicotine and nicotine-free preparation with lower ratings of “like drug effects” or “rush” 
compared to the products with more nicotine.  In addition, participants with more experience 
(longer waterpipe tobacco use history) may have produced a different pattern of smoke 
topography and thus impacted CO and or nicotine/caffeine exposure. Unfortunately, there are 
few studies on the various patterns of use for waterpipe tobacco smokers. One example among a 
group of high frequency Syrian waterpipe tobacco smokers (N=61; M =7.8 waterpipe 
episodes/week for on average 8.5 years) indicated during a single session this group inhaled a 
larger total smoke volume (M = 79.1 L; Maziak et al., 2009) than the current study (NIC M = 
31.2 L).  Many attributes of smoke topography including total smoke volume are positively 
correlated with nicotine and CO delivery.  If experienced users inhaled more smoke, higher 
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nicotine and/or higher plasma caffeine concentrations may have been observed which could have 
impacted cardiovascular and/or subjective effects.  More smoke inhalation or more frequent 
puffing also could alter the temperature of the tobacco potentially producing a different exposure 
profile of the measured constituents: nicotine, caffeine, and CO.   
Another important  design feature that may have influenced smoking behavior was that 
individuals smoked alone, and group use of the waterpipe often is reported in the U.S. (Smith-
Simone et al., 2008; Ward et al., 2007).  The influence of sharing the waterpipe has not yet been 
assessed empirically, but one potential implication is that during sharing the IPI or the time 
between puffs may be shortened, and the waterpipe tobacco may be heated to higher 
temperatures than those observed during singleton use.  Higher temperatures could have affected 
caffeine volatilization, but currently there is no way to determine whether this factor had any 
effect on caffeine exposure.  
Other features of the design of this study may have influenced the ability to detect blood 
plasma caffeine concentration increases.  For example, the lack of control over dose in this study 
is a limitation not easily remedied.  Previous examinations of novel nicotine/tobacco products 
have used methods to control dose specifically such as controlled puffing regimens (Advance 
cigarettes, Breland et al., 2002; electronic nicotine delivery devices, Vansickel et al., 2010), gum 
chewing protocols (nicotine gum; Blank et al., 2008), or short administration periods (snus, 
nicotine lozenge; Cobb et al., 2010).  A future study of waterpipe products that contain nicotine 
and/or caffeine could utilize a controlled puffing regimen to limit dose-related variability among 
participants.  The head size and amount of tobacco loaded is another dose-related consideration.  
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Increasing the amount of the tobacco or product in the head would have increased the amount of 
nicotine and caffeine available for volatilization.  A larger head termed a “phunnel” is often used 
to smoke the Tangiers brand of tobacco.  This head is characterized by its large size and raised 
center that is in contrast to a typical waterpipe head with small holes lining the bottom (see 
Figure 19).  To fill this head adequately, approximately 20 g of product would be necessary 
compared to 10 g used in the current study.  Considering the caffeine concentration per gram of 
tobacco (0.5 mg), 10 mg of caffeine would be available for inhalation per “phunnel” head with a 
potential increase in plasma caffeine concentration of 131 ng/ml (10*13.12 ng/ml; Zandvliet et 
al., 2005).   
Another important design feature was the CAFF/LN condition.  An ideal comparison 
condition would have been a product that contained no nicotine and only caffeine, but this 
product was unavailable. With this caffeine only condition, we may have been able to determine 
whether there were any specific caffeine-related effects (if there was caffeine exposure).  Lastly, 
blindness integrity assessment at the conclusion of each session may have been beneficial to 
determine whether double-blinding was successful (Mooney, White, & Hatsukami, 2004).  
Any study using inferential statistics is susceptible to rejecting the null hypothesis when it is true 
(Type I error) and/or failing to reject the null when it is false (Type II: Keppel, 1991).  As 231 F-
tests were reported for the time course analysis, some (5%; 12) of the significant results may by 
chance reflect Type 1 error. However, for some of the variables that the null hypothesis was 
rejected (i.e., statistically significant), a similar pattern of results was observed for the time 
course and for the peak effects analysis (e.g., POMS factors tension/anxiety and   
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Figure 19. Waterpipe tobacco head used in the current study (left) and the “phunnel” (right).   
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depression/dejection, PANAS Factor NA) or a pattern of results repeated those that were 
previously reported among waterpipe smokers (e.g., gradual increase in plasma nicotine; HR 
increase during nicotine exposure; Cobb et al., 2011; Blank et al., 2011; CO increase in response 
to high smoke volumes; Maziak et al., 2009).  These findings suggest that Type I error did not 
influence the conclusions that can be drawn from this study.  In addition, the use of Tukey’s 
HSD, a conservative post-hoc test that maintains a specific alpha level across multiple 
comparisons (Howell, 1992) minimizes the influence of Type I error.  
The Type II error rate is a function of several factors including sample size and the alpha 
level. The initial sample size of 40 in this study was based on previous work (Blank et al., 2007) 
and other power calculations that suggested that thirty participants were necessary to detect a 
moderate effect size (i.e., f  ≥ 0.35) with a small or moderate correlation between repeated 
measures (i.e., r  ≥  0.50) with a power of 0.80 and alpha level < 0.05 (Barcikowski & Robey, 
1985).  The current sample size of 32 was deemed sufficient after careful inspection of individual 
raw plasma caffeine concentration data from the first twenty completers. During inspection, there 
were very few indications of a systematic increase in plasma caffeine during a session where a 
caffeinated product was administered. Figures 20 and 21 display the raw data of 32 study 
completers for each of the caffeinated product conditions (CAFF/LN; CAFF/NIC,  results from 
one individual omitted for ease of presentation).  In addition, the low dose of caffeine present in 
the CAFF/NIC and CAFF/LN preparations suggested that expected plasma caffeine exposure 
would be very low. Importantly, the current study was well-powered to detect increases in 
plasma nicotine concentration.  
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Figure 20. Raw plasma caffeine concentrations during the CAFF/LN condition (low nicotine/caffeine) from the first 16 study 
completers (Panel A) and the following 16 study completers (Panel B).   
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Figure 21. Raw plasma caffeine concentrations during the CAFF/NIC condition (caffeine/nicotine) from the first 16 study completers 
(Panel A) and the following 15 study completers (Panel B).  Data from one individual who completed the study were omitted from 
Panel B due to extremely high levels at baseline and to allow more precise visual inspection of the other participants’ results. 
Timecourse data for the omitted participant in minutes (min) relative to product administration are as follows: -5 min=5123 ng/ml, 5 
min=5372 ng/ml, 15 min=5393 ng/ml, 30 min=5221 ng/ml, 45 min=5972 ng/ml, 60 min=5021 ng/ml, 90 min=4272 ng/ml, and 120 
min=4673 ng/ml.    
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Conclusions 
The current study replicated many effects that have been reported elsewhere in the 
clinical laboratory waterpipe tobacco smoking literature (Blank et al., 2011; Maziak et al., 2009; 
Jacob III et al., 2011; Shafagoj et al., 2002).  These effects included significant plasma nicotine 
exposure when products smoked contained nicotine and cardiovascular changes associated with 
nicotine administration.  In addition, significant expired air CO exposure was observed during all 
conditions.  Results also suggested that nicotine/caffeine content in the waterpipe tobacco 
preparation smoked may not induce significant differences in subjective effects under the 
conditions utilized here and elsewhere (Blank et al., 2011).  The influence of non-
pharmacological stimuli on patterns of waterpipe tobacco smoking and subjective effects is an 
important consideration for future examinations of this tobacco use method.  Findings also 
indicated there was no exposure to tobacco smoke-delivered (i.e., volatilized) caffeine during 
this study, and thus there was no evidence for a potential nicotine and caffeine interaction when 
smoking these products.  While these findings do not address the issue of whether caffeine can 
be delivered via volatilization, they did suggest that for the products examined and under the 
conditions explored here measurable caffeine exposure was not observed. 
Importantly, tobacco dependence and toxicity capabilities are still concerns for these and 
other waterpipe tobacco products.  While the dependence likelihood of waterpipe tobacco 
smoking has yet to be quantified, there is early evidence that waterpipe tobacco smokers report 
some difficulty quitting (Ward et al., 2005) and smoking to relieve negative affect (Auf et al., 
2011).  In another clinical study, significant increases in the metabolites of known carcinogens 
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(NNK; polycyclic aromatic hydrocarbon) were observed following a single waterpipe tobacco 
smoking episode (Jacob III et al., 2011).  These findings as well as a recent meta-analysis of the 
adverse health effects associated with waterpipe tobacco smoking (Akl et al., 2010) should give 
cause for alarm among the public health community and support the need for more research 
concerning the potential for tobacco dependence from waterpipe tobacco smoking.   
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APPENDIX A 
 
 
Telephone Screening Form 
 
Interviewer:  “I would like to ask you some questions about yourself and your health status as 
well as your use of nicotine, alcohol, and other drugs.  The purpose of these questions is to 
determine whether or not you are eligible to participate in either the study/studies I just described 
or in any of the other studies being conducted in the lab.  All of your responses are confidential.  
You are not required to answer any question and you may stop this interview at any time.  May I 
begin the questions?” 
 
Document caller’s response by circling either:   Yes      or      No 
 
If Yes: begin form.  If No: thank caller for calling. 
 
 
How did you hear about us/our studies?   ________________________ 
Personal Information: 
1.  “What is your first name?”     ________________________ 
 
2.  “What is a phone number at which you can be contacted?” ______________________ 
4.  “If we call and you are not available, may we leave a message?”    
                      Circle        Yes      or      No 
 
5.  “What is your date of birth?”     ________________________  
6.  “What is your height?”      __________ (feet and inches)  
7.  “What is your weight?”      ________________ (pounds) 
 
8.  “Did you graduate high school?”         Circle         Yes      or      No 
 
If Yes: Skip the next question. 
 
9.  “Did you obtain your GED?”:        Circle         Yes      or      No 
------------------------------------------------------------------------------------------------------------ 
General health status: 
 
10.  “Do you have any chronic health concerns or problems?”    Circle     Yes      or      No 
 
  If Yes: “Please describe the concern or problem”: 
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11.  “Are you under a doctor’s care for a medical condition?”     Circle     Yes      or      No 
 
  If Yes: “Please describe the condition”: 
 
12. “Are you taking any prescription or over-the-counter medications?”                      
              Circle     Yes      or      No 
  If Yes: “Please identify the medication”: 
 
13.  Do you have any psychiatric conditions like depression or anxiety?     
              Circle     Yes      or      No 
  If Yes: “Please describe the condition”: 
 
14.  “Have you ever been diagnosed with high or low blood pressure?”   
               Circle     Yes      or      No 
  If Yes: “Please indicate whether it is high or low”: 
 
------------------------------------------------------------------------------------------------------------
Cigarette use: 
15.  “Do you currently smoke tobacco cigarettes?”          Circle     Yes      or      No 
 
If No:  Skip the remainder of this section 
 
16.  “What brand of cigarettes do you smoke?”          ____________________ 
            
      Circle:    
       i) Hard pack / Soft Pack 
       ii) Regular / Light / Ultra Lt 
       iii) Non-menthol / Menthol  
      iv) Regular / 100s / Other  
 
17.  “How many cigarettes/day do you smoke?”           ________ (num of cigs) 
[Note to interviewer:  Please note exact number of cigarettes per day] 
 
18.  “For how long have you smoked this number?”          ________ (mnths or yrs) 
 
19.  “How soon after you wake up do you smoke your first cigarette?” 
          Circle: Within 30 min. 
                After 30 min. 
20.  “Do you find it difficult to refrain from smoking in places where it 
         is forbidden (e.g., at the library, at the movies)?”         Circle     Yes      or      No 
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21.  “Which cigarette would you hate to give up the most?”        Circle: 1st in the morning 
                Any other 
 
22.  “Do you smoke more frequently during the first hours after awakening than during the rest 
of the day?”            Circle     Yes      or      No 
 
23.  “Do you smoke if you are so ill that you are in bed most of the day?”  
               Circle     Yes      or      No 
24.  “Have you ever used an electronic cigarette?”    Circle Yes      or      
No 
 
If Yes: “Which product?”       
 ____________________ 
  “How often do you use this product?”   
 ____________________ 
 
Waterpipe use: “The next few questions are about smoking tobacco in a waterpipe.  A waterpipe 
is also known as a hookah or shisha.  When I ask you about smoking a waterpipe, I mean 
tobacco smoking only.” 
25.  Have you ever tried smoking tobacco in a waterpipe, even one or two puffs?   
           Circle Yes      
or      No 
If No, skip the remainder of this section. 
If  “Yes” continue with this section: 
 
26.  “During the past year, have you tried smoking tobacco in a waterpipe, even one or two 
puffs?” 
                                                                                               Circle  Yes      or      No 
 
27. “During the past 30 days, have you tried smoking tobacco in a waterpipe, even one or two 
puffs?” 
                                                                                              Circle  Yes      or      No 
 
28. “Think back over the last 6 months.  On average, about how often would you say that you 
smoked tobacco using a waterpipe?” 
 
(Check one)   
         Less than 2 times per month?               __________________ 
         2-5 times per month?                            __________________ 
         5-20 times per month?                          __________________ 
         More than 21 times per month?            __________________ 
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29.  “Do you own a waterpipe?”                                           Circle  Yes      or      No 
 
30.   “What brand of tobacco do you prefer?”___________________________________ 
 
31.  “What flavor of tobacco do you prefer?”                  
1st choice   __________________________ 
2nd choice   __________________________ 
 
32.  “Do you ever smoke a waterpipe with a group of people?” Circle  Yes      or      No 
 
33.  “Do you ever smoke a waterpipe when you are by yourself?”  
                                                                                                Circle  Yes      or      No 
 
34.  “Do you ever drink/consume caffeinated products while smoking the waterpipe?” 
        Circle Yes      or      No 
 
If Yes: “Which drink/product?”    ____________________ 
 “How often do you use these drinks/products while smoking the waterpipe?”
 ________ 
 
------------------------------------------------------------------------------------------------------------ 
Smokeless Tobacco Use: 
35.  “Do you use smokeless tobacco (i.e., snuff, dip, or chew)?”   
Circle Yes      or      No 
 
If No: Skip the remainder of this section. 
 
36.  “What brand of smokeless tobacco do you use?  ____________________ 
 
37.  “How many times/day do you use smokeless tobacco?” ____________________ 
 
38.  “For how long have you used smokeless tobacco?” ________ (mnths or yrs) 
 
39.  “How many cigarettes have you smoked in the past 6 months?” ____________________ 
------------------------------------------------------------------------------------------------------------ 
 
Caffeine use: 
40.  “Do you ever drink beverages which contain caffeine?”Circle Yes      or      No 
 
If No: Skip to Question 46. 
 
41.  “How many cups of instant coffee do you drink per day?”____________________  
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42.  “How many cups of filtered coffee do you drink per day?”____________________ 
 
43.  “How many cups of caffeinated (not herbal) tea do you drink per day?” 
____________________ 
 
44.  “How many cups of decaffeinated (not herbal) tea do you drink per day?” 
__________________ 
 
45.  “How many caffeinated sodas/energy drinks do you drink per day (12 ounces = 1 can)?” 
__________________ 
 
If Yes: “Which drinks?”      ____________________ 
 
46.  “Do you eat any foods which contain caffeine such as coffee flavored ice cream or yogurt?”  
        Circle Yes      or      No 
 
If Yes: “Which foods?”      ____________________ 
 “How often do you eat these foods?”   ____________________ 
  
47.  “Do you take NoDoz, Vivarin, or other pills to help you stay awake?”  
Circle Yes      or      No  
 
If Yes: “How often do you take these pills?”   ____________________ 
 
48.  “Do you use other over-the-counter medications containing caffeine, such as Excedrin?” 
        Circle Yes      or      No 
 
If Yes: “How often do you take these medications?” ____________________ 
 
49.  “Do you take any prescription medications containing caffeine?”   
Circle Yes      or      No 
 
If Yes: “Which medications do you take?    ____________________ 
 “How often do you take these medications?”  ____________________ 
------------------------------------------------------------------------------------------------------------ 
Interviewer: “I’d like to ask you some additional questions about your use of alcohol and other 
drugs.” 
 
Alcohol use: 
50.  “Have you ever been treated for alcohol abuse/dependence?”   
Circle Yes      or      No 
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If Yes: “When was your treatment completed?”:              ___________ (mnth/year) 
 
51.  “Do you use (drink) alcoholic beverages?”  Circle Yes      or      No 
 
If No: Skip the remainder of this section. 
 
52.  “How many alcoholic drinks (by alcohol I mean beer, wine, or liquor) do you have on a 
typical day?       _______ (num of drinks) 
 
53.  “How many days out of the last 30 have you used alcohol?”_______ (num of days) 
 
------------------------------------------------------------------------------------------------------------
Marijuana use: 
54.  Have you ever, in your lifetime, smoked marijuana or hashish?   
Circle Yes      or      No 
 
If No: Skip the next question. 
 
55.  “How many days out of the last 30 have you smoked marijuana?” 
_______ (number of days) 
 
---------------------------------------------------------------------------------------------------------------------
---------------------------------------------Other drug use: 
56.  “Have you used any other illegal drugs within the past month?” 
Circle Yes      or      No 
 
If Yes: “Please identify which drug or drugs.” 
 
------------------------------------------------------------------------------------------------------------ 
For women only: 
57.  “Are you currently pregnant?”    Circle Yes      or      No 
 
58.  “Are you currently breast-feeding a child?”  Circle Yes      or      No 
 
59.  “What was the first day of your last period?”  ________________ 
 
Interviewer:  “Thank you for responding to these questions.  I need to pass on your responses to 
the principal investigator who will then determine whether or not you are eligible to participate 
in a study; someone will contact you within approximately one week if you are eligible.  If you 
are not eligible for any of our current studies, then you will not be contacted.” 
 [If respondent does not have a phone, they can call us back in a few days] 
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APPENDIX B 
 
 
Title.  Evaluating the acute effects of caffeinated waterpipe tobacco 
 
VCU IRB Number: HM12422 
 
Investigators. Dr. Thomas Eissenberg 
 
Sponsor.  National Cancer Institute 
 
This consent form may contain words that you do not understand.  Please ask the study 
staff to explain any words that you do not clearly understand.  You may take home an unsigned 
copy of this consent form to think about or discuss with family or friends before making your 
decision. 
 
Purpose of the study.  The purpose of this research study is to examine how caffeinated 
waterpipe tobacco smoking effects you.  A waterpipe is also known as a hookah, shisha, or 
narghile. 
 
Description of the study and procedures.  You have indicated interest in participating 
in a study of waterpipe users.  If you agree to join the study, you will be asked questions about 
your general health, smoking history, and drug and alcohol use.  You will need to provide a urine 
sample that will be tested immediately for recent use of illicit drugs (cocaine, heroin-like drugs, 
benzodiazepines, and methamphetamine) and also, if you are a woman, for pregnancy.  To help 
us protect your privacy, we have obtained a Certificate of Confidentiality from the National 
Institutes of Health. With this Certificate, we cannot be forced to disclose information that may 
identify you, even by a court subpoena, in any federal, state, or local civil, criminal, 
administrative, legislative, or other proceedings. We will use the Certificate to resist any 
demands for information that would identify you, except as explained below. 
 
The Certificate of Confidentiality cannot be used to resist a demand for information from 
personnel of the United States Government that is used for auditing or evaluation of federally 
funded projects or for information that must be disclosed in order to meet the requirements of the 
federal Food and Drug Administration (FDA). 
 
You should understand that a Certificate of Confidentiality does not prevent you or a 
member of your family from voluntarily releasing information about yourself or your 
involvement in this research. If an insurer, employer, or other person obtains your written 
consent to receive research information, then the researchers may not use the Certificate to 
withhold that information. 
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If you use illicit drugs, or are pregnant, you cannot participate in this study.  We will also 
ask you questions about your background, your health history, and your use of tobacco and other 
substances.  Your responses will be confidential. 
 
If the urine tests and your answers to our questions indicate that you fulfill the entry 
criteria, we will ask you to participate in four, approximately 3-hour sessions here at the Clinical 
Behavioral Pharmacology Laboratory located on VCU’s medical campus.  The four sessions will 
begin at approximately the same time each day, and will be separated by at least 48 hours.  
Before each session, we will ask you to abstain from all caffeine containing food and beverages 
and all tobacco products, for at least 12 hours before each session.  We will also ask you to 
abstain from all food for 1 hour before each session.  In addition, the use of any nicotine-
containing products (like the gum or patch) is prohibited.  We will ask you to take a simple 
breath and saliva test to make sure that you have complied with these restrictions.  Our tests are 
not perfect, but they are the only measures that we can accept to make certain that you have 
complied with the no caffeine/no tobacco/no nicotine restrictions.  
 
In each of the four sessions you will be asked to smoke a waterpipe in the laboratory.  We 
want you to smoke the waterpipe as you normally would.  The waterpipe that you smoke may or 
may not contain your preferred brand/flavor of tobacco, but will always contain a product 
marketed and sold for waterpipe smoking.  Please note that the product that you smoke may or 
may not contain tobacco and/or caffeine.  The waterpipe will be loaded only once, and we ask 
that you use it for at least 45 minutes, though you may take as many or as few puffs as you like 
during that period.  The waterpipe will be started with a single charcoal disk, but you may add 
additional ½ disks as you like.  All tobacco products used in this study are available to adults in 
the U.S. without a prescription. 
 
At the beginning of each session, and after you provide the breath and saliva sample used 
to assess compliance with the no caffeine/no tobacco restrictions, a nurse will insert a thin needle 
into your arm that will stay there for the entire session.  This needle will be used to draw blood 
periodically (approximately two tablespoons per sample, 8 samples per session, for a total of 
approximately 1/3 cup per session or 1 and 1/3 cups for the four-day study).  We use this method 
because participants tell us that it is more comfortable than repeated "sticks" with a needle.  Over 
the four days that you participate in this study, we will take less blood than the amount you 
would give in a single donation at a blood drive.  In addition to taking blood and breath samples, 
we will also ask you to participate in other procedures that include monitoring your heart rate 
and blood pressure and responding to several questionnaires to measure how you feel before, 
during, and after you smoke the waterpipe.  When you smoke the waterpipe you will notice that 
it is connected to a computer.  The computer is measuring how you smoke (the size and number 
of the puffs that you take).  This information allows us to understand waterpipe tobacco smoking 
better.  You will have an opportunity to experience all of the questionnaires and see all of the 
equipment before your first session. 
 
 159 
Risks and Discomforts.  You may experience some discomfort during sessions when 
you are not using your preferred brand/flavor of waterpipe tobacco, or when you are not using 
any caffeine or tobacco before a session.  Side effects from tobacco abstinence can include 
irritability, anxiety, restlessness, excessive hunger, difficulty concentrating, and sleep 
disturbance. Side effects from caffeine abstinence can include headache, fatigue, decreased 
energy/activeness, depressed mood, difficulty concentrating, and flu-like symptoms. Though 
uncomfortable, these feelings are not medically dangerous.  Side effects from products that 
contain tobacco/nicotine can include sweating, lightheadedness, dizziness, nausea, and 
nervousness. Side effects from products that contain caffeine can include restlessness, tension, 
and anxiety.  These effects are unlikely in individuals who use caffeine and tobacco products 
regularly.  You may also feel some discomfort when the nurse inserts or withdraws the needle, or 
when blood samples are taken.  Risk of bruising, bleeding, fainting or feeling lightheaded, and 
infection may occur. We try very hard to minimize your discomfort at these times, and the use of 
a trained nurse and sterile, disposable equipment enhances comfort while reducing the risk of 
bruising and infection.  If you find any effects or data collection procedures unacceptable, you 
may stop your participation at any time. Medical personnel will be on call should they be needed.  
 
Benefits. You will derive no personal benefit from this study. However, your 
participation will help us in the future as we try to understand the effects of different types of 
tobacco products. 
 
Costs of Participation.  There is no cost to you for participation except for your time.  
Participating in this study will take about 12 hours in the laboratory. 
 
Payment for Participation.  You will be paid for the time that you are not using tobacco 
prior to session and for your time in the laboratory: you will receive $75 after the first session, 
$75 after the second,  $100 after the third session, and $100 after the fourth session.  In all, you 
can earn $350 for successful completion of this study.   
 
Alternatives.  This is not a therapeutic study.  You have the alternative not to participate. 
 
Confidentiality. We will not tell anyone the answers that you give us; however, 
information from the study and the consent form signed by you may be looked at or copied for 
research or legal purposes by the sponsor of the research, or by Virginia Commonwealth 
University.  
 
Confidentiality of your records will be maintained by keeping all data in a locked file and 
in a coded database.  Release of this information will be withheld, consistent with the law, unless 
you give permission to release this information.  The information obtained in this study may be 
published, but your identity will not be revealed. 
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Compensation for Injury.  Virginia Commonwealth University and the VCU Health 
System (formerly known as the Medical College of Virginia Hospitals) have no plan for 
providing long-term care or compensation in the event that you suffer injury as a result of your 
participation in this research study.  If you are injured or if you become ill as a result of your 
participation in this study, contact your study nurse immediately. Your study nurse will arrange 
for short term emergency care or referral if it is needed.  Fees for such treatment may be billed to 
you or to appropriate third party insurance.  Your health insurance company may or may not pay 
for treatment of injuries as a result of your participation in this study. 
 
Pregnancy.  Every effort will be made to have women enter this study on an equal basis 
with men.  Tobacco use may be harmful to a fetus, and pregnant women may not participate in 
this study.  If you suspect that you are pregnant, or if you are currently breast-feeding a baby, 
please inform the investigator now and do not participate.  We will conduct a urine pregnancy 
test during the screening evaluation visit to ensure that pregnant women do not participate.  
 
Voluntary Participation and Withdrawal.  You do not have to participate in this study.  
If you choose to participate you may stop at any time without any penalty.  You may also choose 
not to answer particular questions that are asked in this study.  The investigators will answer any 
questions that you may have.  If you choose not to participate or to discontinue your 
participation, this choice will in no way affect any medical care you receive now or in the future 
at this institution.  If during the course of the study you experience adverse effects, or if you do 
not comply with the study restrictions, your participation may be stopped by Dr. Eissenberg 
without your consent.  Any significant new findings that develop during the course of the 
research study that may affect your willingness to continue to participate will be provided to you.   
 
Questions.  You can call Dr. Eissenberg at 827-3562 for information about the research 
or about research-related injury. 
 
Participants' Rights Information.  If you have questions about your rights as a research 
participant, you may contact: 
 
Office for Research Subjects Protection 
Virginia Commonwealth University 
Virginia Biotechnology Research Park, BioTech One 
800 East Leigh Street, Suite 115 
P.O. Box 980219 
Richmond, VA 23298-0219 
Telephone: 804-828-0868 
 
If you agree to join this study, please print and sign your name below.  You will receive a 
copy of this consent form.   
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Consent.  I have read this consent form.  I understand the information about this study.  
All my questions about the study and my participation in it have been answered.  I freely consent 
to participate in this research study. 
 
By signing this consent form I have not waived any of the legal rights which I otherwise 
would have as a participant in a research study. 
 
______________________________________   
Participant’s Printed Name     
 
______________________________________  __________________ 
Signature of Participant    Date 
 
______________________________________  __________________ 
Signature of Person Performing Consent  Date 
 
______________________________________   
Witness’s Printed Name     
 
______________________________________        __________________ 
Signature of Witness     Date 
 
______________________________________        __________________ 
Signature of Investigator    Date 
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